CINXE.COM

<!DOCTYPE html><html><head><meta charSet="utf-8"/><meta name="viewport" content="width=device-width"/><title>NIDDK Central Repository</title><meta name="next-head-count" content="3"/><link data-next-font="size-adjust" rel="preconnect" href="/" crossorigin="anonymous"/><link rel="preload" href="/_next/static/css/93e60cbdc9b67ef2.css" as="style"/><link rel="stylesheet" href="/_next/static/css/93e60cbdc9b67ef2.css" data-n-g=""/><link rel="preload" href="/_next/static/css/b306b64fe2aa70b4.css" as="style"/><link rel="stylesheet" href="/_next/static/css/b306b64fe2aa70b4.css" data-n-p=""/><noscript data-n-css=""></noscript><script defer="" nomodule="" src="/_next/static/chunks/polyfills-42372ed130431b0a.js"></script><script src="/_next/static/chunks/webpack-dcf4136cb4ed4a3e.js" defer=""></script><script src="/_next/static/chunks/framework-e952fed463eb8e34.js" defer=""></script><script src="/_next/static/chunks/main-97bba83dfe7e8d62.js" defer=""></script><script src="/_next/static/chunks/pages/_app-daedab1e29253550.js" defer=""></script><script src="/_next/static/chunks/4b358913-bc2fb375bb992c8b.js" defer=""></script><script src="/_next/static/chunks/3e726ff7-e9e1abc93e6e379f.js" defer=""></script><script src="/_next/static/chunks/238-4af308b231a3ae46.js" defer=""></script><script src="/_next/static/chunks/977-2288711ec40003fc.js" defer=""></script><script src="/_next/static/chunks/162-7a3ebc863ebe5c8a.js" defer=""></script><script src="/_next/static/chunks/707-ea7047ac214e2ed2.js" defer=""></script><script src="/_next/static/chunks/589-ad74826c928ee8c0.js" defer=""></script><script src="/_next/static/chunks/63-1a36f41d83b9a9b2.js" defer=""></script><script src="/_next/static/chunks/pages/home-4e4ab1671f29d792.js" defer=""></script><script src="/_next/static/4IwPCL7p9Vb_-_lB6rNWm/_buildManifest.js" defer=""></script><script src="/_next/static/4IwPCL7p9Vb_-_lB6rNWm/_ssgManifest.js" defer=""></script></head><body><div id="__next"><div class="CoreLayout_coreLayout__AbvUo "><div class="CoreLayout_container__C25fM"><div class="GovBanner_govBanner__l6GMd"><div class="GovBanner_bannerHeader__OJ1DM"><img src="/images/us_flag_small.png"/><p>An official website of the United States government</p><p><button><a>Here's how you would know <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 16 16" width="10" height="10" fill="currentColor" class="bi bi-chevron-down"><path fill-rule="evenodd" d="M1.646 4.646a.5.5 0 0 1 .708 0L8 10.293l5.646-5.647a.5.5 0 0 1 .708.708l-6 6a.5.5 0 0 1-.708 0l-6-6a.5.5 0 0 1 0-.708"></path></svg></a></button></p></div></div><div class="PageHeader_logoContainer__lq_Xl row"><div class="PageHeader_content__Yo7eT col"><a href="https://www.niddk.nih.gov"><div><svg version="1.1" id="Layer_1" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" width="300px" height="100px" viewBox="-528 662 578 130" enable-background="new -528 662 578 130" xml:space="preserve"><title>NIH: National Institute of Diabetes and Digestive and Kidney Diseases</title><g><g><path fill="#646569" d="M-383.6,698.1v58h-10.1l0,0v-26.3h-26.6v26.3h-10.1v-58h10.1v23.2h26.6v-23.2l0,0H-383.6z M-440.6,756.4 L-440.6,756.4h-10.1v-58h10.1V756.4z M-460.7,756.4L-460.7,756.4h-10.8l-26.6-42.8h-0.3v42.8h-9.8l0,0v-58l0,0h10.8l0,0l26.6,42.8 h0.3v-42.8h9.8V756.4z M-347.7,727l-35.9-65h-132.6c-6.7,0-11.9,5.4-11.9,11.9v106c0,6.7,5.4,11.9,11.9,11.9h132.3L-347.7,727z"></path><path fill="#71963E" d="M-374.5,792l36.1-65l-35.9-65h9c4.9,0,10.8,3.6,13.2,7.7l31.5,57.3l-31.7,57.3c-2.3,4.4-8.3,7.7-13.4,7.7 H-374.5z"></path></g><g><path fill="#616365" d="M-305,674.6h4.4l10.8,17.5l0,0v-17.5h3.9v24h-4.4l-10.8-17.5l0,0v17.5h-3.9 C-305,698.6-305,674.6-305,674.6z"></path><path fill="#616365" d="M-266.6,694.8c0,0.3,0,0.8,0.3,1c0,0.3,0.3,0.3,0.8,0.3h1v2.6c-0.3,0-0.5,0-0.5,0.3c-0.3,0-0.5,0-0.8,0.3 h-1.3c-0.8,0-1.5-0.3-2.1-0.5c-0.5-0.3-1-1-1-1.5c-0.8,0.8-1.8,1.3-2.8,1.5c-1,0.3-2.1,0.5-3.1,0.5c-0.8,0-1.5,0-2.3-0.3 c-0.8-0.3-1.3-0.5-1.8-1c-0.5-0.5-1-1-1.3-1.5c-0.3-0.8-0.5-1.5-0.5-2.3c0-0.8,0.3-1.8,0.5-2.6c0.3-0.5,1-1.3,1.5-1.5 c0.5-0.5,1.3-0.8,2.1-0.8c0.8-0.3,1.5-0.3,2.3-0.3c0.8-0.3,1.3-0.3,2.1-0.3c0.5,0,1,0,1.5-0.3c0.3,0,0.8-0.3,1-0.5 c0.3-0.3,0.5-0.8,0.5-1.3c0-0.5,0-0.8-0.3-1.3l-0.8-0.8c-0.3-0.3-0.8-0.3-1-0.3h-1.3c-1,0-1.8,0.3-2.6,0.8s-1.3,1.3-1.3,2.1h-3.9 c0-1,0.3-2.1,0.8-2.8c0.5-0.8,1-1.3,1.8-1.8c0.8-0.5,1.5-0.8,2.6-1c1-0.3,1.8-0.3,2.8-0.3c0.8,0,1.8,0,2.6,0.3l2.3,0.8 c0.5,0.3,1.3,1,1.5,1.5c0.5,0.8,0.8,1.5,0.5,2.3V694.8L-266.6,694.8L-266.6,694.8z M-270.5,689.9c-0.8,0.3-1.3,0.5-2.1,0.8 c-0.8,0-1.8,0.3-2.6,0.3s-0.8,0.3-1.3,0.3s-0.8,0.3-1,0.5l-0.8,0.8c-0.3,0.5-0.3,0.8-0.3,1.3c0,0.3,0,0.8,0.3,1l0.8,0.8 c0.3,0.3,0.8,0.3,1,0.3h1c0.5,0,0.8,0,1.3-0.3c0.5,0,1-0.3,1.3-0.5c0.5-0.3,0.8-0.5,1-1c0.3-0.5,0.5-1,0.5-1.5v-2.6L-270.5,689.9 L-270.5,689.9z"></path><path fill="#616365" d="M-264.3,681.3h2.8v-5.2h3.9v5.2h3.4v2.8h-3.4v10.3c0,0.3,0,0.5,0.3,0.8c0,0.3,0.3,0.5,0.5,0.5 c0.3,0.3,0.8,0.3,1,0.3h1.5v2.8c-0.5,0-0.8,0-1.3,0.3h-1.3c-0.8,0-1.5,0-2.3-0.3l-1.5-0.8c-0.3-0.5-0.5-0.8-0.8-1.3 c0-0.5-0.3-1.3-0.3-1.8v-10.3h-2.8v-3.4L-264.3,681.3L-264.3,681.3z"></path><path fill="#616365" d="M-251.4,674.6h3.9v3.6h-3.9V674.6z M-251.4,681.3h3.9v17.3h-3.9V681.3z"></path><path fill="#616365" d="M-235.4,699.1c-1.3,0-2.6-0.3-3.6-0.8c-2.1-0.8-3.9-2.6-4.6-4.6c-0.5-1-0.5-2.3-0.5-3.6s0.3-2.3,0.5-3.6 c0.5-1,1-2.1,1.8-2.8c0.8-0.8,1.8-1.5,2.8-1.8c2.3-1,4.9-1,7.2,0c2.1,0.8,3.9,2.6,4.6,4.6c0.5,1,0.5,2.3,0.5,3.6s-0.3,2.3-0.5,3.6 c-0.5,1-1,2.1-1.8,2.8c-0.8,0.8-1.8,1.5-2.8,1.8C-232.8,698.9-234.1,699.1-235.4,699.1z M-235.4,696c0.8,0,1.5-0.3,2.3-0.5 c0.5-0.3,1-0.8,1.5-1.3c0.5-0.5,0.8-1.3,0.8-2.1c0.3-1.5,0.3-3.1,0-4.6c-0.3-0.8-0.5-1.3-0.8-2.1c-0.5-0.5-1-1-1.5-1.3 c-0.8-0.3-1.5-0.5-2.3-0.5c-0.8,0-1.5,0.3-2.3,0.5c-0.5,0.3-1,0.8-1.5,1.3s-0.8,1.3-0.8,2.1c-0.3,1.5-0.3,3.1,0,4.6 c0.3,0.8,0.5,1.3,0.8,2.1c0.5,0.5,1,1,1.5,1.3C-236.9,696-236.2,696-235.4,696z"></path><path fill="#616365" d="M-223.3,681.3h3.6v2.6l0,0c0.5-1,1.3-1.8,2.3-2.3c1-0.5,2.1-0.8,3.1-0.8c2.8-0.3,5.7,1.8,5.9,4.9 c0,0.3,0,0.8,0,1v11.9h-3.9v-10.8c0-1-0.3-2.1-0.8-3.1c-0.5-0.8-1.5-1.3-2.6-1c-0.5,0-1.3,0-1.8,0.3s-1,0.5-1.3,1 c-0.3,0.5-0.5,1-0.8,1.5c-0.3,0.5-0.3,1.3-0.3,1.8v10.3h-3.6V681.3z"></path><path fill="#616365" d="M-189.5,694.8c0,0.3,0,0.8,0.3,1c0,0.3,0.3,0.3,0.8,0.3h1v2.6c-0.3,0-0.5,0-0.5,0.3c-0.3,0-0.5,0-0.8,0.3 h-1.3c-0.8,0-1.5-0.3-2.1-0.5c-0.5-0.3-1-1-1-1.5c-0.8,0.8-1.8,1.3-2.8,1.5s-2.1,0.5-3.1,0.5c-0.8,0-1.5,0-2.3-0.3 c-0.8-0.3-1.3-0.5-1.8-1c-0.5-0.5-1-1-1.3-1.5c-0.3-0.8-0.5-1.5-0.5-2.3c0-0.8,0.3-1.8,0.5-2.6c0.3-0.5,1-1.3,1.5-1.5 c0.5-0.5,1.3-0.8,2.1-0.8c0.8-0.3,1.5-0.3,2.3-0.3c0.8-0.3,1.3-0.3,2.1-0.3c0.5,0,1,0,1.5-0.3c0.3,0,0.8-0.3,1-0.5 c0.3-0.3,0.5-0.8,0.5-1.3c0-0.5,0-0.8-0.3-1.3l-0.8-0.8c-0.3-0.3-0.8-0.3-1-0.3h-1.3c-1,0-1.8,0.3-2.6,0.8 c-0.8,0.5-1.3,1.3-1.3,2.1h-3.9c0-1,0.3-2.1,0.8-2.8c0.5-0.8,1-1.3,1.8-1.8c0.8-0.5,1.5-0.8,2.6-1c1-0.3,1.8-0.3,2.8-0.3 c0.8,0,1.8,0,2.6,0.3l2.3,0.8c0.5,0.3,1.3,1,1.5,1.5c0.5,0.8,0.8,1.5,0.5,2.3V694.8L-189.5,694.8L-189.5,694.8z M-193.1,689.9 c-0.8,0.3-1.3,0.5-2.1,0.8c-0.8,0-1.8,0.3-2.6,0.3s-0.8,0.3-1.3,0.3c-0.5,0-0.8,0.3-1,0.5l-0.8,0.8c-0.3,0.5-0.3,0.8-0.3,1.3 c0,0.3,0,0.8,0.3,1l0.8,0.8c0.3,0.3,0.8,0.3,1,0.3h1c0.5,0,0.8,0,1.3-0.3c0.5,0,1-0.3,1.3-0.5c0.5-0.3,0.8-0.5,1-1 c0.3-0.5,0.5-1,0.5-1.5v-2.6L-193.1,689.9L-193.1,689.9z"></path><path fill="#616365" d="M-185.1,674.6h3.9v24h-3.9V674.6z"></path><path fill="#616365" d="M-167.3,674.6h4.1v24h-4.1V674.6z"></path><path fill="#616365" d="M-158.5,681.3h3.6v2.6l0,0c0.5-1,1.3-1.8,2.3-2.3c1-0.5,2.1-0.8,3.1-0.8c2.8-0.3,5.7,1.8,5.9,4.9 c0,0.3,0,0.8,0,1v11.9h-3.9v-10.8c0-1-0.3-2.1-0.8-3.1c-0.5-0.8-1.5-1.3-2.6-1c-0.5,0-1.3,0-1.8,0.3c-0.5,0.3-1,0.5-1.3,1 c-0.3,0.5-0.5,1-0.8,1.5c-0.3,0.5-0.3,1.3-0.3,1.8v10.3h-3.9v-17.3L-158.5,681.3L-158.5,681.3z"></path><path fill="#616365" d="M-136.3,693c0,1,0.5,1.8,1.3,2.3c0.8,0.5,1.5,0.8,2.6,0.8h1.3c0.5,0,0.8-0.3,1.3-0.3s0.8-0.3,1-0.8 c0.3-0.5,0.3-0.8,0.3-1.3c0-0.5-0.3-1-0.5-1.3c-0.5-0.3-0.8-0.5-1.3-0.8c-0.5-0.3-1.3-0.3-1.8-0.5c-0.8-0.3-1.3-0.3-2.1-0.5 c-0.8-0.3-1.3-0.3-2.1-0.5c-0.8-0.3-1.3-0.5-1.8-1c-0.5-0.5-1-1-1.3-1.5c-0.3-0.8-0.5-1.5-0.5-2.3c0-0.8,0.3-1.8,0.8-2.3 c0.5-0.5,1-1,1.8-1.5c0.8-0.5,1.5-0.8,2.3-0.8c1.8-0.3,3.4-0.3,5.2,0c0.8,0.3,1.5,0.5,2.3,1c1.5,0.8,2.3,2.6,2.3,4.1h-3.9 c0-0.8-0.5-1.5-1.3-1.8c-0.8-0.3-1.5-0.5-2.3-0.5h-1c-0.3,0-0.8,0-1,0.3c-0.3,0-0.5,0.3-0.8,0.5c-0.3,0.3-0.3,0.8-0.3,1 c0,0.5,0.3,0.8,0.5,1c0.5,0.3,0.8,0.5,1.3,0.8c0.5,0.3,1.3,0.3,1.8,0.5c0.8,0.3,1.3,0.3,2.1,0.5c0.8,0.3,1.3,0.3,2.1,0.5 c0.8,0.3,1.3,0.5,1.8,1c0.5,0.3,1,0.8,1.3,1.5c0.3,0.5,0.5,1.3,0.5,2.1c0,1-0.3,1.8-0.8,2.6c-0.5,0.8-1,1.3-1.8,1.8 c-0.8,0.5-1.5,0.8-2.6,1c-1,0.3-1.8,0.3-2.8,0.3c-1,0-2.1,0-3.1-0.3c-0.8-0.3-1.5-0.5-2.3-1c-0.8-0.5-1.3-1-1.5-1.8 c-0.5-0.8-0.5-1.8-0.5-2.6h3.6L-136.3,693L-136.3,693z"></path><path fill="#616365" d="M-123.7,681.3h2.8v-5.2h3.9v5.2h3.4v2.8h-3.4v10.3c0,0.3,0,0.5,0.3,0.8c0,0.3,0.3,0.5,0.5,0.5 c0.3,0,0.8,0.3,1,0.3h1.5v2.8c-0.5,0-0.8,0-1.3,0.3h-1.3c-0.8,0-1.5,0-2.3-0.3l-1.5-0.8c-0.3-0.5-0.5-0.8-0.8-1.3 c0-0.5-0.3-1.3-0.3-1.8v-10.3h-2.8v-3.4L-123.7,681.3L-123.7,681.3z"></path><path fill="#616365" d="M-110.5,674.6h3.9v3.6h-3.9V674.6z M-110.5,681.3h3.9v17.3h-3.9V681.3z"></path><path fill="#616365" d="M-104.4,681.3h2.8v-5.2h3.9v5.2h3.4v2.8h-3.4v10.3c0,0.3,0,0.5,0.3,0.8c0,0.3,0.3,0.5,0.5,0.5 c0.3,0,0.8,0.3,1,0.3h1.5v2.8c-0.5,0-0.8,0-1.3,0.3h-1.3c-0.8,0-1.5,0-2.3-0.3l-1.5-0.8c-0.3-0.5-0.5-0.8-0.8-1.3 c0-0.5-0.3-1.3-0.3-1.8v-10.3h-2.8v-3.4L-104.4,681.3L-104.4,681.3z"></path><path fill="#616365" d="M-76,698.6h-3.9v-2.3l0,0c-0.5,0.8-1.3,1.5-2.1,2.1c-0.8,0.5-1.8,0.8-2.8,0.8c-1.8,0.3-3.6-0.5-4.9-1.8 c-1.3-1.5-1.8-3.4-1.5-5.2v-11.1h3.9v10.6c-0.3,1,0.3,2.3,0.8,3.1c0.5,0.5,1.5,1,2.3,1c0.8,0,1.3,0,2.1-0.3c0.5-0.3,1-0.5,1.3-1 l0.8-1.5c0.3-0.5,0.3-1.3,0.3-1.8v-10.1h3.9V698.6L-76,698.6L-76,698.6z"></path><path fill="#616365" d="M-73.7,681.3h2.8v-5.2h3.9v5.2h3.4v2.8H-67v10.3c0,0.3,0,0.5,0.3,0.8c0,0.3,0.3,0.5,0.5,0.5 c0.3,0,0.8,0.3,1,0.3h1.5v2.8c-0.5,0-0.8,0-1.3,0.3h-1.3c-0.8,0-1.5,0-2.3-0.3l-1.5-0.8c-0.3-0.5-0.5-0.8-0.8-1.3 c0-0.5-0.3-1.3-0.3-1.8v-10.3h-2.8v-3.4L-73.7,681.3L-73.7,681.3z"></path><path fill="#616365" d="M-57.9,690.9c0,0.8,0,1.3,0.3,2.1c0.3,0.5,0.5,1,0.8,1.5c0.5,0.5,1,0.8,1.5,1c0.5,0.3,1.3,0.5,2.1,0.5 c1,0,1.8-0.3,2.6-0.8c0.8-0.5,1.3-1.3,1.5-2.1h3.6c-0.3,1-0.5,1.8-1,2.6c-0.5,0.8-1,1.3-1.8,1.8c-0.8,0.5-1.5,0.8-2.3,1 c-0.8,0.3-1.8,0.3-2.6,0.3c-1.3,0-2.6-0.3-3.6-0.8c-1-0.3-1.8-1-2.6-1.8c-0.8-0.8-1.3-1.8-1.5-2.8c-0.3-1.3-0.5-2.3-0.5-3.6 s0.3-2.3,0.5-3.6c0.5-1,1-1.8,1.5-2.8c0.8-0.8,1.5-1.5,2.6-2.1c1-0.5,2.3-0.8,3.6-0.8c1.3,0,2.6,0.3,3.6,0.8 c1,0.5,2.1,1.3,2.6,2.3c0.8,1,1.3,2.1,1.5,3.4c0.3,1.3,0.5,2.6,0.3,3.9L-57.9,690.9L-57.9,690.9z M-48.9,688.3 c0-0.5-0.3-1.3-0.3-1.8l-0.8-1.5c-0.3-0.5-0.8-0.8-1.3-1c-1.3-0.3-2.3-0.3-3.6,0c-0.5,0.3-1,0.5-1.3,1c-0.5,0.5-0.8,1-1,1.5 c-0.3,0.5-0.3,1.3-0.5,1.8H-48.9z"></path><path fill="#616365" d="M-24.9,699.1c-1.3,0-2.6-0.3-3.6-0.8c-2.1-0.8-3.9-2.6-4.6-4.6c-0.5-1-0.5-2.3-0.5-3.6s0.3-2.3,0.5-3.6 c0.5-1,1-2.1,1.8-2.8c0.8-0.8,1.8-1.5,2.8-1.8c2.3-1,4.9-1,7.2,0c2.1,0.8,3.9,2.6,4.6,4.6c0.5,1,0.5,2.3,0.5,3.6s-0.3,2.3-0.5,3.6 c-0.5,1-1,2.1-1.8,2.8c-0.8,0.8-1.8,1.5-2.8,1.8C-22.3,699.1-23.6,699.4-24.9,699.1z M-24.9,696c0.8,0,1.5-0.3,2.3-0.5 c0.5-0.3,1-0.8,1.5-1.3c0.5-0.5,0.8-1.3,0.8-2.1c0.3-1.5,0.3-3.1,0-4.6c-0.3-0.8-0.5-1.3-0.8-2.1c-0.5-0.5-1-1-1.5-1.3 c-0.8-0.3-1.5-0.5-2.3-0.5s-1.5,0.3-2.3,0.5c-0.5,0.3-1,0.8-1.5,1.3c-0.5,0.5-0.8,1.3-0.8,2.1c-0.3,1.5-0.3,3.1,0,4.6 c0.3,0.8,0.5,1.3,0.8,2.1c0.5,0.5,1,1,1.5,1.3C-26.5,696-25.7,696-24.9,696z"></path><path fill="#616365" d="M-14.6,681.3h2.8v-1.5c0-0.8,0.3-1.8,0.5-2.6c0-0.5,0.5-1.3,1-1.5l1.5-0.8c0.5,0,1.3-0.3,1.8-0.3 c0.8,0,1.8,0,2.6,0.3v3.1c-0.3,0-0.5,0-0.8-0.3h-1c-0.5,0-1,0-1.3,0.3c-0.3,0.5-0.5,1-0.5,1.5v1.8h3.4v2.8h-3.4v14.4h-3.9v-14.4 h-2.8L-14.6,681.3L-14.6,681.3L-14.6,681.3z"></path><path fill="#616365" d="M-304.8,715.1h9.8c1.5,0,3.4,0.3,4.6,1c1.3,0.8,2.3,1.5,3.4,2.6s1.5,2.6,1.8,3.9c0.5,1.5,0.5,3.1,0.5,4.6 s-0.3,3.1-0.5,4.6c-0.3,1.3-1,2.8-1.8,3.9c-0.8,1-2.1,2.1-3.4,2.6c-1.5,0.5-3.1,1-4.6,1h-9.8V715.1L-304.8,715.1z M-300.6,735.8 h4.1c1.3,0,2.8-0.3,4.1-0.8c1-0.3,1.8-1,2.3-1.8c0.5-0.8,1-1.8,1.3-2.8c0.3-2.3,0.3-4.4,0-6.7c-0.3-1-0.5-2.1-1.3-2.8 c-0.8-0.8-1.5-1.3-2.3-1.8c-1.3-0.5-2.8-0.8-4.1-0.8h-4.1V735.8L-300.6,735.8z"></path><path fill="#616365" d="M-281,715.1h3.9v3.6h-3.9V715.1z M-281,721.8h3.9v17.3h-3.9V721.8z"></path><path fill="#616365" d="M-258.6,735.3c0,0.3,0,0.8,0.3,1c0,0.3,0.3,0.3,0.8,0.3h1v2.6c-0.3,0-0.5,0-0.5,0.3 c-0.3,0.3-0.5,0-0.8,0.3h-1.3c-0.8,0-1.5-0.3-2.1-0.5c-0.5-0.3-1-1-1-1.5c-0.8,0.8-1.8,1.3-2.8,1.5c-1,0.3-2.1,0.5-3.1,0.5 c-0.8,0-1.5,0-2.3-0.3s-1.3-0.5-1.8-1c-0.5-0.5-1-1-1.3-1.5c-0.3-0.8-0.5-1.5-0.5-2.3c0-0.8,0.3-1.8,0.5-2.6 c0.3-0.5,1-1.3,1.5-1.5c0.5-0.5,1.3-0.8,2.1-0.8c0.8-0.3,1.5-0.3,2.3-0.3c0.8-0.3,1.3-0.3,2.1-0.3c0.5,0,1,0,1.5-0.3 c0.3,0,0.8-0.3,1-0.5c0.3-0.3,0.5-0.8,0.5-1.3c0-0.5,0-0.8-0.3-1.3l-0.8-0.8c-0.3-0.3-0.8-0.3-1-0.3h-1.3c-1,0-1.8,0.3-2.6,0.8 c-0.8,0.5-1.3,1.3-1.3,2.1h-3.9c0-1,0.3-2.1,0.8-2.8c0.5-0.8,1-1.3,1.8-1.8c0.8-0.5,1.5-0.8,2.6-1c1-0.3,1.8-0.3,2.8-0.3 c0.8,0,1.8,0,2.6,0.3l2.3,0.8c0.5,0.3,1.3,1,1.5,1.5c0.5,0.8,0.8,1.5,0.5,2.3V735.3L-258.6,735.3L-258.6,735.3z M-262.5,730.4 c-0.8,0.3-1.3,0.5-2.1,0.8c-0.8,0-1.8,0.3-2.6,0.3s-0.8,0.3-1.3,0.3s-0.8,0.3-1,0.5l-0.8,0.8c-0.3,0.5-0.3,0.8-0.3,1.3 c0,0.3,0,0.8,0.3,1l0.8,0.8c0.3,0.3,0.8,0.3,1,0.3h1c0.5,0,0.8,0,1.3-0.3c0.5,0,1-0.3,1.3-0.5c0.5-0.3,0.8-0.5,1-1 c0.3-0.5,0.5-1,0.5-1.5v-2.6L-262.5,730.4L-262.5,730.4z"></path><path fill="#616365" d="M-254.5,715.1h3.9v8.8l0,0c0.3-0.5,0.5-0.8,1-1c0.5-0.3,0.8-0.5,1.3-0.8s1-0.5,1.5-0.5 c0.5,0,1-0.3,1.5-0.3c1.3,0,2.6,0.3,3.6,0.8c1,0.5,1.8,1.3,2.6,2.1c0.8,0.8,1.3,1.8,1.5,2.8c0.3,1.3,0.5,2.3,0.5,3.6 c0,1-0.3,2.3-0.5,3.4c-0.3,1-0.8,2.1-1.3,2.8c-0.5,0.8-1.3,1.5-2.3,2.1c-1,0.5-2.3,0.8-3.4,0.8h-1.8c-0.5,0-1.3-0.3-1.8-0.5 c-0.5-0.3-1-0.5-1.5-0.8s-0.8-0.8-1-1.3l0,0v2.3h-3.9V715.1z M-241.1,730.4c0-0.8,0-1.5-0.3-2.3c-0.3-0.8-0.5-1.5-1-2.1 c-0.5-0.5-1-1-1.5-1.3c-0.5-0.3-1.3-0.5-2.1-0.5c-1.3,0-2.8,0.5-3.6,1.5c-0.8,1.3-1.3,2.8-1.3,4.4c0,0.8,0,1.5,0.3,2.3 c0.3,0.8,0.5,1.3,1,1.8s1,1,1.5,1.3s1.3,0.5,2.1,0.5c0.8,0,1.5-0.3,2.3-0.5c0.5-0.3,1-0.8,1.5-1.3c0.5-0.5,0.8-1.3,0.8-2.1 C-241.3,731.4-241.1,731.1-241.1,730.4z"></path><path fill="#616365" d="M-231,731.4c0,0.8,0,1.3,0.3,2.1c0.3,0.5,0.5,1,0.8,1.5c0.5,0.5,1,0.8,1.5,1c0.5,0.3,1.3,0.5,2.1,0.5 c1,0,1.8-0.3,2.6-0.8c0.8-0.5,1.3-1.3,1.5-2.1h3.6c-0.3,1-0.5,1.8-1,2.6c-0.5,0.8-1,1.3-1.8,1.8c-1.5,0.8-3.1,1.3-4.9,1.5 c-1.3,0-2.6-0.3-3.6-0.8c-1-0.3-1.8-1-2.6-1.8c-0.8-0.8-1.3-1.8-1.5-2.8c-0.3-1.3-0.5-2.3-0.5-3.6s0.3-2.3,0.5-3.6 c0.5-1,1-1.8,1.5-2.8c0.8-0.8,1.5-1.5,2.6-2.1c1-0.5,2.3-0.8,3.6-0.8c1.3,0,2.6,0.3,3.6,0.8c1,0.5,2.1,1.3,2.6,2.3 c0.8,1,1.3,2.1,1.5,3.4c0.3,1.3,0.5,2.6,0.3,3.9H-231V731.4L-231,731.4z M-221.7,728.8c0-0.5-0.3-1.3-0.3-1.8l-0.8-1.5 c-0.3-0.5-0.8-0.8-1.3-1c-1.3-0.3-2.3-0.3-3.6,0c-0.5,0.3-1,0.5-1.3,1c-0.5,0.5-0.8,1-1,1.5c-0.3,0.5-0.3,1.3-0.3,1.8H-221.7z"></path><path fill="#616365" d="M-216.8,721.8h2.8v-5.2h3.9v5.2h3.4v2.8h-3.4V735c0,0.3,0,0.5,0.3,0.8c0,0.3,0.3,0.5,0.5,0.5 c0.3,0.3,0.8,0.3,1,0.3h1.5v2.8c-0.5,0-0.8,0-1.3,0.3h-1.3c-0.8,0-1.5,0-2.3-0.3l-1.5-0.8c-0.3-0.5-0.5-0.8-0.8-1.3 c0-0.5-0.3-1.3-0.3-1.8v-10.3h-2.8v-3.4L-216.8,721.8L-216.8,721.8z"></path><path fill="#616365" d="M-200.8,731.4c0,0.8,0,1.3,0.3,2.1c0.3,0.5,0.5,1,0.8,1.5c0.5,0.5,1,0.8,1.5,1c0.5,0.3,1.3,0.5,2.1,0.5 c1,0,1.8-0.3,2.6-0.8c0.8-0.5,1.3-1.3,1.5-2.1h3.6c-0.3,1-0.5,1.8-1,2.6c-0.5,0.8-1,1.3-1.8,1.8c-1.5,0.8-3.1,1.3-4.9,1.5 c-1.3,0-2.6-0.3-3.6-0.8c-1-0.3-1.8-1-2.6-1.8c-0.8-0.8-1.3-1.8-1.5-2.8c-0.3-1.3-0.5-2.3-0.5-3.6s0.3-2.3,0.5-3.6 c0.5-1,1-1.8,1.5-2.8c0.8-0.8,1.5-1.5,2.6-2.1c1-0.5,2.3-0.8,3.6-0.8c1.3,0,2.6,0.3,3.6,0.8c1,0.5,2.1,1.3,2.6,2.3 c0.8,1,1.3,2.1,1.5,3.4c0.3,1.3,0.5,2.6,0.3,3.9h-12.6V731.4L-200.8,731.4z M-192.1,728.8c0-0.5-0.3-1.3-0.3-1.8l-0.8-1.5 c-0.3-0.5-0.8-0.8-1.3-1c-1.3-0.3-2.3-0.3-3.6,0c-0.5,0.3-1,0.5-1.3,1c-0.5,0.5-0.8,1-1,1.5c-0.3,0.5-0.3,1.3-0.3,1.8H-192.1z"></path><path fill="#616365" d="M-182.2,733.4c0,1,0.5,1.8,1.3,2.3c0.8,0.5,1.5,0.8,2.6,0.8h1.3c0.5,0,0.8-0.3,1.3-0.3 c0.5-0.3,0.8-0.5,1-0.8c0.3-0.5,0.3-0.8,0.3-1.3c0-0.5-0.3-1-0.5-1.3c-0.5-0.3-0.8-0.5-1.3-0.8c-0.5-0.3-1.3-0.3-1.8-0.5 c-0.8-0.3-1.3-0.3-2.1-0.5c-0.8-0.3-1.3-0.3-2.1-0.5c-0.8-0.3-1.3-0.5-1.8-1c-0.5-0.3-1-0.8-1.3-1.5c-0.3-0.8-0.5-1.5-0.5-2.3 c0-0.8,0.3-1.8,0.8-2.3c0.5-0.5,1-1,1.8-1.5c0.8-0.5,1.5-0.8,2.3-0.8c1.8-0.3,3.4-0.3,5.2,0c0.8,0.3,1.5,0.5,2.3,1 c1.5,0.8,2.3,2.6,2.3,4.1h-3.9c0-0.8-0.5-1.5-1.3-1.8c-0.8-0.3-1.5-0.5-2.3-0.5h-1c-0.3,0-0.8,0-1,0.3c-0.3,0-0.5,0.3-0.8,0.5 c-0.3,0.3-0.3,0.8-0.3,1c0,0.5,0.3,0.8,0.5,1c0.5,0.3,0.8,0.5,1.3,0.8c0.5,0.3,1.3,0.3,1.8,0.5c0.8,0.3,1.3,0.3,2.1,0.5 c0.8,0.3,1.3,0.3,2.1,0.5c0.8,0.3,1.3,0.5,1.8,1c0.5,0.3,1,0.8,1.3,1.5c0.3,0.5,0.5,1.3,0.5,2.1c0,1-0.3,1.8-0.8,2.6 c-0.5,0.8-1,1.3-1.8,1.8c-0.8,0.5-1.5,0.8-2.6,1c-1,0.3-1.8,0.3-2.8,0.3s-2.1,0-3.1-0.3c-0.8-0.3-1.5-0.5-2.3-1 c-0.8-0.5-1.3-1-1.5-1.8c-0.5-0.8-0.5-1.8-0.5-2.6h3.6V733.4L-182.2,733.4z"></path><path fill="#616365" d="M-144.1,735.3c0,0.3,0,0.8,0.3,1c0,0.3,0.3,0.3,0.8,0.3h1v2.6c-0.3,0-0.5,0-0.5,0.3 c-0.3,0.3-0.5,0-0.8,0.3h-1.3c-0.8,0-1.5-0.3-2.1-0.5c-0.5-0.3-1-1-1-1.5c-0.8,0.8-1.8,1.3-2.8,1.5c-1,0.3-2.1,0.5-3.1,0.5 c-0.8,0-1.5,0-2.3-0.3c-0.8-0.3-1.3-0.5-1.8-1c-0.5-0.5-1-1-1.3-1.5c-0.3-0.8-0.5-1.5-0.5-2.3c0-0.8,0.3-1.8,0.5-2.6 c0.3-0.5,1-1.3,1.5-1.5c0.5-0.5,1.3-0.8,2.1-0.8c0.8-0.3,1.5-0.3,2.3-0.3c0.8-0.3,1.3-0.3,2.1-0.3c0.5,0,1,0,1.5-0.3 c0.3,0,0.8-0.3,1-0.5c0.3-0.3,0.5-0.8,0.5-1.3c0-0.5,0-0.8-0.3-1.3l-0.8-0.8c-0.3-0.3-0.8-0.3-1-0.3h-1.3c-1,0-1.8,0.3-2.6,0.8 c-0.8,0.5-1.3,1.3-1.3,2.1h-3.6c0-1,0.3-2.1,0.8-2.8c0.5-0.8,1-1.3,1.8-1.8c0.8-0.5,1.5-0.8,2.6-1c1-0.3,1.8-0.3,2.8-0.3 c0.8,0,1.8,0,2.6,0.3l2.3,0.8c0.5,0.3,1.3,1,1.5,1.5c0.5,0.8,0.8,1.5,0.5,2.3v8.8L-144.1,735.3L-144.1,735.3z M-147.9,730.4 c-0.8,0.3-1.3,0.5-2.1,0.8c-0.8,0-1.8,0.3-2.6,0.3s-0.8,0.3-1.3,0.3c-0.5,0-0.8,0.3-1,0.5l-0.8,0.8c-0.3,0.5-0.3,0.8-0.3,1.3 c0,0.3,0,0.8,0.3,1l0.8,0.8c0.3,0.3,0.8,0.3,1,0.3h1c0.5,0,0.8,0,1.3-0.3c0.5,0,1-0.3,1.3-0.5c0.5-0.3,0.8-0.5,1-1 c0.3-0.5,0.5-1,0.5-1.5v-2.6L-147.9,730.4L-147.9,730.4z"></path><path fill="#616365" d="M-139.9,721.8h3.6v2.6l0,0c0.5-1,1.3-1.8,2.3-2.3c1-0.5,2.1-0.8,3.1-0.8c2.8-0.3,5.7,1.8,5.9,4.9 c0,0.3,0,0.8,0,1v11.9h-3.9v-10.8c0-1-0.3-2.1-0.8-3.1c-0.5-0.8-1.5-1.3-2.6-1c-0.5,0-1.3,0-1.8,0.3s-1,0.5-1.3,1 c-0.3,0.5-0.5,1-0.8,1.5c-0.3,0.5-0.3,1.3-0.3,1.8v10.3h-3.9v-17.3L-139.9,721.8L-139.9,721.8z"></path><path fill="#616365" d="M-104.4,739.1h-3.6v-2.3l0,0c-0.5,1-1.3,1.8-2.3,2.1c-1,0.5-2.1,0.8-3.1,0.8c-1.3,0-2.6-0.3-3.6-0.8 c-1-0.5-1.8-1.3-2.6-2.1c-0.8-0.8-1.3-1.8-1.5-2.8c-0.3-1.3-0.5-2.3-0.5-3.6c0-1.3,0.3-2.8,0.5-4.1c0.5-1,1-2.1,1.8-2.8 c0.5-0.8,1.5-1.3,2.3-1.5c1-0.3,1.8-0.5,2.8-0.5c0.5,0,1,0,1.5,0.3c0.5,0,1,0.3,1.5,0.5l1.5,0.8c0.5,0.3,0.8,0.8,1,1.3l0,0v-8.8 h3.9v23.7H-104.4z M-117.8,730.6c0,0.8,0,1.3,0.3,2.1c0.3,0.5,0.5,1.3,0.8,1.8c0.5,0.5,1,1,1.5,1.3s1.3,0.5,2.1,0.5 c0.8,0,1.5-0.3,2.3-0.5c0.5-0.3,1-0.8,1.5-1.3c0.5-0.5,0.8-1.3,0.8-2.1c0.3-0.8,0.3-1.5,0.3-2.3c0-1.5-0.5-3.1-1.3-4.4 c-0.8-1-2.3-1.5-3.6-1.5c-0.8,0-1.5,0.3-2.3,0.5c-0.8,0.3-1.3,0.8-1.5,1.5c-0.5,0.5-0.8,1.3-0.8,2.1 C-117.5,729.1-117.5,729.8-117.8,730.6z"></path><path fill="#616365" d="M-90.2,715.1h9.8c1.5,0,3.4,0.3,4.6,1c1.3,0.5,2.3,1.5,3.4,2.6s1.5,2.3,1.8,3.9c0.5,1.5,0.5,3.1,0.5,4.6 s-0.3,3.1-0.5,4.6c-0.3,1.3-1,2.8-1.8,3.9c-0.8,1-2.1,2.1-3.4,2.6c-1.5,0.5-3.1,1-4.6,1h-9.8V715.1L-90.2,715.1z M-86,735.8h4.1 c1.3,0,2.8-0.3,4.1-0.8c1-0.3,1.8-1,2.3-1.8c0.5-0.8,1-1.8,1.3-2.8c0.3-2.3,0.3-4.4,0-6.7c-0.3-1-0.5-2.1-1.3-2.8 c-0.5-0.8-1.3-1.5-2.3-1.8c-1.3-0.5-2.8-0.8-4.1-0.8H-86L-86,735.8L-86,735.8z"></path><path fill="#616365" d="M-66.2,715.1h3.9v3.6h-3.9V715.1z M-66.2,721.8h3.9v17.3h-3.9V721.8z"></path><path fill="#616365" d="M-42.2,738.1c0.3,2.3-0.8,4.4-2.3,5.9c-1.8,1.3-4.1,2.1-6.4,1.8c-0.8,0-1.8,0-2.6-0.3 c-0.8-0.3-1.5-0.5-2.3-1c-0.8-0.5-1.3-1-1.8-1.8c-0.5-0.8-0.8-1.5-0.8-2.6h3.9c0,0.5,0.3,1,0.5,1.3c0.3,0.3,0.5,0.5,1,0.8 c0.5,0.3,0.8,0.3,1.3,0.3h1.3c2.1,0.5,4.1-1,4.4-2.8c0-0.5,0-1,0-1.5v-2.6l0,0c-0.5,1-1.3,1.8-2.3,2.3c-1,0.5-2.1,0.8-3.1,0.8 c-1.3,0-2.6-0.3-3.6-0.8c-1-0.5-1.8-1-2.3-2.1c-0.5-0.8-1-1.8-1.3-2.8c-0.3-1.3-0.5-2.3-0.5-3.6c0-1,0.3-2.3,0.5-3.4 c0.3-1,0.8-2.1,1.5-2.8c0.8-0.8,1.5-1.5,2.6-1.8c1-0.5,2.3-0.8,3.4-0.8s2.1,0.3,3.1,0.8c0.8,0.5,1.5,1.3,2.1,2.1l0,0v-2.3h3.9 L-42.2,738.1L-42.2,738.1z M-50.7,736c0.8,0,1.5-0.3,2.1-0.5c0.5-0.3,1-0.8,1.5-1.3c0.3-0.8,0.5-1.3,0.8-2.1 c0.3-0.8,0.3-1.5,0.3-2.3c0-0.8,0-1.3-0.3-2.1c-0.3-0.5-0.5-1.3-0.8-1.8c-0.3-0.5-0.8-1-1.5-1.3c-1.3-0.8-2.8-0.8-4.1,0 c-0.5,0.3-1,0.8-1.3,1.3c-0.3,0.8-0.5,1.3-0.8,2.1c-0.3,1.3-0.3,2.8,0,4.1c0.3,0.5,0.5,1.3,0.8,1.8c0.3,0.5,0.8,1,1.3,1.3 C-52.2,735.8-51.5,736-50.7,736L-50.7,736z"></path><path fill="#616365" d="M-35.5,731.4c0,0.8,0,1.3,0.3,2.1c0.3,0.5,0.5,1,0.8,1.5c0.5,0.5,1,0.8,1.5,1c0.5,0.3,1.3,0.5,2.1,0.5 c1,0,1.8-0.3,2.6-0.8c0.8-0.5,1.3-1.3,1.5-2.1h3.6c-0.3,1-0.5,1.8-1,2.6c-0.5,0.8-1,1.3-1.8,1.8c-1.5,0.8-3.1,1.3-4.9,1.5 c-1.3,0-2.6-0.3-3.6-0.8c-1-0.3-1.8-1-2.6-1.8c-0.8-0.8-1.3-1.8-1.5-2.8c-0.3-1.3-0.5-2.3-0.5-3.6s0.3-2.3,0.5-3.6 c0.5-1,1-1.8,1.5-2.8c0.8-0.8,1.5-1.5,2.6-2.1c1-0.5,2.3-0.8,3.6-0.8s2.6,0.3,3.6,0.8c1,0.5,2.1,1.3,2.6,2.3 c0.8,1,1.3,2.1,1.5,3.4s0.5,2.6,0.3,3.9h-12.6V731.4L-35.5,731.4z M-26.5,728.8c0-0.5-0.3-1.3-0.3-1.8l-0.8-1.5 c-0.3-0.5-0.8-0.8-1.3-1c-1.3-0.3-2.3-0.3-3.6,0c-0.5,0.3-1,0.5-1.3,1c-0.5,0.5-0.8,1-1,1.5c-0.3,0.5-0.3,1.3-0.5,1.8H-26.5z"></path><path fill="#616365" d="M-16.9,733.4c0,1,0.5,1.8,1.3,2.3c0.8,0.5,1.5,0.8,2.6,0.8h1.3c0.5,0,0.8-0.3,1.3-0.3 c0.5-0.3,0.8-0.5,1-0.8c0.3-0.5,0.3-0.8,0.3-1.3c0-0.5-0.3-1-0.5-1.3c-0.5-0.3-0.8-0.5-1.3-0.8c-0.5-0.3-1.3-0.3-1.8-0.5 c-0.8-0.3-1.3-0.3-2.1-0.5c-0.8-0.3-1.3-0.3-2.1-0.5c-0.8-0.3-1.3-0.5-1.8-1c-0.5-0.3-1-0.8-1.3-1.5c-0.3-0.8-0.5-1.5-0.5-2.3 c0-0.8,0.3-1.8,0.8-2.3c0.5-0.5,1-1,1.8-1.5c0.8-0.5,1.5-0.8,2.3-0.8c1.8-0.3,3.4-0.3,5.2,0c0.8,0.3,1.5,0.5,2.3,1 c1.5,0.8,2.3,2.6,2.3,4.1h-3.9c0-0.8-0.5-1.5-1.3-1.8c-0.8-0.3-1.5-0.5-2.3-0.5h-1c-0.3,0-0.8,0-1,0.3c-0.3,0.3-0.5,0.3-0.8,0.5 c-0.3,0.3-0.3,0.8-0.3,1c0,0.5,0.3,0.8,0.5,1c0.5,0.3,0.8,0.5,1.3,0.8c0.5,0.3,1.3,0.3,1.8,0.5c0.8,0.3,1.3,0.3,2.1,0.5 c0.8,0.3,1.3,0.3,2.1,0.5c0.8,0.3,1.3,0.5,1.8,1c0.5,0.3,1,0.8,1.3,1.5c0.3,0.5,0.5,1.3,0.5,2.1c0,1-0.3,1.8-0.8,2.6 c-0.5,0.8-1,1.3-1.8,1.8c-0.8,0.5-1.5,0.8-2.6,1c-1,0.3-1.8,0.3-2.8,0.3s-2.1,0-3.1-0.3c-0.8-0.3-1.5-0.5-2.3-1s-1.3-1-1.5-1.8 c-0.5-0.8-0.5-1.8-0.5-2.6h3.6L-16.9,733.4L-16.9,733.4z"></path><path fill="#616365" d="M-4,721.8h2.8v-5.2h3.9v5.2H6v2.8H2.7V735c0,0.3,0,0.5,0.3,0.8l0.5,0.5c0.3,0,0.8,0.3,1,0.3H6v2.8 c-0.5,0-0.8,0-1.3,0.3H3.5c-0.8,0-1.5,0-2.3-0.3l-1.5-0.8c-0.3-0.5-0.5-0.8-0.8-1.3c0-0.5-0.3-1.3-0.3-1.8v-10.3h-2.8v-3.4H-4 L-4,721.8z"></path><path fill="#616365" d="M8.9,715.1h3.9v3.6H8.9V715.1z M8.9,721.8h3.9v17.3H8.9V721.8z"></path><path fill="#616365" d="M15.1,721.8h4.1l4.4,13.4l0,0l4.1-13.4h3.9l-6.2,17.3H21L15.1,721.8z"></path><path fill="#616365" d="M37.3,731.4c0,0.8,0,1.3,0.3,2.1c0.3,0.5,0.5,1,0.8,1.5c0.5,0.5,1,0.8,1.5,1c0.5,0.3,1.3,0.5,2.1,0.5 c1,0,1.8-0.3,2.6-0.8c0.8-0.5,1.3-1.3,1.5-2.1h3.6c-0.3,1-0.5,1.8-1,2.6c-0.5,0.8-1,1.3-1.8,1.8c-1.5,0.8-3.1,1.3-4.9,1.5 c-1.3,0-2.6-0.3-3.6-0.8c-1-0.3-1.8-1-2.6-1.8c-0.8-0.8-1.3-1.8-1.5-2.8c-0.3-1.3-0.5-2.3-0.5-3.6s0.3-2.3,0.5-3.6 c0.5-1,1-1.8,1.5-2.8c0.8-0.8,1.5-1.5,2.6-2.1c1-0.5,2.3-0.8,3.6-0.8c1.3,0,2.6,0.3,3.6,0.8c1,0.5,2.1,1.3,2.6,2.3 c0.8,1,1.3,2.1,1.5,3.4c0.3,1.3,0.5,2.6,0.3,3.9H37.3V731.4L37.3,731.4z M46.3,728.8c0-0.5-0.3-1.3-0.3-1.8l-0.8-1.5 c-0.3-0.5-0.8-0.8-1.3-1c-1.3-0.3-2.3-0.3-3.6,0c-0.5,0.3-1,0.5-1.3,1c-0.5,0.5-0.8,1-1,1.5c-0.3,0.5-0.3,1.3-0.5,1.8H46.3z"></path><path fill="#616365" d="M-290.8,775.5c0,0.3,0,0.8,0.3,1c0,0.3,0.3,0.3,0.8,0.3h1v2.6c-0.3,0-0.5,0-0.5,0.3c-0.3,0-0.5,0-0.8,0.3 h-1.3c-0.8,0-1.5-0.3-2.1-0.5c-0.5-0.3-1-1-1-1.5c-0.8,0.8-1.8,1.3-2.8,1.5s-2.1,0.5-3.1,0.5c-0.8,0-1.5,0-2.3-0.3s-1.3-0.5-1.8-1 s-1-1-1.3-1.5c-0.3-0.8-0.5-1.5-0.5-2.3c0-0.8,0.3-1.8,0.5-2.6c0.3-0.5,1-1.3,1.5-1.5c0.5-0.5,1.3-0.8,2.1-0.8 c0.8-0.3,1.5-0.3,2.3-0.5c0.8-0.3,1.3-0.3,2.1-0.3c0.5,0,1,0,1.5-0.3c0.3,0,0.8-0.3,1-0.5c0.3-0.3,0.5-0.8,0.5-1.3 c0-0.5,0-0.8-0.3-1.3l-0.8-0.8c-0.3-0.3-0.8-0.3-1-0.3h-1.3c-1,0-1.8,0.3-2.6,0.8c-0.8,0.5-1.3,1.3-1.3,2.1h-3.9 c0-1,0.3-2.1,0.8-2.8c0.5-0.8,1-1.3,1.8-1.8c0.8-0.5,1.5-0.8,2.6-1c1-0.3,1.8-0.3,2.8-0.3c0.8,0,1.8,0,2.6,0.3l2.3,0.8 c0.5,0.3,1.3,1,1.5,1.5c0.5,0.8,0.8,1.5,0.5,2.3V775.5L-290.8,775.5L-290.8,775.5z M-294.7,770.6c-0.8,0.3-1.3,0.5-2.1,0.8 c-0.8,0-1.8,0.3-2.6,0.3s-0.8,0.3-1.3,0.3c-0.5,0-0.8,0.3-1,0.5l-0.8,0.8c-0.3,0.5-0.3,0.8-0.3,1.3c0,0.3,0,0.8,0.3,1l0.8,0.8 c0.3,0.3,0.8,0.3,1,0.3h1c0.5,0,0.8,0,1.3-0.3c0.5,0,1-0.3,1.3-0.5c0.5-0.3,0.8-0.5,1-1c0.3-0.5,0.5-1,0.5-1.5v-2.6L-294.7,770.6 L-294.7,770.6z"></path><path fill="#616365" d="M-286.7,762.1h3.6v2.6l0,0c0.5-1,1.3-1.8,2.3-2.3c1-0.5,2.1-0.8,3.1-0.8c2.8-0.3,5.7,1.8,5.9,4.9 c0,0.3,0,0.8,0,1v11.9h-3.9v-10.8c0-1-0.3-2.1-0.8-3.1c-0.5-0.8-1.5-1.3-2.6-1c-0.5,0-1.3,0-1.8,0.3s-1,0.5-1.3,1 c-0.3,0.5-0.5,1-0.8,1.5c-0.3,0.5-0.3,1.3-0.3,1.8v10.3h-3.9v-17.3L-286.7,762.1L-286.7,762.1z"></path><path fill="#616365" d="M-251.1,779.4h-3.6V777l0,0c-0.5,1-1.3,1.8-2.3,2.1c-1,0.5-2.1,0.8-3.1,0.8c-1.3,0-2.6-0.3-3.6-0.8 c-1-0.5-1.8-1.3-2.6-2.1c-0.8-0.8-1.3-1.8-1.5-2.8c-0.3-1.3-0.5-2.3-0.5-3.6s0.3-2.8,0.5-4.1c0.5-1,1-2.1,1.8-2.8 c0.5-0.8,1.5-1.3,2.3-1.5c1-0.3,1.8-0.5,2.8-0.5c0.5,0,1,0,1.5,0.3c0.5,0,1,0.3,1.5,0.5l1.5,0.8c0.5,0.3,0.8,0.8,1,1.3l0,0v-8.8 h3.9v23.7H-251.1L-251.1,779.4z M-264.5,770.8c0,0.8,0,1.3,0.3,2.1c0.3,0.5,0.5,1.3,0.8,1.8c0.5,0.5,1,1,1.5,1.3s1.3,0.5,2.1,0.5 s1.5-0.3,2.3-0.5c0.5-0.3,1-0.8,1.5-1.3c0.5-0.5,0.8-1.3,0.8-2.1c0-0.8,0.3-1.5,0.3-2.3c0-1.5-0.5-3.1-1.3-4.4 c-0.8-1-2.3-1.5-3.6-1.5c-0.8,0-1.5,0.3-2.3,0.5c-0.5,0.3-1.3,1-1.5,1.5c-0.5,0.5-0.8,1.3-0.8,2.1V770.8L-264.5,770.8z"></path><path fill="#616365" d="M-237.2,755.4h4.1v10.8l10.6-10.8h5.2l-9.5,9.5l10.3,14.4h-5.2l-7.7-11.3l-3.4,3.4v8h-4.1v-24 L-237.2,755.4L-237.2,755.4z"></path><path fill="#616365" d="M-214.2,755.4h3.9v3.6h-3.9V755.4z M-214.2,762.1h3.9v17.3h-3.9V762.1z"></path><path fill="#616365" d="M-190,779.4h-3.6V777l0,0c-0.5,1-1.3,1.8-2.3,2.1c-1,0.5-2.1,0.8-3.1,0.8c-1.3,0-2.6-0.3-3.6-0.8 c-1-0.5-1.8-1.3-2.6-2.1c-0.8-0.8-1.3-1.8-1.5-2.8c-0.3-1.3-0.5-2.3-0.5-3.6s0.3-2.8,0.5-4.1c0.5-1,1-2.1,1.8-2.8 c0.5-0.8,1.5-1.3,2.3-1.5c1-0.3,1.8-0.5,2.8-0.5c0.5,0,1,0,1.5,0.3c0.5,0,1,0.3,1.5,0.5l1.5,0.8c0.5,0.3,0.8,0.8,1,1.3l0,0v-8.8 h3.9v23.7H-190L-190,779.4z M-203.4,770.8c0,0.8,0,1.3,0.3,2.1c0.3,0.5,0.5,1.3,0.8,1.8c0.5,0.5,1,1,1.5,1.3 c0.5,0.3,1.3,0.5,2.1,0.5c0.8,0,1.5-0.3,2.3-0.5c0.5-0.3,1-0.8,1.5-1.3c0.5-0.5,0.8-1.3,0.8-2.1c0-0.8,0.3-1.5,0.3-2.3 c0-1.5-0.5-3.1-1.3-4.4c-0.8-1-2.3-1.5-3.6-1.5c-0.8,0-1.5,0.3-2.3,0.5c-0.5,0.3-1.3,1-1.5,1.5c-0.5,0.5-0.8,1.3-0.8,2.1V770.8z"></path><path fill="#616365" d="M-185.9,762.1h3.6v2.6l0,0c0.5-1,1.3-1.8,2.3-2.3c1-0.5,2.1-0.8,3.1-0.8c2.8-0.3,5.7,1.8,5.9,4.9 c0,0.3,0,0.8,0,1v11.9h-3.9v-10.8c0-1-0.3-2.1-0.8-3.1c-0.5-0.8-1.5-1.3-2.6-1c-0.5,0-1.3,0-1.8,0.3c-0.5,0.3-1,0.5-1.3,1 c-0.3,0.5-0.5,1-0.8,1.5c-0.3,0.5-0.3,1.3-0.3,1.8v10.3h-3.9v-17.3L-185.9,762.1L-185.9,762.1z"></path><path fill="#616365" d="M-163.7,771.6c0,0.8,0,1.3,0.3,2.1c0.3,0.5,0.5,1,0.8,1.5c0.3,0.5,1,1,1.5,1c0.5,0.3,1.3,0.5,2.1,0.5 c1,0,1.8-0.3,2.6-0.8c0.8-0.5,1.3-1.3,1.5-2.1h3.6c-0.3,1-0.5,1.8-1,2.6c-0.5,0.8-1,1.3-1.8,1.8c-0.8,0.5-1.5,0.8-2.3,1 c-0.8,0.3-1.8,0.3-2.6,0.3c-1.3,0-2.6-0.3-3.6-0.8c-1-0.3-1.8-1-2.6-1.8c-0.8-0.8-1.3-1.8-1.5-2.8c-0.3-1.3-0.5-2.3-0.5-3.6 s0.3-2.3,0.5-3.6c0.5-1,1-1.8,1.5-2.8c0.8-0.8,1.5-1.5,2.6-2.1c1-0.5,2.3-0.8,3.6-0.8c1.3,0,2.6,0.3,3.6,0.8 c1,0.5,2.1,1.3,2.6,2.3c0.8,1,1.3,2.1,1.5,3.4c0.3,1.3,0.5,2.6,0.3,3.9L-163.7,771.6L-163.7,771.6z M-154.7,769 c0-0.5-0.3-1.3-0.3-1.8l-0.8-1.5c-0.3-0.5-0.8-0.8-1.3-1c-1.3-0.3-2.3-0.3-3.6,0c-0.5,0.3-1,0.5-1.3,1c-0.5,0.5-0.8,1-1,1.5 c-0.3,0.5-0.3,1.3-0.3,1.8H-154.7z"></path><path fill="#616365" d="M-150,762.1h4.1l4.6,12.9l0,0l4.4-12.9h3.9l-6.7,18.3c-0.3,0.8-0.5,1.5-1,2.3c-0.3,0.5-0.5,1.3-1,1.8 c-0.5,0.5-1,1-1.5,1.3c-0.8,0.3-1.8,0.5-2.6,0.5c-0.8,0-1.8,0-2.6-0.3V783c0.3,0,0.8,0,1,0.3s0.8,0.3,1,0c0.3,0,0.8,0,1-0.3 c0.3,0,0.5-0.3,0.8-0.5c0.3-0.3,0.3-0.5,0.5-0.8s0.3-0.8,0.3-1l0.5-1.3L-150,762.1z"></path><path fill="#616365" d="M-120.6,755.4h9.8c1.5,0,3.4,0.3,4.6,1c1.3,0.5,2.3,1.5,3.4,2.6c1,1,1.5,2.3,1.8,3.9 c0.5,1.5,0.5,3.1,0.5,4.6s-0.3,3.1-0.5,4.6c-0.5,1.3-1,2.6-1.8,3.9c-0.8,1-2.1,2.1-3.4,2.6c-1.5,0.5-3.1,1-4.6,1h-9.8V755.4 L-120.6,755.4z M-116.5,776h4.1c1.3,0,2.8-0.3,4.1-0.8c1-0.3,1.8-1,2.3-1.8s1-1.8,1.3-2.8c0.3-2.3,0.3-4.4,0-6.7 c-0.3-1-0.5-2.1-1.3-2.8c-0.5-0.8-1.3-1.5-2.3-1.8c-1.3-0.5-2.8-0.8-4.1-0.8h-4.1V776L-116.5,776z"></path><path fill="#616365" d="M-96.9,755.4h3.9v3.6h-3.9V755.4z M-96.9,762.1h3.9v17.3h-3.9V762.1z"></path><path fill="#616365" d="M-86,773.7c0,1,0.5,1.8,1.3,2.3c0.8,0.5,1.5,0.8,2.6,0.8h1.3c0.5,0,0.8-0.3,1.3-0.3c0.5,0,0.8-0.3,1-0.8 c0.3-0.5,0.3-0.8,0.3-1.3c0-0.5-0.3-1-0.5-1.3c-0.5-0.3-0.8-0.5-1.3-0.8s-1.3-0.3-1.8-0.5c-0.8-0.3-1.3-0.3-2.1-0.5 c-0.8-0.3-1.3-0.3-2.1-0.5c-0.8-0.3-1.3-0.5-1.8-1c-0.5-0.3-1-0.8-1.3-1.5c-0.3-0.8-0.5-1.5-0.5-2.3c0-0.8,0.3-1.8,0.8-2.3 c0.5-0.5,1-1,1.8-1.5c0.8-0.5,1.5-0.8,2.3-0.8c1.8-0.3,3.4-0.3,5.2,0c0.8,0.3,1.5,0.5,2.3,1c0.5,0.3,1.3,1,1.5,1.5 c0.5,0.8,0.8,1.5,0.8,2.6h-3.9c0-0.8-0.5-1.5-1.3-1.8c-0.8-0.3-1.5-0.5-2.3-0.5h-1c-0.3,0-0.8,0-1,0.3c-0.3,0-0.5,0.3-0.8,0.5 c-0.3,0.3-0.3,0.8-0.3,1c0,0.5,0.3,0.8,0.5,1c0.5,0.3,0.8,0.5,1.3,0.8s1.3,0.3,1.8,0.5c0.8,0.3,1.3,0.3,2.1,0.5 c0.8,0.3,1.3,0.3,2.1,0.5c0.8,0.3,1.3,0.5,1.8,1c0.5,0.3,1,0.8,1.3,1.5c0.3,0.5,0.5,1.3,0.5,2.1c0,1-0.3,1.8-0.8,2.6 c-0.5,0.8-1,1.3-1.8,1.8c-0.8,0.5-1.5,0.8-2.6,1c-1,0.3-1.8,0.3-2.8,0.3c-1,0-2.1,0-3.1-0.3c-0.8-0.3-1.5-0.5-2.3-1 c-0.8-0.5-1.3-1-1.5-1.8c-0.5-0.8-0.5-1.8-0.5-2.6h3.6L-86,773.7L-86,773.7z"></path><path fill="#616365" d="M-68.2,771.6c0,0.8,0,1.3,0.3,2.1c0.3,0.5,0.5,1,0.8,1.5c0.3,0.5,1,1,1.5,1c0.5,0.3,1.3,0.5,2.1,0.5 c1,0,1.8-0.3,2.6-0.8c0.8-0.5,1.3-1.3,1.5-2.1h3.6c-0.3,1-0.5,1.8-1,2.6c-0.5,0.8-1,1.3-1.8,1.8c-0.8,0.5-1.5,0.8-2.3,1 c-0.8,0.3-1.8,0.3-2.6,0.3c-1.3,0-2.6-0.3-3.6-0.8c-1-0.3-1.8-1-2.6-1.8c-0.8-0.8-1.3-1.8-1.5-2.8c-0.3-1.3-0.5-2.3-0.5-3.6 s0.3-2.3,0.5-3.6c0.5-1,1-1.8,1.5-2.8c0.8-0.8,1.5-1.5,2.6-2.1c1-0.5,2.3-0.8,3.6-0.8s2.6,0.3,3.6,0.8c1,0.5,2.1,1.3,2.6,2.3 c0.8,1,1.3,2.1,1.5,3.4c0.3,1.3,0.5,2.6,0.3,3.9L-68.2,771.6L-68.2,771.6z M-59.5,769c0-0.5-0.3-1.3-0.3-1.8l-0.8-1.5 c-0.3-0.5-0.8-0.8-1.3-1c-1.3-0.3-2.3-0.3-3.6,0c-0.5,0.3-1,0.5-1.3,1c-0.5,0.5-0.8,1-1,1.5c-0.3,0.5-0.3,1.3-0.5,1.8H-59.5z"></path><path fill="#616365" d="M-38.1,775.5c0,0.3,0,0.8,0.3,1c0.3,0.3,0.5,0.3,0.8,0.3h1v2.6c-0.3,0-0.5,0-0.5,0.3c-0.3,0-0.5,0-0.8,0.3 c-0.3,0-0.5,0-0.8,0h-0.5c-0.8,0-1.5-0.3-2.1-0.5c-0.5-0.3-1-1-1-1.5c-0.8,0.8-1.8,1.3-2.8,1.5s-2.1,0.5-3.1,0.5 c-0.8,0-1.5,0-2.3-0.3c-0.8-0.3-1.3-0.5-1.8-1s-1-1-1.3-1.5c-0.3-0.8-0.5-1.5-0.5-2.3c0-0.8,0.3-1.8,0.5-2.6 c0.3-0.5,1-1.3,1.5-1.5c0.5-0.5,1.3-0.8,2.1-0.8c0.8-0.3,1.5-0.3,2.3-0.5c0.8-0.3,1.3-0.3,2.1-0.3c0.5,0,1.3-0.3,1.5-0.3 c0.3,0,0.8-0.3,1-0.5c0.3-0.3,0.5-0.8,0.5-1.3c0-0.5,0-0.8-0.3-1.3l-0.8-0.8c-0.3-0.3-0.8-0.3-1-0.3h-1.3c-1,0-1.8,0.3-2.6,0.8 c-0.8,0.5-1.3,1.3-1.3,2.1H-53c0-1,0.3-2.1,0.8-2.8c0.5-0.8,1-1.3,1.8-1.8c0.8-0.5,1.5-0.8,2.6-1c1-0.3,1.8-0.3,2.8-0.3 c0.8,0,1.8,0,2.6,0.3l2.3,0.8c0.5,0.3,1.3,1,1.5,1.5c0.5,0.8,0.8,1.5,0.5,2.3V775.5L-38.1,775.5z M-41.9,770.6 c-0.8,0.3-1.3,0.5-2.1,0.8c-0.8,0-1.8,0.3-2.6,0.3c-0.8,0-0.8,0.3-1.3,0.3s-0.8,0.3-1,0.5l-0.8,0.8c-0.3,0.5-0.3,0.8-0.3,1.3 c0,0.3,0,0.8,0.3,1l0.8,0.8c0.3,0.3,0.8,0.3,1,0.3h1c0.5,0,0.8,0,1.3-0.3c0.5,0,1-0.3,1.3-0.5c0.5-0.3,0.8-0.5,1-1 c0.3-0.5,0.5-1,0.5-1.5v-2.6L-41.9,770.6L-41.9,770.6z"></path><path fill="#616365" d="M-31.1,773.7c0,1,0.5,1.8,1.3,2.3c0.8,0.5,1.5,0.8,2.6,0.8h1.3c0.5,0,0.8-0.3,1.3-0.3s0.8-0.3,1-0.8 c0.3-0.5,0.3-0.8,0.3-1.3c0-0.5-0.3-1-0.5-1.3c-0.5-0.3-0.8-0.5-1.3-0.8s-1.3-0.3-1.8-0.5c-0.8-0.3-1.3-0.3-2.1-0.5 c-0.8-0.3-1.3-0.3-2.1-0.5c-0.8-0.3-1.3-0.5-1.8-1c-0.5-0.3-1-0.8-1.3-1.5c-0.3-0.8-0.5-1.5-0.5-2.3c0-0.8,0.3-1.8,0.8-2.3 c0.5-0.5,1-1,1.8-1.5c0.8-0.5,1.5-0.8,2.3-0.8c1.8-0.3,3.4-0.3,5.2,0c0.8,0.3,1.5,0.5,2.3,1c0.5,0.3,1.3,1,1.5,1.5 c0.5,0.8,0.8,1.5,0.8,2.6h-3.9c0-0.8-0.5-1.5-1.3-1.8c-0.8-0.3-1.5-0.5-2.3-0.5h-1c-0.3,0-0.8,0-1,0.3c-0.3,0-0.5,0.3-0.8,0.5 c-0.3,0.3-0.3,0.8-0.3,1c0,0.5,0.3,0.8,0.5,1c0.5,0.3,0.8,0.5,1.3,0.8c0.5,0.3,1.3,0.3,1.8,0.5c0.8,0.3,1.3,0.3,2.1,0.5 c0.8,0.3,1.3,0.3,2.1,0.5c0.8,0.3,1.3,0.5,1.8,1c0.5,0.3,1,0.8,1.3,1.5c0.3,0.5,0.5,1.3,0.5,2.1c0,1-0.3,1.8-0.8,2.6 c-0.5,0.8-1,1.3-1.8,1.8c-0.8,0.5-1.5,0.8-2.6,1c-1,0.3-1.8,0.3-2.8,0.3s-2.1,0-3.1-0.3c-0.8-0.3-1.5-0.5-2.3-1 c-0.8-0.5-1.3-1-1.5-1.8c-0.5-0.8-0.5-1.8-0.5-2.6h3.6L-31.1,773.7L-31.1,773.7z"></path><path fill="#616365" d="M-13.6,771.6c0,0.8,0,1.3,0.3,2.1c0.3,0.5,0.5,1,0.8,1.5c0.3,0.5,1,1,1.5,1c0.5,0.3,1.3,0.5,2.1,0.5 c1,0,1.8-0.3,2.6-0.8c0.8-0.5,1.3-1.3,1.5-2.1h3.6c-0.3,1-0.5,1.8-1,2.6c-0.5,0.8-1,1.3-1.8,1.8c-0.8,0.5-1.5,0.8-2.3,1 c-0.8,0.3-1.8,0.3-2.6,0.3c-1.3,0-2.6-0.3-3.6-0.8c-1-0.3-1.8-1-2.6-1.8c-0.8-0.8-1.3-1.8-1.5-2.8c-0.3-1.3-0.5-2.3-0.5-3.6 s0.3-2.3,0.5-3.6c0.5-1,1-1.8,1.5-2.8c0.8-0.8,1.5-1.5,2.6-2.1c1-0.5,2.3-0.8,3.6-0.8s2.6,0.3,3.6,0.8c1,0.5,2.1,1.3,2.6,2.3 c0.8,1,1.3,2.1,1.5,3.4c0.3,1.3,0.5,2.6,0.3,3.9L-13.6,771.6L-13.6,771.6z M-4.8,769c0-0.5-0.3-1.3-0.3-1.8l-0.8-1.5 c-0.3-0.5-0.8-0.8-1.3-1c-1.3-0.3-2.3-0.3-3.6,0c-0.5,0.3-1,0.5-1.3,1c-0.5,0.5-0.8,1-1,1.5c-0.3,0.5-0.3,1.3-0.5,1.8H-4.8z"></path><path fill="#616365" d="M5,773.7c0,1,0.5,1.8,1.3,2.3c0.8,0.5,1.5,0.8,2.6,0.8h1.3c0.5,0,0.8-0.3,1.3-0.3c0.5,0,0.8-0.3,1-0.8 c0.3-0.5,0.3-0.8,0.3-1.3c0-0.5-0.3-1-0.5-1.3c-0.5-0.3-0.8-0.5-1.3-0.8s-1.3-0.3-1.8-0.5c-0.8-0.3-1.3-0.3-2.1-0.5 c-0.8-0.3-1.3-0.3-2.1-0.5c-0.8-0.3-1.3-0.5-1.8-1c-0.5-0.3-1-0.8-1.3-1.5c-0.3-0.8-0.5-1.5-0.5-2.3c0-0.8,0.3-1.8,0.8-2.3 c0.5-0.5,1-1,1.8-1.5c0.8-0.5,1.5-0.8,2.3-0.8c1.8-0.3,3.4-0.3,5.2,0c0.8,0.3,1.5,0.5,2.3,1c0.5,0.3,1.3,1,1.5,1.5 c0.5,0.8,0.8,1.5,0.8,2.6h-3.9c0-0.8-0.5-1.5-1.3-1.8c-0.8-0.3-1.5-0.5-2.3-0.5h-1c-0.3,0-0.8,0-1,0.3c-0.3,0-0.5,0.3-0.8,0.5 c-0.3,0.3-0.3,0.8-0.3,1c0,0.5,0.3,0.8,0.5,1c0.5,0.3,0.8,0.5,1.3,0.8s1.3,0.3,1.8,0.5c0.8,0.3,1.3,0.3,2.1,0.5 c0.8,0.3,1.3,0.3,2.1,0.5c0.8,0.3,1.3,0.5,1.8,1c0.5,0.3,1,0.8,1.3,1.5c0.3,0.5,0.5,1.3,0.5,2.1c0,1-0.3,1.8-0.8,2.6 c-0.5,0.8-1,1.3-1.8,1.8c-0.8,0.5-1.5,0.8-2.6,1c-1,0.3-1.8,0.3-2.8,0.3s-2.1,0-3.1-0.3c-0.8-0.3-1.5-0.5-2.3-1 c-0.8-0.5-1.3-1-1.5-1.8c-0.5-0.8-0.5-1.8-0.5-2.6H5L5,773.7L5,773.7z"></path></g></g></svg></div></a></div><div class="PageHeader_searchContent__5k0zQ col"><input name="query" type="text" placeholder="Search the Website..." value=""/><button aria-label="" class="Button_button__OFOdO Button_auto__peQWd Button_primary__WTwSy a a-primary"><svg xmlns="http://www.w3.org/2000/svg" width="23" height="23" fill="currentColor" class="bi bi-search" viewBox="0 0 16 16"><path d="M11.742 10.344a6.5 6.5 0 1 0-1.397 1.398h-.001c.03.04.062.078.098.115l3.85 3.85a1 1 0 0 0 1.415-1.414l-3.85-3.85a1.007 1.007 0 0 0-.115-.1zM12 6.5a5.5 5.5 0 1 1-11 0 5.5 5.5 0 0 1 11 0z"></path></svg></button></div></div><div class="NavBar_stickyContainer___XV6p"><div class="NavBar_headerContainer__KSr1m row"><div class="NavBar_content__GxtKX col"><a href="/home">NIDDK Central Repository</a></div><div class="NavBar_content__GxtKX col"><a href="/user/login"><button aria-label="Sign In / Register" class="Button_button__OFOdO Button_auto__peQWd Button_login__gkznn a a-primary">Sign In / Register</button></a></div></div><nav class="NavBar_NavigationBar__3wGqF navbar navbar-expand navbar-light"><button aria-controls="navbar-collapse" type="button" aria-label="Toggle navigation" class="NavBar_toggle__rY7gT navbar-toggler collapsed"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 16 16" width="30" height="30" fill="white" class="bi bi-list"><path fill-rule="evenodd" d="M2.5 12a.5.5 0 0 1 .5-.5h10a.5.5 0 0 1 0 1H3a.5.5 0 0 1-.5-.5m0-4a.5.5 0 0 1 .5-.5h10a.5.5 0 0 1 0 1H3a.5.5 0 0 1-.5-.5m0-4a.5.5 0 0 1 .5-.5h10a.5.5 0 0 1 0 1H3a.5.5 0 0 1-.5-.5"></path></svg></button><div class="NavBar_collapse__Ki_F1 navbar-collapse collapse" id="navbar-collapse"><div class="NavBar_navItem__ePCO5 dropdown nav-item"><a id="react-aria-:R9ssm:" aria-expanded="false" role="button" class="NavBar_dropdownToggle__8BR17 dropdown-toggle nav-link" tabindex="0" href="#"><div>Repository Resources<svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 16 16" width="1em" height="1em" fill="currentColor" class="bi bi-caret-down-fill"><path d="M7.247 11.14 2.451 5.658C1.885 5.013 2.345 4 3.204 4h9.592a1 1 0 0 1 .753 1.659l-4.796 5.48a1 1 0 0 1-1.506 0z"></path></svg></div></a></div><div class="NavBar_navItem__ePCO5 dropdown nav-item"><a id="react-aria-:Rassm:" aria-expanded="false" role="button" class="NavBar_dropdownToggle__8BR17 dropdown-toggle nav-link" tabindex="0" href="#"><div>Helpful Information<svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 16 16" width="1em" height="1em" fill="currentColor" class="bi bi-caret-down-fill"><path d="M7.247 11.14 2.451 5.658C1.885 5.013 2.345 4 3.204 4h9.592a1 1 0 0 1 .753 1.659l-4.796 5.48a1 1 0 0 1-1.506 0z"></path></svg></div></a></div><div class="NavBar_navItem__ePCO5 dropdown nav-item"><a id="react-aria-:Rbssm:" aria-expanded="false" role="button" class="NavBar_dropdownToggle__8BR17 dropdown-toggle nav-link" tabindex="0" href="#"><div>Requests<svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 16 16" width="1em" height="1em" fill="currentColor" class="bi bi-caret-down-fill"><path d="M7.247 11.14 2.451 5.658C1.885 5.013 2.345 4 3.204 4h9.592a1 1 0 0 1 .753 1.659l-4.796 5.48a1 1 0 0 1-1.506 0z"></path></svg></div></a></div><div class="NavBar_navItem__ePCO5 dropdown nav-item"><a id="react-aria-:Rcssm:" aria-expanded="false" role="button" class="NavBar_dropdownToggle__8BR17 dropdown-toggle nav-link" tabindex="0" href="#"><div>About NIDDK-CR<svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 16 16" width="1em" height="1em" fill="currentColor" class="bi bi-caret-down-fill"><path d="M7.247 11.14 2.451 5.658C1.885 5.013 2.345 4 3.204 4h9.592a1 1 0 0 1 .753 1.659l-4.796 5.48a1 1 0 0 1-1.506 0z"></path></svg></div></a></div></div></nav></div><div class="SideWidget_widgetContainer__LeQ_n"><button type="button" aria-label="Feedbaack" class="SideWidget_widget__QowIW SideWidget_primary__UBfd4 a a-primary"><div class="SideWidget_labelContainer__8_LUg"><div class="SideWidget_label__KPvJW">Feedbaack</div><div></div></div></button><div class="SideWidget_popup__iq0K3" style="display:none"><button class="SideWidget_popupClose__iAsPl"><svg width="20" height="20" viewBox="-6 -6 24 24" fill="none" xmlns="http://www.w3.org/2000/svg"><path d="M11 1L1 11" stroke="currentColor" stroke-width="2" stroke-miterlimit="10"></path><path d="M11 11L1 1" stroke="currentColor" stroke-width="2" stroke-miterlimit="10"></path></svg></button><p>NIDDK looks forward to getting feedback from NIDDK-CR R4R users. Contact the Repository below.</p><hr/><a href="/contact"><button class="SideWidget_popupButton__5NnXW">Submit Feedback <svg width="9" height="15" viewBox="0 0 9 15" fill="none" xmlns="http://www.w3.org/2000/svg"><path d="M1 14L7 7.58025L0.999999 1" stroke="currentColor" stroke-width="2"></path></svg></button></a></div></div><div style="position:relative;overflow:hidden;width:100%" class="Homepage_heroParallax__4pdSR"></div><div class="Homepage_Container__OKNxQ undefined container"><div class="row"><div class="Homepage_faqContainer__Z1uRx"><div class="Homepage_faqLabel___lvj8">New to NIDDK-CR R4R?</div><a class="Homepage_faqAction__nYbRd" href="/faq"><div>Access the Frequently Asked Questions <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 16 16" width="1em" height="1em" fill="currentColor" class="bi bi-arrow-right"><path fill-rule="evenodd" d="M1 8a.5.5 0 0 1 .5-.5h11.793l-3.147-3.146a.5.5 0 0 1 .708-.708l4 4a.5.5 0 0 1 0 .708l-4 4a.5.5 0 0 1-.708-.708L13.293 8.5H1.5A.5.5 0 0 1 1 8"></path></svg></div></a></div></div></div><div class="Homepage_customRow__aDQjF Homepage_highchartsContainer__Ee7_g row"><div class="HighchartsCharts_cardCol__RKZpH Card_info__ZXlh_ card"><div style="background-image:url(/images/Pattern5.png);background-color:#29796f" class="undefined Card_infoHeader__gjqLK card-header"><span>Studies by NIDDK Research Area</span></div><div class="undefined Card_chartBody__GVNRg card-body"><div></div></div></div><div class="HighchartsCharts_cardCol__RKZpH Card_info__ZXlh_ card"><div style="background-image:url(/images/Pattern5.png);background-color:#60427f" class="undefined Card_infoHeader__gjqLK card-header"><span>Studies by NIDDK Division</span></div><div class="undefined Card_chartBody__GVNRg card-body"><div></div></div></div><div class="HighchartsCharts_cardCol__RKZpH Card_info__ZXlh_ card"><div style="background-image:url(/images/Pattern5.png)" class="undefined Card_infoHeader__gjqLK card-header"><span>Specimens by Type</span></div><div class="undefined Card_chartBody__GVNRg card-body"><div></div></div></div></div><div class="Homepage_customRow__aDQjF row"><div class="Homepage_section__8bgMd col"><div class="Homepage_resources__HF8Wb"><div class="Homepage_resourcesHeader__2jb6w"><h2>Looking to request resources?</h2>Start by clicking on a request button or watch our <a href="/pages/instructional_materials">Request Tutorial</a> to learn more.</div><div class="Homepage_blogCardContainer__tlHUU Homepage_centered__EZSm8"><div class="Homepage_centered__EZSm8 col-lg-6"><div class="Homepage_blogCard__7ca_s card"><div class="card-body"><div class="Homepage_blogCardContent__M_Pab"><div><div class="Homepage_studyCount__Ns5H0"><span class="Homepage_dataCount__LS_gd">157</span></div><div class="Homepage_studyHeader__Tq0_I">Studies with data available for request</div><div><div class="Homepage_studyContent__E2Xu_">Apply for access to data from one or more studies in NIDDK-CR.</div><a href="/requests/reuse/data-request"><button aria-label="Start a Data Request" class="Button_button__OFOdO Button_auto__peQWd Button_primary__WTwSy a a-primary">Start a Data Request</button></a></div></div><div class="Homepage_list__OLt_l">Available Data Types:<ul><li>Clinical phenotype data</li><li>Clinical lab tests/results</li><li>Genotype/genetic data</li><li>Survey data</li><li>Biospecimen inventory data</li><li>Qualitative data</li><li>Images</li><li>Continuous glucose monitoring</li></ul></div></div></div></div></div><div class="Homepage_centered__EZSm8 col-lg-6"><div class="Homepage_blogCard__7ca_s undefined card"><div class="card-body"><div class="Homepage_blogCardContent__M_Pab"><div><div class="Homepage_studyCount__Ns5H0"><span class="Homepage_specimenCount__p3wle">102</span></div><div class="Homepage_studyHeader__Tq0_I">Studies with specimens available for request</div><div><div class="Homepage_studyContent__E2Xu_">Apply for access to specimens and data from one or more studies in NIDDK-CR.</div><a href="/requests/biospecimen_type"><button aria-label="Start a Specimen Request" class="Button_button__OFOdO Button_auto__peQWd Button_primary__WTwSy a a-primary">Start a Specimen Request</button></a></div></div><div class="Homepage_list__OLt_l">Available Specimen Types:<ul><li>Fluids</li><li>Biological Macromolecules</li><li>Cells</li><li>Tissue</li></ul></div></div></div></div></div></div><div class="Homepage_statsContainer__yahWn Homepage_centered__EZSm8"><div class="Homepage_stat__0CFhh"><svg width="65" height="80" viewBox="0 0 65 80" fill="none" xmlns="http://www.w3.org/2000/svg"><path d="M7.5625 10.9375C6.62011 10.9375 6.25164 10.1088 6.19495 8.95612C5.98561 4.69963 10.4207 2.00002 14.6823 2.00002L52.125 2.00002C57.6479 2.00002 62.125 6.47718 62.125 12L62.125 65.4687C62.125 69.8954 59.2272 74.3012 54.8006 74.2671C53.4559 74.2568 52.5448 73.9177 52.8114 72.9313C53.1736 71.5913 53.0328 69.6441 52.9129 68.5791C52.8552 68.0669 52.8094 67.5537 52.8055 67.0383L52.4306 17.5473C52.4146 15.4343 51.3969 13.4542 49.6879 12.2114V12.2114C48.5496 11.3835 47.1782 10.9375 45.7706 10.9375L12.5926 10.9375C12.5926 10.9375 12.5926 10.9375 12.5926 10.9375C12.5926 10.9375 9.52688 10.9375 7.5625 10.9375Z" stroke="white" stroke-opacity="0.45" stroke-width="4"></path><rect x="52.5625" y="78" width="50.5625" height="66.9313" rx="8" transform="rotate(-180 52.5625 78)" stroke="white" stroke-width="4"></rect><path d="M34.0002 17.4667C35.1637 16.9381 36.7334 16.625 38.4375 16.625C40.1416 16.625 41.7113 16.9381 42.8748 17.4667C43.9896 17.9737 44.9375 18.7841 44.9375 19.875C44.9375 20.9659 43.9896 21.7763 42.8748 22.2833C41.7113 22.8119 40.1416 23.125 38.4375 23.125C36.7334 23.125 35.1637 22.8119 34.0002 22.2833C32.8854 21.7763 31.9375 20.9659 31.9375 19.875C31.9375 18.7841 32.8854 17.9737 34.0002 17.4667Z" fill="white"></path><path d="M31.9375 22.3125V23.2003C31.9375 24.266 32.8854 25.0575 34.0002 25.5528C35.1637 26.0681 36.7334 26.375 38.4375 26.375C40.1416 26.375 41.7113 26.0692 42.8748 25.5528C43.9896 25.0575 44.9375 24.266 44.9375 23.2003V22.3125C44.4424 22.7697 43.8498 23.1072 43.3233 23.3411C41.9887 23.9337 40.2597 24.2586 38.4375 24.2586C36.6153 24.2586 34.8863 23.9337 33.5517 23.3411C33.0252 23.1083 32.4326 22.7697 31.9375 22.3125Z" fill="white"></path><path d="M31.9375 25.5625V26.4367C31.9375 27.4859 32.8854 28.2653 34.0002 28.7529C35.1637 29.2614 36.7334 29.5625 38.4375 29.5625C40.1416 29.5625 41.7113 29.2614 42.8748 28.7529C43.9896 28.2653 44.9375 27.4859 44.9375 26.4367V25.5625C44.4424 26.0126 43.8498 26.345 43.3233 26.5753C41.9887 27.1587 40.2597 27.4786 38.4375 27.4786C36.6153 27.4786 34.8863 27.1587 33.5517 26.5753C33.0252 26.346 32.4326 26.0126 31.9375 25.5625Z" fill="white"></path><path d="M11.8125 34.4013H15.1875" stroke="white" stroke-opacity="0.45" stroke-width="3" stroke-linecap="round"></path><path d="M11.8125 38.9049H15.1875" stroke="white" stroke-opacity="0.45" stroke-width="3" stroke-linecap="round"></path><path d="M20.25 34.4013H43.875" stroke="white" stroke-opacity="0.45" stroke-width="3" stroke-linecap="round"></path><path d="M20.25 38.9049H43.875" stroke="white" stroke-opacity="0.45" stroke-width="3" stroke-linecap="round"></path><rect x="12.1875" y="45.4714" width="31.3125" height="25.1473" rx="3.5" stroke="white" stroke-width="3"></rect><path d="M11.8125 51.2898H43.875" stroke="white" stroke-width="3" stroke-linecap="round"></path><path d="M12.375 57.4821H43.875" stroke="white" stroke-width="3" stroke-linecap="round"></path><path d="M12.375 64.8004H43.875" stroke="white" stroke-width="3" stroke-linecap="round"></path><path d="M20.8125 45.6603V70.4299" stroke="white" stroke-width="3" stroke-linecap="round"></path></svg><div><div class="Homepage_statNum__8QUqE">5767</div><div class="Homepage_statName__dODIY">Datasets <a tabindex="0"><svg width="15" height="15" viewBox="0 0 15 15" fill="none" xmlns="http://www.w3.org/2000/svg"><circle cx="7.5" cy="7.5" r="7.5" fill="rgba(255, 255, 255, 0.7)"></circle><path d="M6.8437 7.772C6.85303 7.744 6.86236 7.674 6.8717 7.562C6.89036 7.44067 6.8997 7.36133 6.8997 7.324C6.8997 7.25867 6.8857 7.198 6.8577 7.142C6.8297 7.07667 6.77836 7.044 6.7037 7.044C6.61036 7.044 6.48436 7.10933 6.3257 7.24C6.17636 7.36133 6.04103 7.492 5.9197 7.632C5.8077 7.76267 5.74236 7.842 5.7237 7.87C5.67703 7.87 5.63503 7.81867 5.5977 7.716C5.56036 7.61333 5.5417 7.54333 5.5417 7.506C5.5977 7.394 5.70503 7.24933 5.8637 7.072C6.02236 6.89467 6.20436 6.71267 6.4097 6.526C6.61503 6.33933 6.82503 6.18533 7.0397 6.064C7.2637 5.93333 7.46903 5.868 7.6557 5.868C7.92636 5.868 8.1457 5.952 8.3137 6.12C8.49103 6.27867 8.5797 6.51667 8.5797 6.834C8.5797 6.92733 8.56103 7.06733 8.5237 7.254C8.4957 7.44067 8.47236 7.57133 8.4537 7.646L7.9497 10.194C7.94036 10.222 7.92636 10.2967 7.9077 10.418C7.89836 10.53 7.8937 10.6047 7.8937 10.642C7.8937 10.7073 7.9077 10.7727 7.9357 10.838C7.9637 10.9033 8.01036 10.936 8.0757 10.936C8.17836 10.936 8.30436 10.8707 8.4537 10.74C8.60303 10.6093 8.73836 10.4787 8.8597 10.348C8.98103 10.208 9.04636 10.124 9.0557 10.096C9.10236 10.096 9.14436 10.1473 9.1817 10.25C9.21903 10.3527 9.2377 10.4273 9.2377 10.474C9.1817 10.586 9.0697 10.7307 8.9017 10.908C8.74303 11.0853 8.55636 11.2673 8.3417 11.454C8.12703 11.6407 7.9077 11.7993 7.6837 11.93C7.4597 12.0513 7.25436 12.112 7.0677 12.112C6.8437 12.112 6.64303 12.0373 6.4657 11.888C6.2977 11.7293 6.2137 11.4773 6.2137 11.132C6.2137 11.0293 6.2277 10.8847 6.2557 10.698C6.29303 10.502 6.31636 10.376 6.3257 10.32L6.8437 7.772ZM8.2997 2.606C8.53303 2.606 8.72436 2.69 8.8737 2.858C9.02303 3.01667 9.0977 3.21733 9.0977 3.46C9.0977 3.75867 8.99036 4.02933 8.7757 4.272C8.56103 4.50533 8.30903 4.622 8.0197 4.622C7.78636 4.622 7.59503 4.538 7.4457 4.37C7.3057 4.19267 7.2357 3.98733 7.2357 3.754C7.2357 3.45533 7.33836 3.18933 7.5437 2.956C7.75836 2.72267 8.01036 2.606 8.2997 2.606Z" fill="rgba(0, 0, 0, 0.5)"></path></svg></a></div></div></div><div class="Homepage_stat__0CFhh"><svg width="82" height="71" viewBox="0 0 82 71" fill="none" xmlns="http://www.w3.org/2000/svg"><path d="M13.4772 5.92574C11.7786 8.4736 13.4786 11.0215 13.4786 11.0215L32.2562 11.8707L39.8067 20.3636L67.4084 21.6375L72.1726 26.7332L70.0494 43.2943L68.2577 62.4032C72.0795 61.9785 75.4767 61.1292 76.7506 57.7321C77.347 56.1417 79.7231 26.3388 79.7231 23.3361C79.7231 16.9664 73.7781 12.72 68.2577 12.72C64.4359 12.2954 55.1787 11.9557 50.4228 12.2954C45.6668 12.6351 41.9299 6.77502 39.8067 5.07646C37.6835 3.3779 36.4095 3.37789 36.4095 3.37789C31.0307 3.37789 22.821 2.95325 21.1224 2.95325C17.3006 2.95325 15.1758 3.37789 13.4772 5.92574Z" stroke="white" stroke-opacity="0.45" stroke-width="4.5"></path><path d="M2.46898 22.398L2.28195 18.3057C2.28195 15.8107 3.26722 13.4179 5.02101 11.6536C6.7748 9.8894 9.15345 8.89825 11.6337 8.89825H28.8035C31.2835 8.89879 33.6618 9.89028 35.4152 11.6546L39.2868 15.5493C41.0402 17.3137 43.4184 18.3052 45.8985 18.3057H64.5178C65.8173 18.3056 67.1026 18.5779 68.2917 19.1053C69.4807 19.6327 70.5475 20.4036 71.4239 21.3689C72.3003 22.3341 72.967 23.4725 73.3817 24.7115C73.7963 25.9504 73.9498 27.2627 73.8321 28.5646L70.8536 61.4907C70.6425 63.828 69.5704 66.0016 67.848 67.5846C66.1255 69.1676 63.877 70.0458 61.5439 70.0468H13.158C10.8249 70.0458 8.57646 69.1676 6.854 67.5846C5.13154 66.0016 4.05951 63.828 3.84837 61.4907L0.869834 28.5646C0.674556 26.386 1.24003 24.2071 2.46898 22.4027V22.398ZM10.1842 23.0094C9.53463 23.0094 8.8922 23.1455 8.29784 23.4091C7.70348 23.6726 7.17023 24.0579 6.73207 24.5402C6.29391 25.0226 5.96047 25.5915 5.75299 26.2107C5.54551 26.8299 5.46854 27.4858 5.527 28.1365L8.50553 61.0626C8.61052 62.2313 9.14596 63.3183 10.0068 64.1103C10.8675 64.9022 11.9915 65.3419 13.158 65.343H61.5439C62.7105 65.3419 63.8344 64.9022 64.6952 64.1103C65.556 63.3183 66.0915 62.2313 66.1964 61.0626L69.175 28.1365C69.2334 27.4858 69.1565 26.8299 68.949 26.2107C68.7415 25.5915 68.4081 25.0226 67.9699 24.5402C67.5318 24.0579 66.9985 23.6726 66.4041 23.4091C65.8098 23.1455 65.1674 23.0094 64.5178 23.0094H10.1842ZM32.114 14.9802C31.6794 14.5428 31.1632 14.196 30.5952 13.9595C30.0271 13.723 29.4183 13.6015 28.8035 13.602H11.6337C10.4088 13.6018 9.23276 14.085 8.35837 14.9479C7.48398 15.8108 6.98109 16.9844 6.95782 18.2163L6.98588 18.8702C7.99275 18.497 9.05885 18.3089 10.1842 18.3057H35.4152L32.114 14.9802Z" fill="white"></path><rect x="35.7051" y="44.5143" width="25.6133" height="6.06632" rx="2" fill="white"></rect><path d="M36.3809 54.6248L60.6461 54.6248" stroke="white" stroke-opacity="0.45" stroke-width="3" stroke-linecap="round"></path><path d="M36.3809 59.343L60.6461 59.343" stroke="white" stroke-opacity="0.45" stroke-width="3" stroke-linecap="round"></path></svg><div><div class="Homepage_statNum__8QUqE">9750</div><div class="Homepage_statName__dODIY">Documents <a tabindex="0"><svg width="15" height="15" viewBox="0 0 15 15" fill="none" xmlns="http://www.w3.org/2000/svg"><circle cx="7.5" cy="7.5" r="7.5" fill="rgba(255, 255, 255, 0.7)"></circle><path d="M6.8437 7.772C6.85303 7.744 6.86236 7.674 6.8717 7.562C6.89036 7.44067 6.8997 7.36133 6.8997 7.324C6.8997 7.25867 6.8857 7.198 6.8577 7.142C6.8297 7.07667 6.77836 7.044 6.7037 7.044C6.61036 7.044 6.48436 7.10933 6.3257 7.24C6.17636 7.36133 6.04103 7.492 5.9197 7.632C5.8077 7.76267 5.74236 7.842 5.7237 7.87C5.67703 7.87 5.63503 7.81867 5.5977 7.716C5.56036 7.61333 5.5417 7.54333 5.5417 7.506C5.5977 7.394 5.70503 7.24933 5.8637 7.072C6.02236 6.89467 6.20436 6.71267 6.4097 6.526C6.61503 6.33933 6.82503 6.18533 7.0397 6.064C7.2637 5.93333 7.46903 5.868 7.6557 5.868C7.92636 5.868 8.1457 5.952 8.3137 6.12C8.49103 6.27867 8.5797 6.51667 8.5797 6.834C8.5797 6.92733 8.56103 7.06733 8.5237 7.254C8.4957 7.44067 8.47236 7.57133 8.4537 7.646L7.9497 10.194C7.94036 10.222 7.92636 10.2967 7.9077 10.418C7.89836 10.53 7.8937 10.6047 7.8937 10.642C7.8937 10.7073 7.9077 10.7727 7.9357 10.838C7.9637 10.9033 8.01036 10.936 8.0757 10.936C8.17836 10.936 8.30436 10.8707 8.4537 10.74C8.60303 10.6093 8.73836 10.4787 8.8597 10.348C8.98103 10.208 9.04636 10.124 9.0557 10.096C9.10236 10.096 9.14436 10.1473 9.1817 10.25C9.21903 10.3527 9.2377 10.4273 9.2377 10.474C9.1817 10.586 9.0697 10.7307 8.9017 10.908C8.74303 11.0853 8.55636 11.2673 8.3417 11.454C8.12703 11.6407 7.9077 11.7993 7.6837 11.93C7.4597 12.0513 7.25436 12.112 7.0677 12.112C6.8437 12.112 6.64303 12.0373 6.4657 11.888C6.2977 11.7293 6.2137 11.4773 6.2137 11.132C6.2137 11.0293 6.2277 10.8847 6.2557 10.698C6.29303 10.502 6.31636 10.376 6.3257 10.32L6.8437 7.772ZM8.2997 2.606C8.53303 2.606 8.72436 2.69 8.8737 2.858C9.02303 3.01667 9.0977 3.21733 9.0977 3.46C9.0977 3.75867 8.99036 4.02933 8.7757 4.272C8.56103 4.50533 8.30903 4.622 8.0197 4.622C7.78636 4.622 7.59503 4.538 7.4457 4.37C7.3057 4.19267 7.2357 3.98733 7.2357 3.754C7.2357 3.45533 7.33836 3.18933 7.5437 2.956C7.75836 2.72267 8.01036 2.606 8.2997 2.606Z" fill="rgba(0, 0, 0, 0.5)"></path></svg></a></div></div></div><div class="Homepage_stat__0CFhh"><svg width="95" height="68" viewBox="0 0 95 68" fill="none" xmlns="http://www.w3.org/2000/svg"><path d="M15.332 4.25C14.669 4.25 14.0331 4.47388 13.5643 4.8724C13.0954 5.27091 12.832 5.81142 12.832 6.375V19.125C12.832 19.6886 12.5686 20.2291 12.0998 20.6276C11.631 21.0261 10.9951 21.25 10.332 21.25C9.66899 21.25 9.03311 21.0261 8.56426 20.6276C8.09542 20.2291 7.83203 19.6886 7.83203 19.125V6.375C7.83203 4.68425 8.62221 3.06274 10.0287 1.86719C11.4353 0.67165 13.3429 0 15.332 0L30.332 0C30.9951 0 31.631 0.223883 32.0998 0.622398C32.5686 1.02091 32.832 1.56141 32.832 2.125C32.832 2.68859 32.5686 3.22909 32.0998 3.6276C31.631 4.02612 30.9951 4.25 30.332 4.25H15.332ZM62.832 2.125C62.832 1.56141 63.0954 1.02091 63.5643 0.622398C64.0331 0.223883 64.669 0 65.332 0L80.332 0C82.3212 0 84.2288 0.67165 85.6353 1.86719C87.0419 3.06274 87.832 4.68425 87.832 6.375V19.125C87.832 19.6886 87.5686 20.2291 87.0998 20.6276C86.631 21.0261 85.9951 21.25 85.332 21.25C84.669 21.25 84.0331 21.0261 83.5643 20.6276C83.0954 20.2291 82.832 19.6886 82.832 19.125V6.375C82.832 5.81142 82.5686 5.27091 82.0998 4.8724C81.631 4.47388 80.9951 4.25 80.332 4.25H65.332C64.669 4.25 64.0331 4.02612 63.5643 3.6276C63.0954 3.22909 62.832 2.68859 62.832 2.125ZM10.332 46.75C10.9951 46.75 11.631 46.9739 12.0998 47.3724C12.5686 47.7709 12.832 48.3114 12.832 48.875V61.625C12.832 62.1886 13.0954 62.7291 13.5643 63.1276C14.0331 63.5261 14.669 63.75 15.332 63.75H30.332C30.9951 63.75 31.631 63.9739 32.0998 64.3724C32.5686 64.7709 32.832 65.3114 32.832 65.875C32.832 66.4386 32.5686 66.9791 32.0998 67.3776C31.631 67.7761 30.9951 68 30.332 68H15.332C13.3429 68 11.4353 67.3284 10.0287 66.1328C8.62221 64.9373 7.83203 63.3158 7.83203 61.625L7.83203 48.875C7.83203 48.3114 8.09542 47.7709 8.56426 47.3724C9.03311 46.9739 9.66899 46.75 10.332 46.75ZM85.332 46.75C85.9951 46.75 86.631 46.9739 87.0998 47.3724C87.5686 47.7709 87.832 48.3114 87.832 48.875V61.625C87.832 63.3158 87.0419 64.9373 85.6353 66.1328C84.2288 67.3284 82.3212 68 80.332 68H65.332C64.669 68 64.0331 67.7761 63.5643 67.3776C63.0954 66.9791 62.832 66.4386 62.832 65.875C62.832 65.3114 63.0954 64.7709 63.5643 64.3724C64.0331 63.9739 64.669 63.75 65.332 63.75H80.332C80.9951 63.75 81.631 63.5261 82.0998 63.1276C82.5686 62.7291 82.832 62.1886 82.832 61.625V48.875C82.832 48.3114 83.0954 47.7709 83.5643 47.3724C84.0331 46.9739 84.669 46.75 85.332 46.75Z" fill="white"></path><path d="M46.9994 45L39.8319 50.4" stroke="white" stroke-width="3" stroke-linecap="round"></path><path d="M44.6328 28.8L24.6328 22.4" stroke="white" stroke-width="3" stroke-linecap="round"></path><path d="M63.0312 24L66.2312 16.8" stroke="white" stroke-width="3" stroke-linecap="round"></path><path d="M62 45L69 53" stroke="white" stroke-width="3" stroke-linecap="round"></path><path d="M67.9327 35.2C67.9327 36.881 67.9323 37.7574 67.7912 38.3223C67.7345 38.5489 67.6783 38.611 67.6659 38.6244C67.6538 38.6374 67.5891 38.7057 67.3447 38.7841C66.7653 38.9698 65.7338 39.053 63.7701 39.0578C62.9148 39.0599 61.9267 39.0485 60.7714 39.0351C60.647 39.0337 60.5207 39.0322 60.3924 39.0308C59.0769 39.0157 57.565 39 55.8327 39C54.0325 39 52.4695 39.0157 51.1166 39.0308C50.9768 39.0323 50.8394 39.0339 50.7044 39.0354C49.5275 39.0486 48.5263 39.0599 47.6647 39.0578C45.6663 39.053 44.6669 38.9681 44.1334 38.7898C44.0232 38.753 43.9633 38.721 43.9345 38.7029C43.9204 38.694 43.913 38.688 43.9099 38.6853C43.9071 38.6828 43.9061 38.6816 43.9057 38.6812L43.9057 38.6812C43.9053 38.6808 43.9033 38.6783 43.8995 38.6721C43.8956 38.6657 43.8889 38.6535 43.8804 38.6333C43.8626 38.5916 43.8379 38.5184 43.8142 38.3975C43.7638 38.1402 43.7369 37.7744 43.7291 37.2158C43.7245 36.8773 43.7267 36.5189 43.7292 36.1084C43.7309 35.8324 43.7327 35.5328 43.7327 35.2C43.7326 28.5174 49.1501 23.1 55.8327 23.1C62.5154 23.1 67.9327 28.5174 67.9327 35.2Z" fill="white" fill-opacity="0.4" stroke="white" stroke-width="3"></path><path d="M58.2324 28C60.6324 28.5333 61.8324 29.6 63.0324 33.2" stroke="white" stroke-width="3" stroke-linecap="round"></path><circle cx="21.7991" cy="19.5671" r="3.7" transform="rotate(-9.23415 21.7991 19.5671)" fill="white" fill-opacity="0.4" stroke="white" stroke-width="3"></circle><circle cx="67.4324" cy="12.4" r="3.7" fill="white" fill-opacity="0.4" stroke="white" stroke-width="3"></circle><circle cx="71.4324" cy="56.4" r="3.7" fill="white" fill-opacity="0.4" stroke="white" stroke-width="3"></circle><circle cx="37.032" cy="53.2" r="3.7" fill="white" fill-opacity="0.4" stroke="white" stroke-width="3"></circle><path d="M0.0234375 39.069L94.6617 39.069" stroke="white" stroke-width="3"></path><mask id="mask0_1786_1247" style="mask-type:alpha" maskUnits="userSpaceOnUse" x="42" y="29" width="28" height="19"><path d="M43.5009 34.3581C43.5009 32.6771 43.5013 31.8007 43.6424 31.2358C43.699 31.0092 43.7553 30.947 43.7677 30.9337C43.7798 30.9207 43.8445 30.8523 44.0889 30.774C44.6683 30.5882 45.6998 30.505 47.6634 30.5003C48.5188 30.4982 49.5069 30.5096 50.6622 30.5229C50.7866 30.5244 50.9129 30.5258 51.0412 30.5273C52.3567 30.5424 53.8686 30.5581 55.6009 30.5581C57.4011 30.5581 58.9641 30.5424 60.317 30.5273C60.4568 30.5258 60.5942 30.5242 60.7292 30.5227C61.9061 30.5095 62.9073 30.4982 63.7689 30.5003C65.7673 30.5051 66.7667 30.5899 67.3002 30.7682C67.4104 30.8051 67.4703 30.8371 67.4991 30.8552C67.5132 30.8641 67.5206 30.8701 67.5236 30.8728C67.5265 30.8753 67.5275 30.8764 67.5279 30.8769L67.5279 30.8769C67.5283 30.8773 67.5303 30.8798 67.5341 30.886C67.5379 30.8924 67.5447 30.9046 67.5532 30.9248C67.571 30.9665 67.5957 31.0396 67.6194 31.1606C67.6698 31.4179 67.6967 31.7837 67.7045 32.3423C67.7091 32.6808 67.7069 33.0392 67.7044 33.4496C67.7027 33.7257 67.7009 34.0252 67.7009 34.3581C67.701 41.0407 62.2835 46.4581 55.6009 46.4581C48.9182 46.4581 43.5009 41.0407 43.5009 34.3581Z" fill="white" fill-opacity="0.4" stroke="white" stroke-width="3"></path></mask><g mask="url(#mask0_1786_1247)"><rect x="39" y="43" width="34" height="17" fill="white"></rect></g></svg><div><div class="Homepage_statNum__8QUqE">15.8M</div><div class="Homepage_statName__dODIY">Image Files <a tabindex="0"><svg width="15" height="15" viewBox="0 0 15 15" fill="none" xmlns="http://www.w3.org/2000/svg"><circle cx="7.5" cy="7.5" r="7.5" fill="rgba(255, 255, 255, 0.7)"></circle><path d="M6.8437 7.772C6.85303 7.744 6.86236 7.674 6.8717 7.562C6.89036 7.44067 6.8997 7.36133 6.8997 7.324C6.8997 7.25867 6.8857 7.198 6.8577 7.142C6.8297 7.07667 6.77836 7.044 6.7037 7.044C6.61036 7.044 6.48436 7.10933 6.3257 7.24C6.17636 7.36133 6.04103 7.492 5.9197 7.632C5.8077 7.76267 5.74236 7.842 5.7237 7.87C5.67703 7.87 5.63503 7.81867 5.5977 7.716C5.56036 7.61333 5.5417 7.54333 5.5417 7.506C5.5977 7.394 5.70503 7.24933 5.8637 7.072C6.02236 6.89467 6.20436 6.71267 6.4097 6.526C6.61503 6.33933 6.82503 6.18533 7.0397 6.064C7.2637 5.93333 7.46903 5.868 7.6557 5.868C7.92636 5.868 8.1457 5.952 8.3137 6.12C8.49103 6.27867 8.5797 6.51667 8.5797 6.834C8.5797 6.92733 8.56103 7.06733 8.5237 7.254C8.4957 7.44067 8.47236 7.57133 8.4537 7.646L7.9497 10.194C7.94036 10.222 7.92636 10.2967 7.9077 10.418C7.89836 10.53 7.8937 10.6047 7.8937 10.642C7.8937 10.7073 7.9077 10.7727 7.9357 10.838C7.9637 10.9033 8.01036 10.936 8.0757 10.936C8.17836 10.936 8.30436 10.8707 8.4537 10.74C8.60303 10.6093 8.73836 10.4787 8.8597 10.348C8.98103 10.208 9.04636 10.124 9.0557 10.096C9.10236 10.096 9.14436 10.1473 9.1817 10.25C9.21903 10.3527 9.2377 10.4273 9.2377 10.474C9.1817 10.586 9.0697 10.7307 8.9017 10.908C8.74303 11.0853 8.55636 11.2673 8.3417 11.454C8.12703 11.6407 7.9077 11.7993 7.6837 11.93C7.4597 12.0513 7.25436 12.112 7.0677 12.112C6.8437 12.112 6.64303 12.0373 6.4657 11.888C6.2977 11.7293 6.2137 11.4773 6.2137 11.132C6.2137 11.0293 6.2277 10.8847 6.2557 10.698C6.29303 10.502 6.31636 10.376 6.3257 10.32L6.8437 7.772ZM8.2997 2.606C8.53303 2.606 8.72436 2.69 8.8737 2.858C9.02303 3.01667 9.0977 3.21733 9.0977 3.46C9.0977 3.75867 8.99036 4.02933 8.7757 4.272C8.56103 4.50533 8.30903 4.622 8.0197 4.622C7.78636 4.622 7.59503 4.538 7.4457 4.37C7.3057 4.19267 7.2357 3.98733 7.2357 3.754C7.2357 3.45533 7.33836 3.18933 7.5437 2.956C7.75836 2.72267 8.01036 2.606 8.2997 2.606Z" fill="rgba(0, 0, 0, 0.5)"></path></svg></a></div></div></div></div></div></div></div><div class="Homepage_Container__OKNxQ container"><div class="Homepage_Row__XOEs_ row"><div class="col-lg-12 col-md-12"><div class="Homepage_infoCard__mQtAX Card_info__ZXlh_ card"><div style="background-image:url(/images/Pattern5.png)" class="undefined Card_infoHeader__gjqLK card-header"><span>Featured News</span></div><div class="undefined Card_infoBody__XzyL8 Card_scrollable__BMLpI card-body" style="height:200px"><div><h6><a href="/news/269">New Features and Enhancements Coming to NIDDK-CR: A Smarter, Sleeker Experience!</a></h6><div>We’re thrilled to announce exciting system upgrades to the NIDDK-CR platform! Get ready for dynamic new features and functionalities, including interactive graphs, comprehensive study information pages, advanced file exploration tools, and next-level search experience. These enhancements are designed with users in mind to make locating and accessin. . . </div></div><div><h6><a href="/news/268">Coming Soon! NIH Data Sharing Index (S-index) Challenge</a></h6><div>The S-index challenge, <a rel="noopener noreferrer" href="https://www.nei.nih.gov/about/news-and-events/news/nei-launches-challenge-promote-data-sharing">led by the National Eye Institute (NEI)</a>, aims to incentivize and reward data sharing by promoting a new metric, the S-index, that will assess how effectively researchers sh. . . </div></div><div><h6><a href="/news/260">2024 DataWorks! Prize Challenge – Phase 1 now open!</a></h6><div>The Federation of American Societies for Experimental Biology (FASEB) and the National Institutes of Health (NIH) partnered together to host the 2024 DataWorks! Prize. This challenge is a collaboration with the seven generalist repositories participating in the NIH-funded Generalist Repositories Ecosystem Initiative (GREI) and will focus on best pr. . . </div></div><div><h6><a href="/news/247">Winners of the Data Centric Challenge presented their winning solution at the May 10th ODSS Data Sharing and Reuse Seminar – Recording Available</a></h6><div>Winners of the Intermediate/Advanced-level Data Centric Challenge, Dr. Ali Loveys and Fiona Meng from FI Consulting, presented Laying the Foundation for AI-Ready Data at the ODSS Data Sharing and Reuse Seminar on May 10, 2024. The FI Consulting team successfully consolidated and unified multiple TrialNet data sets and identified data outliers, then. . . </div></div><div><h6><a href="/news/243">New NIDDK Central Repository Policy Released!</a></h6><div>NIDDK Central Repository (NIDDK-CR) has released a revised policy that aligns with the NIH Data Management and Sharing (DMS) policy and NIDDK DMS Guidance: <a href="https://grants.nih.gov/grants/guide/notice-files/NOT-DK-24-003.html">https://grants.nih.gov/grants/guide/notice-files/NOT-DK-24-003.html</a>. More details and complete . . . </div></div><div><h6><a href="/news/241">NIDDK Central Repository Data Centric Challenge – Winners Announced!</a></h6><div>In September 2023, the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Central Repository announced the Data Centric Challenge aimed at enhancing NIDDK datasets for future artificial intelligence (AI) applications. Challenge participants were tasked to generate an AI-ready dataset that can be used for future data challenges. . . </div></div><div><h6><a href="/news/216">Ready for use: Study Digital Object Identifiers (DOIs) and citations to increase research visibility</a></h6><div>DOIs are now available for every NIDDK-CR R4R study! DOIs increase resource visibility and accessibility and enable appropriate credit citation and interoperability. Researchers are encouraged to use them when making public releases using NIDDK-CR R4R resources. A study’s DOI can be found at the top of the study’s overview page along with citation . . . </div></div><div><h6><a href="/news/215">NIH’s New Data Management and Sharing Policy is in effect!</a></h6><div>As of January 25, 2023, the <a rel="noopener noreferrer" href="https://grants.nih.gov/grants/guide/notice-files/NOT-OD-21-013.html">NIH Policy for Data Management and Sharing</a> (DMS) is in effect. All research that is funded in whole or in part by NIH is required to submit a DMS plan outlining how scientific data and accompanying . . . </div></div><div><h6><a href="/news/217">Updates to the NIDDK-CR Resources for Research (R4R) biospecimen request process are coming soon</a></h6><div>This revamped, streamlined process for requesting biospecimens incorporates user feedback to better facilitate access to biospecimens. Certain requests will still require an X01 Resource Access Award; however, many will need only an administrative review or will leverage existing grant applications peer review if one was submitted. The new request . . . </div></div><div><h6><a href="/news/218">NIDDK Central Repository joins Vivli to strengthen and expand the data ecosystem</a></h6><div>Vivli and the National Institute of Diabetes and Digestive and Kidney Disease (NIDDK), part of the National Institutes of Health (NIH), will be working together to broaden exposure and strengthen NIDDK data ecosystem. As part of Vivli’s award to serve as one of six generalist repositories that will work with the NIH Office of Data Science Strategy . . . </div></div><div><h6><a href="/news/219">NLP-based CDE tagging to improve FAIRness of studies in the NIDDK Central Repository</a></h6><div>The NIDDK Central Repository (CR) plays a crucial role in making data Findable, Accessible, Interoperable, and Reusable (FAIR). To enhance FAIRness of studies in the Repository, NIDDK and Booz Allen Hamilton, the current Data Repository contractor, have piloted a natural language processing (NLP) pipeline project for harmonizing study variables wit. . . </div></div></div><div class="undefined Card_infoFooter__GFXj1 card-footer"><a href="/news"><button aria-label="See More" class="Button_button__OFOdO Button_auto__peQWd Button_homepage__kyCEa a a-primary">See More<span class="Button_iconRight__TBy6s"><svg width="9" height="15" viewBox="0 0 9 15" fill="none" xmlns="http://www.w3.org/2000/svg"><path d="M1 14L7 7.58025L0.999999 1" stroke="currentColor" stroke-width="2"></path></svg></span></button></a></div></div></div></div><div class="Homepage_Row__XOEs_ row"><div class="col-lg-5 col-md-12"><div class="Homepage_infoCard__mQtAX Card_info__ZXlh_ card"><div style="background-image:url(/images/Pattern5.png)" class="undefined Card_infoHeader__gjqLK card-header"><span>Events</span></div><div class="undefined Card_infoBody__XzyL8 Card_scrollable__BMLpI card-body" style="height:170px"><div class="Homepage_noContentContainer__Gu07W"><div class="Homepage_noContent__ktRNo Homepage_lightBox__lZpPz">There are currently no future events at this time.</div></div></div><div class="undefined Card_infoFooter__GFXj1 card-footer"><a href="/events"><button aria-label="See Past Events" class="Button_button__OFOdO Button_auto__peQWd Button_homepage__kyCEa a a-primary">See Past Events<span class="Button_iconRight__TBy6s"><svg width="9" height="15" viewBox="0 0 9 15" fill="none" xmlns="http://www.w3.org/2000/svg"><path d="M1 14L7 7.58025L0.999999 1" stroke="currentColor" stroke-width="2"></path></svg></span></button></a></div></div></div><div class="col-lg-7 col-md-12"><div class="Homepage_infoCard__mQtAX Card_info__ZXlh_ Card_colored__1aflA card"><div style="background-image:url(/images/Pattern5.png)" class="undefined Card_infoHeader__gjqLK card-header"><span>Updates to R4R Resources</span></div><div class="undefined Card_infoBody__XzyL8 Card_scrollable__BMLpI card-body" style="height:170px"><div class="Homepage_event__7OtHZ"><h6><span>11/27/2024 | </span><a href="/study/102">Data Update for CFLD PUSH (CFLD PUSH)</a></h6><div class="Homepage_newsItem__JFF4g">Data have been updated for Prediction by Ultrasound of the Risk of Hepatic Cirrhosis in Cystic Fibrosis Liver Disease (CFLD PUSH). This update includes final study datasets. If you have already be. . . </div></div><div class="Homepage_event__7OtHZ"><h6><span>10/29/2024 | </span><a href="/study/185">Data Update for TN19 (TN19)</a></h6><div class="Homepage_newsItem__JFF4g">Data have been updated for Antithymocyte Globulin (ATG) and Pegylated Granulocyte Colony Stimulating Factor (GCSF) in New Onset Type 1 Diabetes (TN19). This update includes additional flow analysis da. . . </div></div><div class="Homepage_event__7OtHZ"><h6><span>10/07/2024 | </span><a href="/study/230">New Study: ELASTIC-CF (ELASTIC-CF)</a></h6><div class="Homepage_newsItem__JFF4g">A new study, Longitudinal Assessment of Transient Elastography in Cystic Fibrosis (ELASTIC-CF), has been posted to the NIDDK Central Repository. Data from this study are now available for request. . . . </div></div><div class="Homepage_event__7OtHZ"><h6><span>09/20/2024 | </span><a href="/study/212">New Study: VIEW (VIEW)</a></h6><div class="Homepage_newsItem__JFF4g">A new study, Validation of Bladder Health Instrument for Evaluation in Women (VIEW), has been posted to the NIDDK Central Repository. Data from this study are now available for request. The VIEW st. . . </div></div><div class="Homepage_event__7OtHZ"><h6><span>09/12/2024 | </span><a href="/study/90">New Study: BASIC (BASIC)</a></h6><div class="Homepage_newsItem__JFF4g">A new study, Biliary Atresia Study in Infants and Children (BASIC), has been posted to the NIDDK Central Repository. Analysis data from this study are now available for request as well as three analys. . . </div></div><div class="Homepage_event__7OtHZ"><h6><span>08/21/2024 | </span><a href="/study/218">New Study: RADIANT (RADIANT)</a></h6><div class="Homepage_newsItem__JFF4g">A new study, Rare and Atypical DIAbetes NeTwork (RADIANT), has been posted to the NIDDK Central Repository. Data from this study are now available for request. The Rare and Atypical DIAbetes NeTwor. . . </div></div><div class="Homepage_event__7OtHZ"><h6><span>08/15/2024 | </span><a href="/study/100">Data Update for LOGIC (LOGIC)</a></h6><div class="Homepage_newsItem__JFF4g">Data have been updated for the Longitudinal Study of Genetic Causes of Intrahepatic Cholestasis (LOGIC) study. This study is part of the Childhood Liver Disease Research Network (ChiLDReN). An additio. . . </div></div><div class="Homepage_event__7OtHZ"><h6><span>07/17/2024 | </span><a href="/study/99">Data Update for PROBE (PROBE)</a></h6><div class="Homepage_newsItem__JFF4g">Data have been updated for A Prospective Database of Infants With Cholestasis (PROBE). This update includes an analysis dataset from PROBE. Additionally, this update includes three analysis datasets . . . </div></div><div class="Homepage_event__7OtHZ"><h6><span>07/16/2024 | </span><a href="/study/167">Data Update for CUTIE (CUTIE)</a></h6><div class="Homepage_newsItem__JFF4g">Data have been updated for Careful Urinary Tract Infection Evaluation (CUTIE). This update includes an additional renal scan dataset. If you have already been approved to receive the CUTIE data pac. . . </div></div><div class="Homepage_event__7OtHZ"><h6><span>07/02/2024 | </span><a href="/study/81">Data Update for HALT-C (HALT-C)</a></h6><div class="Homepage_newsItem__JFF4g">Data have been updated for The Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis Trial (HALT-C). This update includes Biopsy Adverse Event data. If you have already been approved to recei. . . </div></div><div class="Homepage_event__7OtHZ"><h6><span>06/20/2024 | </span><a href="/study/38">Data Update for DPP (DPP)</a></h6><div class="Homepage_newsItem__JFF4g">Data have been updated for Diabetes Prevention Program (DPP). This update includes PFAS (per- and polyfluoroalkyl substances) Secondary data. If you have already been approved to receive the DPP da. . . </div></div><div class="Homepage_event__7OtHZ"><h6><span>06/20/2024 | </span><a href="/study/40">Data Update for DPPOS (DPPOS)</a></h6><div class="Homepage_newsItem__JFF4g">Data have been updated for Diabetes Prevention Program Outcomes Study (DPPOS). This update includes Phase 3 data and PFAS (per- and polyfluoroalkyl substances) Secondary data. If you have already b. . . </div></div><div class="Homepage_event__7OtHZ"><h6><span>06/04/2024 | </span><a href="/study/24">Data Update for TEDDY (TEDDY)</a></h6><div class="Homepage_newsItem__JFF4g">Data have been updated for The Environmental Determinants of Diabetes in the Young (TEDDY) study. This update includes additional analysis datasets for M199, M208, M233, and M239. If you have alrea. . . </div></div><div class="Homepage_event__7OtHZ"><h6><span>05/21/2024 | </span><a href="/study/113">Data Update for TN10 (TN10)</a></h6><div class="Homepage_newsItem__JFF4g">Data have been updated for Anti-CD3 Mab (Teplizumab) for Prevention of Diabetes in Relatives At-Risk for Type 1 Diabetes Mellitus (TN10) study. This update includes additional secondary outcomes analy. . . </div></div><div class="Homepage_event__7OtHZ"><h6><span>05/09/2024 | </span><a href="/study/98">Data Update for START (START)</a></h6><div class="Homepage_newsItem__JFF4g">Data have been updated for A Randomized, Double-Blinded, Placebo-Controlled Trial of Corticosteroid Therapy Following Portoenterostomy in Infants with Biliary Atresia (START) study. This update includ. . . </div></div><div class="Homepage_event__7OtHZ"><h6><span>05/09/2024 | </span><a href="/study/187">Data Update for FORCE (FORCE)</a></h6><div class="Homepage_newsItem__JFF4g">Data have been updated for FibroScan in Pediatric Cholestatic Liver Disease (FORCE) study. This update includes an additional biomarkers analysis dataset. If you have already been approved to recei. . . </div></div><div class="Homepage_event__7OtHZ"><h6><span>04/19/2024 | </span><a href="/study/228">New Study: IMAGINE-II (IMAGINE-II)</a></h6><div class="Homepage_newsItem__JFF4g">A new study, Extension Study to Evaluate the Long-Term Safety and Durability of Effect of LUM001 in the Treatment of Cholestatic Liver Disease in Pediatric Subjects with Alagille Syndrome (IMAGINE-II). . . </div></div><div class="Homepage_event__7OtHZ"><h6><span>04/19/2024 | </span><a href="/study/227">New Study: PRIME (PRIME)</a></h6><div class="Homepage_newsItem__JFF4g">A new study, A Phase I/IIa Trial of Intravenous Immunoglobulin (IVIG) Therapy Following Portoenterostomy in Infants with Biliary Atresia (PRIME), has been posted to the NIDDK Central Repository. Data . . . </div></div><div class="Homepage_event__7OtHZ"><h6><span>04/02/2024 | </span><a href="/study/89">New Study: NAFLD Pediatric Database 2 (NAFLD Pediatric Database 2)</a></h6><div class="Homepage_newsItem__JFF4g">A new study, Nonalcoholic Fatty Liver Disease Pediatric Database 2 (NAFLD Pediatric Database 2), has been posted to the NIDDK Central Repository. Data and biospecimens from this study are now availabl. . . </div></div><div class="Homepage_event__7OtHZ"><h6><span>03/20/2024 | </span><a href="/study/53">Data Update for Teen-LABS (Teen-LABS)</a></h6><div class="Homepage_newsItem__JFF4g">Data have been updated for the Adolescent Bariatrics: Assessing Health Benefits & Risks (Teen-LABS) study. This update includes data through the end of the study and additional analysis datasets. I. . . </div></div><div class="Homepage_event__7OtHZ"><h6><span>02/08/2024 | </span><a href="/study/331">New Study: HBRN Immunology Cohort (HBRN Immunology Cohort)</a></h6><div class="Homepage_newsItem__JFF4g">A new study, Immune Regulation and Costimulation in Natural History of Chronic Hepatitis B (HBRN Immunology Cohort), has been posted to the NIDDK Central Repository. Data from this study are now avail. . . </div></div><div class="Homepage_event__7OtHZ"><h6><span>02/06/2024 | </span><a href="/study/136">New Study: HBRN Immunology Treatment (HBRN Immunology Treatment)</a></h6><div class="Homepage_newsItem__JFF4g">A new study, Immune Regulation and Costimulation in Natural History and Therapeutic Outcome of Chronic Hepatitis B (HBRN Immunology Treatment), has been posted to the NIDDK Central Repository. Data fr. . . </div></div><div class="Homepage_event__7OtHZ"><h6><span>01/05/2024 | </span><a href="/study/88">New Study: NAFLD Adult Database 2 (NAFLD Adult Database 2)</a></h6><div class="Homepage_newsItem__JFF4g">A new study, Nonalcoholic Fatty Liver Disease Adult Database 2 (NAFLD Adult Database 2), has been posted to the NIDDK Central Repository. Data and biospecimens from this study are now available for re. . . </div></div><div class="Homepage_event__7OtHZ"><h6><span>12/06/2023 | </span><a href="/study/330">New Study: HBRN Immune Active (HBRN Immune Active)</a></h6><div class="Homepage_newsItem__JFF4g">A new study, Combination Therapy of Peginterferon Alfa-2a and Tenofovir versus Tenofovir Monotherapy in HBeAg-positive and HBeAg-negative Chronic Hepatitis B (HBRN Immune Active), has been posted to t. . . </div></div><div class="Homepage_event__7OtHZ"><h6><span>11/28/2023 | </span><a href="/study/135">New Study: HBRN Pediatric Immune Tolerant Trial (HBRN Immune Tolerant P)</a></h6><div class="Homepage_newsItem__JFF4g">A new study, Clinical Trial of Entecavir/Pegylated Interferon in Immune Tolerant Children With Chronic HBV Infection (HBRN Immune Tolerant P), has been posted to the NIDDK Central Repository. Data and. . . </div></div></div><div class="undefined Card_infoFooter__GFXj1 card-footer"><a href="/updates"><button aria-label="See More" class="Button_button__OFOdO Button_auto__peQWd Button_homepage__kyCEa a a-primary">See More<span class="Button_iconRight__TBy6s"><svg width="9" height="15" viewBox="0 0 9 15" fill="none" xmlns="http://www.w3.org/2000/svg"><path d="M1 14L7 7.58025L0.999999 1" stroke="currentColor" stroke-width="2"></path></svg></span></button></a></div></div></div></div></div><footer class="Footer_footer__ylvxI"><div class="Footer_footerBackground__oz0ra Footer_colorful__6nhIt "></div><div class="Footer_content__kdMvs"><div class="container"><div class="Footer_footerHeader__BQGGW row">NIH... Turning Discovery into Health ®</div><div class="mb-2 row"><div class="Footer_column__P3enx undefined col-sm-3"><p class="Footer_columnTitle__wFePf Footer_gray__JEbav"><a href="/pages/repository">Repository Resources</a></p><a href="/search/study">Studies</a><a href="/search/counts">Material Counts</a><a href="/requests/approved/data">List of Approved Requestors</a><a href="/publications">Publications</a></div><div class="Footer_column__P3enx col-sm-3"><p class="Footer_columnTitle__wFePf Footer_teal__of3yb"><a href="/pages/helpful_information">Helpful Information</a></p><a href="/pages/general_information">General Information</a><a href="/pages/for_requestors">For Requestors</a><a href="/pages/for_submitters">For Submitters</a><a href="/pages/instructional_materials">Educational/Instructional Information</a><a href="/pages/data_challenges">Data Challenges</a><a href="/pages/externa_links">External Links</a></div><div class="Footer_column__P3enx col-sm-3"><p class="Footer_columnTitle__wFePf Footer_blue__h5Qmd"><a href="/pages/requests">Requests</a></p><a href="/requests/reuse/data-request">Data Request</a><a href="/requests/biospecimen_types">Specimen Request</a></div><div class="Footer_column__P3enx col-sm-3"><p class="Footer_columnTitle__wFePf Footer_blue__h5Qmd"><a href="/pages/about_niddk_cr">About NIDDK-CR</a></p><a href="/pages/about">About NIDDK-CR</a><a href="/news">R4R News</a><a href="/faq">Frequently Asked Questions</a><a href="/pages/site_map">Site Navigation Map</a><a href="/pages/definitions">Definitions</a><a href="/contact">Contact the NIDDK-CR</a></div></div></div></div><div class="Footer_blackFooter__dTd_Q"><div class="Footer_blackFooterContainer__eegTA container"><div class="Footer_footerLinks__5nXNj row"><ul><li>v. 02.0.1</li><li><a href="/pages/privacy/">Privacy Policy</a></li><li><a href="https://www.niddk.nih.gov/freedom-information-act">Freedom of Information Act</a></li><li><a href="/pages/accessibility/">Accessibility</a></li><li><a href="https://www.niddk.nih.gov/disclaimers">Disclaimers</a></li><li><a href="https://www.niddk.nih.gov/copyright">Copyright</a></li><li><a href="https://www.hhs.gov/vulnerability-disclosure-policy/index.html">Vulnerability Disclosure Policy</a></li><li><a href="/pages/site_map/">Site Map</a></li></ul><ul><li><a href="https://www.hhs.gov/"><span>U.S. Department of Health and Human Services</span></a></li><li itemProp="memberOf" itemType="http://schema.org/GovernmentOrganization"><a href="https://www.nih.gov/" itemProp="url"><span itemProp="name">National Institutes of Health</span></a></li><li><a href="https://www.niddk.nih.gov/">NIDDK Home</a></li></ul></div><div class="Footer_ctsContainer__dnT05 row"><a href="https://doi.org/10.34894/NOYYSF" target="_blank" rel="noopener noreferrer"><img src="/images/CoreTrustSeal-logo-transparent.png" class="Footer_ctsLogo__nRZwO" alt="Core Trust Seal Logo"/></a><div><a href="https://amt.coretrustseal.org/certificates">Core Trustworthy Data Repository</a></div></div></div></div></footer></div></div></div><script id="__NEXT_DATA__" type="application/json">{"props":{"pageProps":{"updates":[{"id":271,"title":"Data Update for CFLD PUSH","content":"Data have been updated for Prediction by Ultrasound of the Risk of Hepatic Cirrhosis in Cystic Fibrosis Liver Disease (CFLD PUSH). This update includes final study datasets. \r\n\r\nIf you have already been approved to receive the CFLD PUSH data package, please contact us through your request to download the updated data package.\r\n\r\nThe Prediction by Ultrasound of the Risk of Hepatic Cirrhosis in Cystic Fibrosis Liver Disease (CFLD PUSH) study was a prospective longitudinal study that aimed to determine the utility of abdominal ultrasound to predict the development of cirrhosis in participants with cystic fibrosis as indicated by a nodular liver on ultrasound.","publishedDate":"2024-11-27T21:56:47Z","studyId":102,"studyName":"Prediction by Ultrasound of the Risk of Hepatic Cirrhosis in Cystic Fibrosis Liver Disease","studyAcronym":"CFLD PUSH"},{"id":267,"title":"Data Update for TN19","content":"Data have been updated for Antithymocyte Globulin (ATG) and Pegylated Granulocyte Colony Stimulating Factor (GCSF) in New Onset Type 1 Diabetes (TN19). This update includes additional flow analysis datasets.\r\n\r\nIf you have already been approved to receive the TN19 data package, please contact us through your request to download the updated data package.\r\n\r\nThe TN19 study was a three-arm, 1:1:1 randomized, placebo controlled, double- blinded trial in which participants either received active Anti-Thymocyte Globulin (ATG) and Granulocyte Colony Stimulating Factor (GCSF), received ATG alone, or received a placebo alone within 100 days from diagnosis of T1D. TrialNet researchers assessed whether ATG used alone or in combination with GCSF helped participants continue to make some of their own insulin.","publishedDate":"2024-10-29T15:33:35Z","studyId":185,"studyName":"Antithymocyte Globulin (ATG) and Pegylated Granulocyte Colony Stimulating Factor (GCSF) in New Onset Type 1 Diabetes","studyAcronym":"TN19"},{"id":266,"title":"New Study: ELASTIC-CF","content":"A new study, Longitudinal Assessment of Transient Elastography in Cystic Fibrosis (ELASTIC-CF), has been posted to the NIDDK Central Repository. Data from this study are now available for request.\r\n\r\nThe ELASTIC-CF study assessed if combining FibroScan® measurement of liver stiffness transient elastography with ultrasound would improve the prediction of the development of a nodular liver on ultrasound and development of portal hypertension over time in children and young adults with CF. Study visits occurred at baseline and for at least two annual follow-up visits.","publishedDate":"2024-10-07T20:11:45Z","studyId":230,"studyName":"Longitudinal Assessment of Transient Elastography in Cystic Fibrosis","studyAcronym":"ELASTIC-CF"},{"id":262,"title":"New Study: VIEW","content":"A new study, Validation of Bladder Health Instrument for Evaluation in Women (VIEW), has been posted to the NIDDK Central Repository. Data from this study are now available for request.\r\n\r\nThe VIEW study prospectively collected data to test and validate bladder health instrument (BHI) items for inclusion in a final bladder health scale (BHS) that assessed the full range of bladder health of women. The study collected data from the general population using mailed surveys, from the clinical population using surveys and in-person evaluations, and from postpartum women.","publishedDate":"2024-09-20T14:18:03Z","studyId":212,"studyName":"Validation of Bladder Health Instrument for Evaluation in Women","studyAcronym":"VIEW"},{"id":261,"title":"New Study: BASIC","content":"A new study, Biliary Atresia Study in Infants and Children (BASIC), has been posted to the NIDDK Central Repository. Analysis data from this study are now available for request as well as three analysis datasets using combined data from the PROBE and BASIC studies.\r\n\r\nThe Biliary Atresia Study in Infants and Children (BASIC) is a prospective, observational study that was established by ChiLDReN to collect pertinent clinical information and biospecimens to aid in the understanding of the disorder. Specific aims of the study include identifying the gene(s) implicated in the etiology of biliary atresia, identifying the polymorphisms that may influence disease progression, and characterizing the natural history of the older, non-transplanted patients with biliary atresia.","publishedDate":"2024-09-12T20:24:33Z","studyId":90,"studyName":"Biliary Atresia Study in Infants and Children","studyAcronym":"BASIC"},{"id":259,"title":"New Study: RADIANT","content":"A new study, Rare and Atypical DIAbetes NeTwork (RADIANT), has been posted to the NIDDK Central Repository. Data from this study are now available for request.\r\n\r\nThe Rare and Atypical DIAbetes NeTwork (RADIANT) is a multicenter prospective cohort study that is dedicated to characterizing (discovering and defining) rare and atypical forms of diabetes. Individuals will be screened for evaluation of suspected atypical diabetes of unknown origin. Among the pool of evaluated individuals, those found to have a known form of diabetes will be excluded from further study. The remaining participants will be prioritized for genetic/genomic analysis and further testing.","publishedDate":"2024-08-21T17:42:09Z","studyId":218,"studyName":"Rare and Atypical Diabetes Network","studyAcronym":"RADIANT"},{"id":258,"title":"Data Update for LOGIC","content":"Data have been updated for the Longitudinal Study of Genetic Causes of Intrahepatic Cholestasis (LOGIC) study. This study is part of the Childhood Liver Disease Research Network (ChiLDReN). An additional analysis dataset is now available for request.\r\n\r\nIf you have already been approved to receive the LOGIC data package, please contact us through your request to download the updated data package. \r\n\r\nThe primary objectives of the LOGIC study include determining the frequency of poor growth and decreased bone mineral density and its predictors; identifying modifier genes that influence the incidence, severity, and progression of liver disease among affected individuals; and developing a repository of biospecimens to be used in ancillary studies of predictor biomarkers.","publishedDate":"2024-08-15T13:49:00Z","studyId":100,"studyName":"Longitudinal Study of Genetic Causes of Intrahepatic Cholestasis","studyAcronym":"LOGIC"},{"id":257,"title":"Data Update for PROBE","content":"Data have been updated for A Prospective Database of Infants With Cholestasis (PROBE). This update includes an analysis dataset from PROBE. Additionally, this update includes three analysis datasets using combined data from the PROBE, BASIC, and START studies.\r\n\r\nIf you have already been approved to receive the PROBE data package, please contact us through your request to download the updated data package.\r\n\r\nPROBE is a multi-center project to establish a prospective database of clinical information and a repository of blood and tissue samples from children with diagnoses of neonatal liver diseases, such as biliary atresia and neonatal hepatitis in order to perform research in these liver problems.","publishedDate":"2024-07-17T20:44:15Z","studyId":99,"studyName":"A Prospective Database of Infants With Cholestasis","studyAcronym":"PROBE"},{"id":256,"title":"Data Update for CUTIE","content":"Data have been updated for Careful Urinary Tract Infection Evaluation (CUTIE). This update includes an additional renal scan dataset.\r\n\r\nIf you have already been approved to receive the CUTIE data package, please contact us through your request to download the updated data package.\r\n\r\nThe CUTIE study was an observational study designed to determine why some children develop kidney scars after urinary tract infections (UTIs). The study was aimed at understanding which children were at the greatest risk of developing renal scarring following a UTI, so physicians can provide targeted therapies and appropriate interventions.","publishedDate":"2024-07-16T15:03:34Z","studyId":167,"studyName":"Careful Urinary Tract Infection Evaluation","studyAcronym":"CUTIE"},{"id":255,"title":"Data Update for HALT-C","content":"Data have been updated for The Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis Trial (HALT-C). This update includes Biopsy Adverse Event data.\r\n\r\nIf you have already been approved to receive the HALT-C data package, please contact us through your request to download the updated data package.\r\n\r\nThe Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis Trial (HALT-C) was a randomized clinical trial of long-term use of peginterferon alfa-2a in participants with chronic hepatitis C. The study investigated whether long-term antiviral therapy could prevent progressive liver disease—including cirrhosis, liver failure, hepatocellular carcinoma, and death—in chronic hepatitis C participants.","publishedDate":"2024-07-02T16:06:41Z","studyId":81,"studyName":"The Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis Trial","studyAcronym":"HALT-C"},{"id":254,"title":"Data Update for DPP","content":"Data have been updated for Diabetes Prevention Program (DPP). This update includes PFAS (per- and polyfluoroalkyl substances) Secondary data.\r\n\r\nIf you have already been approved to receive the DPP data package, please contact us through your request to download the updated data package.\r\n\r\nThe Diabetes Prevention Program (DPP) is a clinical trial that investigated whether modest weight loss through dietary changes and increased physical activity or treatment with the oral diabetes drug metformin (Glucophage) could prevent or delay the onset of type 2 diabetes in high risk individuals with prediabetes.","publishedDate":"2024-06-20T19:45:20Z","studyId":38,"studyName":"Diabetes Prevention Program","studyAcronym":"DPP"},{"id":253,"title":"Data Update for DPPOS","content":"Data have been updated for Diabetes Prevention Program Outcomes Study (DPPOS). This update includes Phase 3 data and PFAS (per- and polyfluoroalkyl substances) Secondary data.\r\n\r\nIf you have already been approved to receive the DPPOS data package, please contact us through your request to download the updated data package.\r\n\r\nThe Diabetes Prevention Program Outcomes Study (DPPOS) is the long-term follow-up of the original DPP (Diabetes Prevention Program) study. The DPPOS sought to evaluate the effects of the interventions on the further development of diabetes and diabetes complications, including retinopathy, microangiopathy, and cardiovascular disease.","publishedDate":"2024-06-20T19:44:24Z","studyId":40,"studyName":"Diabetes Prevention Program Outcomes Study","studyAcronym":"DPPOS"},{"id":252,"title":"Data Update for TEDDY","content":"Data have been updated for The Environmental Determinants of Diabetes in the Young (TEDDY) study. This update includes additional analysis datasets for M199, M208, M233, and M239.\r\n\r\nIf you have already been approved to receive the TEDDY data package, please contact us through your request to download the updated data package.\r\n\r\nThe TEDDY study is a multicenter prospective cohort study that was established in response to these gaps in understanding of type 1 diabetes (T1D). The primary objectives of the study include identifying environmental factors—such as infectious agents, dietary factors, and psychosocial factors—that trigger or protect against the development of islet autoimmunity and T1D and examining genetic-environmental interactions to investigate interactive effects that contribute to T1D.","publishedDate":"2024-06-04T16:35:45Z","studyId":24,"studyName":"The Environmental Determinants of Diabetes in the Young","studyAcronym":"TEDDY"},{"id":251,"title":"Data Update for TN10","content":"Data have been updated for Anti-CD3 Mab (Teplizumab) for Prevention of Diabetes in Relatives At-Risk for Type 1 Diabetes Mellitus (TN10) study. This update includes additional secondary outcomes analysis datasets.\r\n\r\nIf you have already been approved to receive the TN10 data package, please contact us through your request to download the updated data package.\r\n\r\nTN10 was a phase 2 prevention trial of TrialNet, studying the effect of teplizumab on insulin production in the relatives of type 1 diabetics who were at high risk of developing the disease. Participants were randomly assigned to either the active or placebo group of the study and monitored and tested over time until diagnosed with diabetes.","publishedDate":"2024-05-21T13:45:52Z","studyId":113,"studyName":"Anti-CD3 Mab (Teplizumab) for Prevention of Diabetes in Relatives At-Risk for Type 1 Diabetes Mellitus","studyAcronym":"TN10"},{"id":250,"title":"Data Update for START","content":"Data have been updated for A Randomized, Double-Blinded, Placebo-Controlled Trial of Corticosteroid Therapy Following Portoenterostomy in Infants with Biliary Atresia (START) study. This update includes an additional vitamin deficiency analysis dataset, and two analysis datasets using combined data from the Prospective Database of Infants with Cholestasis (PROBE) and START studies.\r\n\r\nIf you have already been approved to receive the START data package, please contact us through your request to download the updated data package.\r\n\r\nThe START study participants were recruited from the PROBE study and randomized into either the corticosteroid or placebo group within 72 hours after the portoenterostomy procedure. Participants were given their assigned treatments daily over the course of 13 weeks. After the treatment period, participants underwent follow-up testing and assessments until age 24 months.","publishedDate":"2024-05-09T21:08:41Z","studyId":98,"studyName":"A Randomized, Double-Blinded, Placebo-Controlled Trial of Corticosteroid Therapy Following Portoenterostomy in Infants with Biliary Atresia","studyAcronym":"START"},{"id":249,"title":"Data Update for FORCE","content":"Data have been updated for FibroScan in Pediatric Cholestatic Liver Disease (FORCE) study. This update includes an additional biomarkers analysis dataset.\r\n\r\nIf you have already been approved to receive the FORCE data package, please contact us through your request to download the updated data package.\r\n\r\nThe FibroScan in Pediatric Cholestatic Liver Disease (FORCE) study, a natural history study within ChiLDReN, was a cross-sectional and longitudinal assessment of the utility of liver stiffness measurement (LSM) in children with chronic cholestatic liver disease.","publishedDate":"2024-05-09T20:05:40Z","studyId":187,"studyName":"FibroScan in Pediatric Cholestatic Liver Disease","studyAcronym":"FORCE"},{"id":246,"title":"New Study: IMAGINE-II","content":"A new study, Extension Study to Evaluate the Long-Term Safety and Durability of Effect of LUM001 in the Treatment of Cholestatic Liver Disease in Pediatric Subjects with Alagille Syndrome (IMAGINE-II), has been posted to the NIDDK Central Repository. Data from this study are now available for request.\r\n\r\nThe IMAGINE-II study was a multicenter, extension study of LUM001 in children diagnosed with Alagille syndrome (ALGS) who had completed participation in a core LUM001 treatment protocol (ITCH study). Efficacy was assessed by evaluating the effect of LUM001 on the biochemical markers and pruritus associated with ALGS.","publishedDate":"2024-04-19T20:23:11Z","studyId":228,"studyName":"Extension Study to Evaluate the Long-Term Safety and Durability of Effect of LUM001 in the Treatment of Cholestatic Liver Disease in Pediatric Subjects with Alagille Syndrome","studyAcronym":"IMAGINE-II"},{"id":245,"title":"New Study: PRIME","content":"A new study, A Phase I/IIa Trial of Intravenous Immunoglobulin (IVIG) Therapy Following Portoenterostomy in Infants with Biliary Atresia (PRIME), has been posted to the NIDDK Central Repository. Data from this study are now available for request.\r\n\r\nThe PRIME study was a multicenter prospective phase I/IIa open label trial, aimed at assessing the feasibility, tolerability, and safety of intravenous immunoglobulin (IVIG) therapy following hepatic portoenterostomy (HPE) in infants with biliary atresia (BA).","publishedDate":"2024-04-19T16:28:33Z","studyId":227,"studyName":"A Phase I/IIa Trial of Intravenous Immunoglobulin (IVIG) Therapy Following Portoenterostomy in Infants with Biliary Atresia","studyAcronym":"PRIME"},{"id":244,"title":"New Study: NAFLD Pediatric Database 2","content":"A new study, Nonalcoholic Fatty Liver Disease Pediatric Database 2 (NAFLD Pediatric Database 2), has been posted to the NIDDK Central Repository. Data and biospecimens from this study are now available for request.\r\n\r\nThe Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN) was initiated in 2002 to conduct multicenter, collaborative studies on the etiology, contributing factors, natural history, complications, and treatment of NASH. The Nonalcoholic Fatty Liver Disease Pediatric Database 2 (NAFLD Pediatric Database 2) continued the longitudinal follow-up of participants enrolled in earlier NASH CRN studies and recruited new participants with recent liver biopsies.","publishedDate":"2024-04-02T16:57:18Z","studyId":89,"studyName":"Nonalcoholic Fatty Liver Disease Pediatric Database 2","studyAcronym":"NAFLD Pediatric Database 2"},{"id":242,"title":"Data Update for Teen-LABS","content":"Data have been updated for the Adolescent Bariatrics: Assessing Health Benefits \u0026 Risks (Teen-LABS) study. This update includes data through the end of the study and additional analysis datasets.\r\n\r\nIf you have already been approved to receive the Teen-LABS, please contact us through your request to download the updated data package.\r\n\r\nTeen-LABS conducted coordinated clinical, epidemiological, and behavioral research focused on adolescent bariatric surgery. The study developed common clinical protocols and a bariatric surgery database for the purpose of collecting information from participating clinical centers that performed bariatric surgery on teenagers.","publishedDate":"2024-03-20T18:15:53Z","studyId":53,"studyName":"Adolescent Bariatrics: Assessing Health Benefits \u0026 Risks","studyAcronym":"Teen-LABS"},{"id":240,"title":"New Study: HBRN Immunology Cohort","content":"A new study, Immune Regulation and Costimulation in Natural History of Chronic Hepatitis B (HBRN Immunology Cohort), has been posted to the NIDDK Central Repository. Data from this study are now available for request.\r\n\r\nThe Immune Regulation and Costimulation in Natural History of Chronic Hepatitis B (HBRN Immunology Cohort) study aimed to assess whether the balance between immune regulatory and effector responses in HBV-infected individuals defines the level of viremia, liver inflammation, and treatment outcomes.","publishedDate":"2024-02-08T15:08:34Z","studyId":331,"studyName":"Immune Regulation and Costimulation in Natural History of Chronic Hepatitis B","studyAcronym":"HBRN Immunology Cohort"},{"id":239,"title":"New Study: HBRN Immunology Treatment","content":"A new study, Immune Regulation and Costimulation in Natural History and Therapeutic Outcome of Chronic Hepatitis B (HBRN Immunology Treatment), has been posted to the NIDDK Central Repository. Data from this study are now available for request.\r\n\r\nImmune Regulation and Costimulation in Natural History and Therapeutic Outcome of Chronic Hepatitis B (HBRN Immunology Treatment) study sought to examine the effects of antiviral therapy in host immune phenotype and to investigate if antiviral immune responses before, during, and after therapy can predict long term therapeutic response.","publishedDate":"2024-02-06T17:48:10Z","studyId":136,"studyName":"Immune Regulation and Costimulation in Natural History and Therapeutic Outcome of Chronic Hepatitis B","studyAcronym":"HBRN Immunology Treatment"},{"id":238,"title":"New Study: NAFLD Adult Database 2","content":"A new study, Nonalcoholic Fatty Liver Disease Adult Database 2 (NAFLD Adult Database 2), has been posted to the NIDDK Central Repository. Data and biospecimens from this study are now available for request.\r\n\r\nThe Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN) was initiated in 2002 to conduct multicenter, collaborative studies on the etiology, contributing factors, natural history, complications, and treatment of NASH. The Nonalcoholic Fatty Liver Disease Adult Database 2 (NAFLD Adult Database 2) continued the longitudinal follow-up of participants enrolled in earlier NASH CRN studies and recruited new participants with recent liver biopsies.","publishedDate":"2024-01-05T15:27:34Z","studyId":88,"studyName":"Nonalcoholic Fatty Liver Disease Adult Database 2","studyAcronym":"NAFLD Adult Database 2"},{"id":236,"title":"New Study: HBRN Immune Active","content":"A new study, Combination Therapy of Peginterferon Alfa-2a and Tenofovir versus Tenofovir Monotherapy in HBeAg-positive and HBeAg-negative Chronic Hepatitis B (HBRN Immune Active), has been posted to the NIDDK Central Repository. Data and biospecimens from this study are now available for request.\r\n\r\nThe Combination Therapy of Peginterferon Alfa-2a and Tenofovir versus Tenofovir Monotherapy in HBeAg-positive and HBeAg-negative Chronic Hepatitis B (HBRN Immune Active) study sought to compare the long-term efficacy of combination therapy with peginterferon plus tenofovir versus tenofovir monotherapy in the treatment of chronic hepatitis B.","publishedDate":"2023-12-06T15:32:11Z","studyId":330,"studyName":"Combination Therapy of Peginterferon Alfa-2a and Tenofovir versus Tenofovir Monotherapy in HBeAg-positive and HBeAg-negative Chronic Hepatitis B","studyAcronym":"HBRN Immune Active"},{"id":235,"title":"New Study: HBRN Pediatric Immune Tolerant Trial","content":"A new study, Clinical Trial of Entecavir/Pegylated Interferon in Immune Tolerant Children With Chronic HBV Infection (HBRN Immune Tolerant P), has been posted to the NIDDK Central Repository. Data and biospecimens from this study are now available for request.\r\n\r\nThe HBRN Pediatric Immune Tolerant Trial (HBRN Immune Tolerant P) sought to determine the safety and efficacy of treatment using a combination of drugs (entecavir and pegylated interferon) in children ages 3-\u003c18 years old with immunotolerant chronic hepatitis B.","publishedDate":"2023-11-28T16:40:17Z","studyId":135,"studyName":"Clinical Trial of Entecavir/Pegylated Interferon in Immune Tolerant Children with Chronic Hepatitis B Virus Infection","studyAcronym":"HBRN Immune Tolerant P"},{"id":234,"title":"New Study: HBRN Adult Immune Tolerant Trial","content":"A new study, Combination Entecavir and Peginterferon Therapy in HBeAg-Positive Immune-Tolerant Adults with Chronic Hepatitis B (HBRN Immune Tolerant A), has been posted to the NIDDK Central Repository. Data and biospecimens from this study are now available for request.\r\n\r\nThe HBRN Adult Immune Tolerant Trial (HBRN Immune Tolerant A) was designed to determine the efficacy of treatment with 8 weeks of entecavir followed by 40 weeks of both entecavir and peginterferon in the treatment of chronic hepatitis B in hepatitis B “e” antigen (HBeAg) positive adults who were in the immune tolerant phase.","publishedDate":"2023-11-27T19:38:02Z","studyId":134,"studyName":"Combination Entecavir and Peginterferon Therapy in HBeAg-Positive Immune-Tolerant Adults with Chronic Hepatitis B","studyAcronym":"HBRN Immune Tolerant A"},{"id":233,"title":"Data Update for HBRN Pediatric Cohort","content":"Data have been updated for the Hepatitis B Research Network Pediatric Cohort Study (HBRN Cohort P). This update includes final study datasets, analysis datasets, and additional ancillary datasets.\r\n\r\nIf you have already been approved to receive the HBRN data package, please contact us through your request to download the updated data package.\r\n\r\nThe HBRN Pediatric Cohort Study (HBRN Cohort P) was designed to describe participants 6 months to \u003c18 years of age with hepatitis B virus (HBV) infection in a prospective cohort in the United States (US) and Canada and identify predictors of disease activation and progression.","publishedDate":"2023-11-07T17:12:09Z","studyId":133,"studyName":"Hepatitis B Research Network Pediatric Cohort Study","studyAcronym":"HBRN Cohort P"},{"id":231,"title":"Data Update for HBRN Adult Cohort","content":"Data have been updated for the Hepatitis B Research Network Adult Cohort Study (HBRN Cohort A). This update includes final study datasets, analysis datasets, and additional ancillary datasets.\r\n\r\nIf you have already been approved to receive the HBRN data package, please contact us through your request to download the updated data package.\r\n\r\nThe HBRN Adult Cohort Study (HBRN Cohort A) was designed to describe participants with hepatitis B virus (HBV) infection and identify predictors of disease activation and progression. The relationship of HBV genotype to clinical, biochemical, and histological characteristics and to pregnancy was also explored.","publishedDate":"2023-09-29T15:08:17Z","studyId":132,"studyName":"Hepatitis B Research Network Adult Cohort Study","studyAcronym":"HBRN Cohort A"},{"id":230,"title":"Data Update for TEDDY","content":"Data have been updated for The Environmental Determinants of Diabetes in the Young (TEDDY) study. This update includes TEDDY data through 2021.\r\n\r\nIf you have already been approved to receive the TEDDY data package, please contact us through your request to download the updated data package.\r\n\r\nThe TEDDY study is a multicenter prospective cohort study that was established in response to these gaps in understanding of type 1 diabetes (T1D). The primary objectives of the study include identifying environmental factors—such as infectious agents, dietary factors, and psychosocial factors—that trigger or protect against the development of islet autoimmunity and T1D and examining genetic-environmental interactions to investigate interactive effects that contribute to T1D.","publishedDate":"2023-09-25T17:04:47Z","studyId":24,"studyName":"The Environmental Determinants of Diabetes in the Young","studyAcronym":"TEDDY"},{"id":228,"title":"Data Update for CRIC","content":"Data have been updated for the Chronic Renal Insufficiency Cohort Study (CRIC). This update includes updated datasets.\r\n\r\nIf you have already been approved to receive the CRIC data package, please contact us through your request to download the updated data package.\r\n\r\nThe Chronic Renal Insufficiency Cohort (CRIC) Study is an observational study that examined risk factors for progression of chronic renal insufficiency (CRI) and cardiovascular disease (CVD) among CRI patients. The study enrolled adults aged 21 to 74 years with a broad spectrum of renal disease severity, half of whom were diagnosed with diabetes mellitus. Subjects underwent extensive clinical evaluation at baseline and at annual clinic visits and via telephone at 6 month intervals.","publishedDate":"2023-08-22T15:15:35Z","studyId":15,"studyName":"Chronic Renal Insufficiency Cohort Study","studyAcronym":"CRIC"},{"id":227,"title":"New Study: STOP-NAFLD","content":"A new study, Losartan for the Treatment of Pediatric Nonalcoholic Fatty Liver Disease (STOP-NAFLD), has been posted to the NIDDK Central Repository. Data and biospecimens from this study are now available for request.\r\n\r\nThe STOP-NAFLD trial was a multicenter, double-masked, placebo-controlled, randomized phase 2 trial designed by the Nonalcoholic Steatohepatitis Clinical Research Network (NASH) to determine whether treatment with losartan improves measures of NAFLD in children.","publishedDate":"2023-07-31T14:24:59Z","studyId":327,"studyName":"Losartan for the Treatment of Pediatric Nonalcoholic Fatty Liver Disease","studyAcronym":"STOP-NAFLD"},{"id":226,"title":"Data Update for TEDDY","content":"Data have been updated for The Environmental Determinants of Diabetes in the Young (TEDDY) study. This update includes additional analysis datasets for M78, M144, M210, and updated TEDDY data through 2020.\r\n\r\nIf you have already been approved to receive the TEDDY data package, please contact us through your request to download the updated data package.\r\n\r\nThe TEDDY study is a multicenter prospective cohort study that was established in response to these gaps in understanding of type 1 diabetes (T1D). The primary objectives of the study include identifying environmental factors—such as infectious agents, dietary factors, and psychosocial factors—that trigger or protect against the development of islet autoimmunity and T1D and examining genetic-environmental interactions to investigate interactive effects that contribute to T1D.","publishedDate":"2023-06-23T22:41:48Z","studyId":24,"studyName":"The Environmental Determinants of Diabetes in the Young","studyAcronym":"TEDDY"},{"id":225,"title":"Data Update for AALF","content":"Data have been updated for the Acute Liver Failure Study Group: Adult Acute Liver Failure Study (AALF). Additional study datasets are now available for request.\r\n\r\nIf you have already been approved to receive the AALF data package, please contact us through your request to download the updated data package.\r\n\r\nALFSG conducted a Multi-Center Trial to Study Adult Acute Liver Failure (AALF) with acute liver failure and acute liver injury participants and those less severe that had coagulopathy but not the threshold of encephalopathy, a pilot study with a subset of AALF participants using rotational thromboelastography as a dynamic measure of coagulation, and a clinical trial with a subset of AALF participants using 13C labeled methacetin breath testing to determine outcomes in acute liver failure patients being considered for transplantation.","publishedDate":"2023-06-13T15:27:50Z","studyId":46,"studyName":"Acute Liver Failure Study Group: Adult Acute Liver Failure Study","studyAcronym":"AALF"},{"id":224,"title":"New Study: MAPP II","content":"A new study, The MAPP II Study of Urologic Chronic Pelvic Pain Syndrome: The Trans-MAPP Symptom Patterns Study (MAPP II), has been posted to the NIDDK Central Repository. Data from this study are now available for request.\r\n\r\nThe second phase (MAPP II) of the NIDDK Multidisciplinary Approach to the Study of Chronic Pelvic Pain (MAPP) Research Network was designed to conduct a prospective, observational study of men and women with urologic chronic pelvic pain syndrome (UCPPS). A central goal of MAPP II, like MAPP I, was to create a new knowledge base for informing future, targeted UCPPS clinical trials and ultimately to provide insights that will improve the clinical management of patients.","publishedDate":"2023-06-08T19:34:46Z","studyId":261,"studyName":"The MAPP II Study of Urologic Chronic Pelvic Pain Syndrome: The Trans-MAPP Symptom Patterns Study","studyAcronym":"MAPP II"},{"id":221,"title":"Data Update for MAPP I","content":"Data have been updated for the Multidisciplinary Approach to the Study of Pelvic Pain (MAPP I). This update includes updated datasets and new derived variables for the MAPP I study.\r\n\r\nIf you have already been approved to receive the MAPP I data package, please contact us through your request to download the updated data package.\r\n\r\nThe Multidisciplinary Approach to the Study of Chronic Pelvic Pain (MAPP) Research Network was established to focus on a broader approach to the study of Interstitial Cystitis (IC)/Painful Bladder Syndrome (PBS) in men and women, and Chronic Prostatitis (CP)/Chronic Pelvic Pain Syndrome (CPPS) in men. Participants with some form or symptoms of IC or CP were asked to join the Trans-MAPP Epidemiology and Phenotyping (EP) Study. Participants with no Urologic Pelvic Pain Syndromes as well as participants with specific conditions (Fibromyalgia (FM), Irritable Bowel Syndrome (IBS), Chronic Fatigue Syndrome (CFS)) were recruited for the Trans-MAPP Control Study. These participants were a reference/control group for the Trans-MAPP EP Study.","publishedDate":"2023-04-28T14:17:32Z","studyId":116,"studyName":"Multidisciplinary Approach to the Study of Pelvic Pain","studyAcronym":"MAPP I"},{"id":220,"title":"Data Update for LURN","content":"Data have been updated for the Symptoms of Lower Urinary Tract Dysfunction Phenotyping Study (LURN). Clinical, Qualitative, and Cognitive interview transcripts are now available for request.\r\n\r\nIf you have already been approved to receive the LURN data package, please contact us through your request to download the updated data package.\r\n\r\nThe Symptoms of Lower Urinary Tract Dysfunction Phenotyping Study (LURN) was established to gain a better understanding of lower urinary tract symptoms in an effort to improve the lives of those with lower urinary tract dysfunction. LURN participants were enrolled at multiple sites within the United States. Participants were assigned to one of four subgroups, based on their symptoms, the outcomes of clinical assessments, and other characteristics. Biological samples were collected from study participants and patients were required to complete certain assessments and examinations at standard time-points during the study period.","publishedDate":"2023-04-11T21:07:36Z","studyId":174,"studyName":"Symptoms of Lower Urinary Tract Dysfunction Phenotyping Study","studyAcronym":"LURN"},{"id":214,"title":"Data Update for TEDDY","content":"Data have been updated for The Environmental Determinants of Diabetes in the Young (TEDDY) study. This update includes additional analysis datasets for M107 and M221.\r\n\r\nIf you have already been approved to receive the TEDDY data package, please contact us through your request to download the updated data package.\r\n\r\nThe TEDDY study is a multicenter prospective cohort study that was established in response to these gaps in understanding of type 1 diabetes (T1D). The primary objectives of the study include identifying environmental factors—such as infectious agents, dietary factors, and psychosocial factors—that trigger or protect against the development of islet autoimmunity and T1D and examining genetic-environmental interactions to investigate interactive effects that contribute to T1D.","publishedDate":"2023-03-29T12:23:53Z","studyId":24,"studyName":"The Environmental Determinants of Diabetes in the Young","studyAcronym":"TEDDY"},{"id":213,"title":"New Study: PRESERVE","content":"A new study, Biomarker Collection and Analysis in the Prevention of Serious Adverse Events Following Angiography (PRESERVE) Trial Cohort, has been posted to the NIDDK Central Repository. Data and biospecimens from this study are now available for request.\r\n\r\nThe Biomarker Collection and Analysis sub-study collected, banked, and analyzed blood and urine of participants from the VA-funded PRESERVE trial. Blood and urine proteins and other markers may predict the development of contrast-induced acute kidney injury and diagnose the very early stages of this condition following angiography.","publishedDate":"2023-03-03T21:55:30Z","studyId":179,"studyName":"Biomarker Collection and Analysis in the Prevention of Serious Adverse Events Following Angiography (PRESERVE) Trial Cohort","studyAcronym":"PRESERVE"},{"id":212,"title":"New Study: LIFE-Moms","content":"A new study, Lifestyle Interventions for Expectant Moms (LIFE-Moms), has been posted to the NIDDK Central Repository. Data and biospecimens from this study are now available for request.\r\n\r\nThe LIFE-Moms consortium was a network of seven clinical centers and a data coordinating center to identify effective behavioral and lifestyle interventions that improve weight, glycemic control, and outcomes in obese and overweight pregnant women and their children.","publishedDate":"2023-03-02T16:13:15Z","studyId":140,"studyName":"Lifestyle Interventions for Expectant Moms","studyAcronym":"LIFE-Moms"},{"id":211,"title":"New Study: HBRN HIV Co-Infection","content":"A new study, Observational Study of Hepatitis B Virus (HBV) in Patients Co-Infected with Human Immunodeficiency Virus (HIV) (HBRN HIV Co-Infection), has been posted to the NIDDK Central Repository. Data and biospecimens from this study are now available for request.\r\n\r\nThe Hepatitis B Research Network (HBRN) was the first major effort to elucidate the natural history and treatment outcomes of persons with chronic HBV in the U.S. This HBRN ancillary study provided a unique opportunity to fill major gaps in HBV-HIV knowledge and to compare HBV-HIV infected persons to those with HBV monoinfection participating in the HBRN.","publishedDate":"2023-02-28T17:39:37Z","studyId":249,"studyName":"Observational Study of Hepatitis B Virus (HBV) in Patients Co-Infected with Human Immunodeficiency Virus (HIV)","studyAcronym":"HBRN HIV Co-Infection"},{"id":210,"title":"New Study: NEPTUNE","content":"A new study, Nephrotic Syndrome Study Network (NEPTUNE), has been posted to the NIDDK Central Repository. Data and biospecimens from this study are now available for request.\r\n\r\nThe NEPTUNE cohort study is a prospective, observational study that enrolls children and adults with FSGS, MCD, and MN. Participants have a proteinuria ≥ 500 mg/day, estimated from a 24-hour or protein to creatinine ratio urine collection. Participants with sub-nephrotic proteinuria are also included to capture the broad spectrum of clinical presentation.","publishedDate":"2023-02-07T20:59:26Z","studyId":115,"studyName":"Nephrotic Syndrome Study Network","studyAcronym":"NEPTUNE"},{"id":209,"title":"New Study: ITCH","content":"A new study, Efficacy and Safety of the Intestinal Bile Acid Transport (IBAT) Inhibitor LUM001 in the Treatment of Pruritus in Alagille Syndrome Patients (ITCH), has been posted to the NIDDK Central Repository. Data from this study are now available for request.\r\n\r\nThe ITCH study was a randomized, double-blind, placebo-controlled, parallel group, multi-center study in children with Alagille syndrome (ALGS). The study was designed to investigate the effects of LUM001 (Maralixibat), compared to placebo, on pruritus, serum bile acids, liver enzymes, and other biochemical markers associated with cholestatic liver disease, following daily dosing over a 13-week period.","publishedDate":"2023-01-31T20:40:08Z","studyId":231,"studyName":"Efficacy and Safety of the Intestinal Bile Acid Transport (IBAT) Inhibitor LUM001 in the Treatment of Pruritus in Alagille Syndrome Patients","studyAcronym":"ITCH"},{"id":208,"title":"Data Update for TEDDY","content":"Data have been updated for The Environmental Determinants of Diabetes in the Young (TEDDY) study. This update includes additional analysis datasets for M55, M115, and additional files for the M109 package.\r\n\r\nIf you have already been approved to receive the TEDDY data package, please contact us through your request to download the updated data package.\r\n\r\nThe TEDDY study is a multicenter prospective cohort study that was established in response to these gaps in understanding of type 1 diabetes (T1D). The primary objectives of the study include identifying environmental factors—such as infectious agents, dietary factors, and psychosocial factors—that trigger or protect against the development of islet autoimmunity and T1D and examining genetic-environmental interactions to investigate interactive effects that contribute to T1D.","publishedDate":"2023-01-12T17:37:14Z","studyId":24,"studyName":"The Environmental Determinants of Diabetes in the Young","studyAcronym":"TEDDY"},{"id":207,"title":"New Study: DAISY","content":"A new study, Diabetes Autoimmunity Study in the Young (DAISY), has been posted to the NIDDK Central Repository. Data from this study are now available for request.\r\n\r\nThe DAISY study follows children determined to be at an increased risk for development of type 1 diabetes (T1D), either due to known genetic markers or due to family history of T1D, and monitors them on an annual basis for development of T1D-related autoimmunity.","publishedDate":"2023-01-11T15:07:09Z","studyId":206,"studyName":"Diabetes Autoimmunity Study in the Young","studyAcronym":"DAISY"},{"id":206,"title":"New Study: TN20","content":"A new study, Immune Effects of Oral Insulin in Relatives at Risk for Type 1 Diabetes Mellitus (TN20 IEOI), has been posted to the NIDDK Central Repository. Data and biospecimens from this study are now available for request.\r\n\r\nThe TrialNet (TN20) study was a two-arm, multi-center, randomized, open-labeled clinical trial designed to assess the effects of varying doses and schedules of oral insulin on immunological and metabolic markers in relatives at risk for type 1 diabetes (T1D).","publishedDate":"2023-01-10T16:26:27Z","studyId":186,"studyName":"Immune Effects of Oral Insulin in Relatives at Risk for Type 1 Diabetes Mellitus","studyAcronym":"TN20"},{"id":204,"title":"Data Update for LOGIC (ChiLDReN)","content":"Data have been updated for the Longitudinal Study of Genetic Causes of Intrahepatic Cholestasis (LOGIC) study. This study is part of the Childhood Liver Disease Research Network (ChiLDReN). Analysis datasets from three publications are now available for request.\r\n\r\nIf you have already been approved to receive the LOGIC data package, please contact us through your request to download the updated data package. \r\n\r\nThe primary objectives of the LOGIC study include determining the frequency of poor growth and decreased bone mineral density and its predictors; identifying modifier genes that influence the incidence, severity, and progression of liver disease among affected individuals; and developing a repository of biospecimens to be used in ancillary studies of predictor biomarkers.","publishedDate":"2022-11-01T17:30:33Z","studyId":100,"studyName":"Longitudinal Study of Genetic Causes of Intrahepatic Cholestasis","studyAcronym":"LOGIC"},{"id":203,"title":"Data Update for TEDDY","content":"Data have been updated for The Environmental Determinants of Diabetes in the Young (TEDDY) study. This update includes additional analysis datasets for M93, M190, and M202.\r\n\r\nIf you have already been approved to receive the TEDDY data package, please contact us through your request to download the updated data package.\r\n\r\nThe TEDDY study is a multicenter prospective cohort study that was established in response to these gaps in understanding of type 1 diabetes (T1D). The primary objectives of the study include identifying environmental factors—such as infectious agents, dietary factors, and psychosocial factors—that trigger or protect against the development of islet autoimmunity and T1D and examining genetic-environmental interactions to investigate interactive effects that contribute to T1D.","publishedDate":"2022-10-27T18:42:40Z","studyId":24,"studyName":"The Environmental Determinants of Diabetes in the Young","studyAcronym":"TEDDY"},{"id":201,"title":"Data Update for PROBE","content":"Data have been updated for the Prospective Database of Infants with Cholestasis (PROBE). This update includes analysis datasets from four publications including combined data from the Biliary Atresia Study in Infants and Children (BASIC) and Longitudinal Study of Genetic Causes of Intrahepatic Cholestasis (LOGIC) studies.\r\n\r\nIf you have already been approved to receive the PROBE data package, please contact us through your request to download the updated data package.\r\n\r\nPROBE is a multi-center project to establish a prospective database of clinical information and a repository of blood and tissue samples from children with diagnoses of neonatal liver diseases, such as biliary atresia and neonatal hepatitis, in order to perform research in these liver problems","publishedDate":"2022-09-14T15:53:50Z","studyId":99,"studyName":"A Prospective Database of Infants With Cholestasis","studyAcronym":"PROBE"},{"id":200,"title":"New Study: PROTECT","content":"A new study, Predicting Response to Standardized Pediatric Colitis Therapy (PROTECT), has been posted to the NIDDK Central Repository. Data and biospecimens from this study are now available for request.\r\n\r\nThis multicenter open-label study was designed to evaluate the safety and efficacy of standardized initial therapy using either mesalamine or corticosteroids then mesalamine for the treatment of children and adolescents newly diagnosed with ulcerative colitis.","publishedDate":"2022-09-09T15:26:46Z","studyId":143,"studyName":"Predicting Response to Standardized Pediatric Colitis Therapy","studyAcronym":"PROTECT"},{"id":199,"title":"Data Update for TN19","content":"Data have been updated for the ATG-GCSF in New Onset Type 1 Diabetes Study (TN19 ATG-GCSF). This update includes final study datasets and secondary ImmunoChip results data.\r\n\r\nIf you have already been approved to receive the TN19 data package, please contact us through your request to download the updated data package.\r\n\r\nThe TrialNet 19 (TN19) study was a three-arm, 1:1:1 randomized, placebo controlled, double- blinded trial in which participants either received active Anti-Thymocyte Globulin (ATG) and Granulocyte Colony Stimulating Factor (GCSF), received ATG alone, or received a placebo alone within 100 days from diagnosis of type 1 diabetes. TrialNet researchers assessed whether ATG used alone or in combination with GCSF helped participants continue to make some of their own insulin.","publishedDate":"2022-08-23T16:59:08Z","studyId":185,"studyName":"Antithymocyte Globulin (ATG) and Pegylated Granulocyte Colony Stimulating Factor (GCSF) in New Onset Type 1 Diabetes","studyAcronym":"TN19"},{"id":198,"title":"Data Update for TEDDY","content":"Data have been updated for The Environmental Determinants of Diabetes in the Young (TEDDY) study. This update includes additional analysis datasets for M72 and M179.\r\n\r\nIf you have already been approved to receive the TEDDY data package, please contact us through your request to download the updated data package.\r\n\r\nThe TEDDY study is a multicenter prospective cohort study that was established in response to these gaps in understanding of type 1 diabetes (T1D). The primary objectives of the study include identifying environmental factors—such as infectious agents, dietary factors, and psychosocial factors—that trigger or protect against the development of islet autoimmunity and T1D and examining genetic-environmental interactions to investigate interactive effects that contribute to T1D.","publishedDate":"2022-08-19T17:14:14Z","studyId":24,"studyName":"The Environmental Determinants of Diabetes in the Young","studyAcronym":"TEDDY"},{"id":197,"title":"Data Update for MAPP1","content":"Data have been updated for the Multidisciplinary Approach to the Study of Pelvic Pain (MAPP1). This update includes full study data for the MAPP1 study.\r\n\r\nIf you have already been approved to receive the MAPP1 data package, please contact us through your request to download the updated data package.\r\n\r\nThe Multidisciplinary Approach to the Study of Chronic Pelvic Pain (MAPP) Research Network was established to focus on a broader approach to the study of Interstitial Cystitis (IC)/Painful Bladder Syndrome (PBS) in men and women, and Chronic Prostatitis (CP)/Chronic Pelvic Pain Syndrome (CPPS) in men. Participants with some form or symptoms of IC or CP were asked to join the Trans-MAPP Epidemiology and Phenotyping (EP) Study. Participants with no Urologic Pelvic Pain Syndromes as well as participants with specific conditions (Fibromyalgia (FM), Irritable Bowel Syndrome (IBS), Chronic Fatigue Syndrome (CFS)) were recruited for the Trans-MAPP Control Study. These participants were a reference/control group for the Trans-MAPP EP Study.","publishedDate":"2022-08-09T18:57:24Z","studyId":116,"studyName":"Multidisciplinary Approach to the Study of Pelvic Pain","studyAcronym":"MAPP I"},{"id":196,"title":"New Study: TODAY2 ECHO","content":"A new study, TODAY2 Control Echocardiogram Sample Data Collection Study (TODAY2 ECHO), has been posted to the NIDDK Central Repository. Data and biospecimens from this study are now available for request.\r\n\r\nIn the last year of the TODAY study, the cohort was assessed by echocardiography. A follow-up echocardiogram was completed 5 years later during the TODAY2 study. During TODAY2, the study also collected comparative echocardiogram control data in individuals without diabetes and hypertension, and also performed a one-time collection of data and blood for storage of serum and plasma in these consented control participants.","publishedDate":"2022-08-05T18:15:53Z","studyId":295,"studyName":"TODAY2 Control Echocardiogram Sample Data Collection Study","studyAcronym":"TODAY2 ECHO"},{"id":195,"title":"New Study: TODAY2","content":"A new study, Treatment Options for Type 2 Diabetes in Adolescents \u0026 Youth Long Term Follow-Up (TODAY2), has been posted to the NIDDK Central Repository. Data and biospecimens from this study are now available for request.\r\n\r\nThe TODAY2 study was a longitudinal follow-up study to the TODAY (Treatment Options for Type 2 Diabetes in Adolescents and Youth) study that continued the care and observation of the TODAY cohort participants beyond the end of the TODAY intervention trial. The TODAY2 study had two phases: 1) Transition of TODAY participants to non-blinded, non-randomized standard diabetes care and management with monitoring and follow-up for up to 24 months, and 2) Long-term longitudinal follow-up of the TODAY cohort based on findings from TODAY.","publishedDate":"2022-08-05T17:00:32Z","studyId":282,"studyName":"Treatment Options for Type 2 Diabetes in Adolescents \u0026 Youth Long Term Follow-Up","studyAcronym":"TODAY2"},{"id":194,"title":"Data Update for Look AHEAD","content":"Data have been updated for Look AHEAD: Action for Health in Diabetes (Look AHEAD). This update includes new and updated datasets for the intervention and post-intervention phases of the study.\r\n\r\nIf you have already been approved to receive the Look AHEAD data package, please contact us through your request to download the updated data package.\r\n\r\nThe Look AHEAD study was a clinical trial designed to assess whether an intensive lifestyle intervention program designed to achieve and maintain weight loss by decreased caloric intake and increased physical activity improves the long-term cardiovascular morbidity and mortality of overweight patients with type 2 diabetes.","publishedDate":"2022-07-06T20:41:47Z","studyId":61,"studyName":"Look AHEAD: Action for Health in Diabetes","studyAcronym":"Look AHEAD"},{"id":193,"title":"New Study: SEARCH","content":"A new study, SEARCH for Diabetes in Youth (SEARCH), has been posted to the NIDDK Central Repository. Data and biospecimens from this study are now available for request.\r\n\r\nThe SEARCH for Diabetes in Youth (SEARCH) study was initiated in 2000 to address major knowledge gaps in the understanding of childhood diabetes. The SEARCH study was conducted at five sites across the U.S. and established a longitudinal cohort to assess the natural history and risk factors for acute and chronic diabetes-related complications, as well as the quality of care and quality of life of persons with diabetes from diagnosis into young adulthood.","publishedDate":"2022-06-15T20:58:43Z","studyId":203,"studyName":"SEARCH for Diabetes in Youth","studyAcronym":"SEARCH"},{"id":192,"title":"Data Update for TN16","content":"Data have been updated for the Long-Term Investigative Follow-Up in TrialNet Study (TN16 LIFT). This update includes a new dataset on health status in addition to updates to existing datasets.\r\n\r\nIf you have already been approved to receive the TN16 data package, please contact us through your request to download the updated data package.\r\n\r\nThe TN16 LIFT study is a clinical study that follows participants from TrialNet prevention studies after diagnosis with type 1 diabetes (T1D). The study follows individuals who developed diabetes while being monitored in the Pathway to Prevention Study or during participation in any prevention trial. The purpose is to study people early in the disease process. Additionally, the study follows individuals who participated in any new onset studies to learn more about diabetes and if there are any long-term effects from the treatments used in those studies.","publishedDate":"2022-06-09T20:06:46Z","studyId":184,"studyName":"Long-Term Investigative Follow-Up in TrialNet Study","studyAcronym":"TN16"},{"id":191,"title":"Data Update for HALT PKD","content":"Data have been updated for the HALT Progression of Polycystic Kidney Disease (HALT PKD). This update includes an additional dataset containing HALT PKD allele frequencies.\r\n\r\nIf you have already been approved to receive the HALT PKD data package, please contact us through your request to download the updated data package.\r\n\r\nThe HALT Progression of Polycystic Kidney Disease (HALT PKD) studies are two simultaneous multicenter clinical trials designed to test the efficacy of interruption of the renin-angiotensin-aldosterone system (RAAS) on the progression of cystic disease and the decline in renal function in autosomal dominant polycystic kidney disease (ADPKD). Specifically, the studies test the effects of ACE-I/ARB combination therapy as compared to ACE-I monotherapy in hypertensive ADPKD subjects.","publishedDate":"2022-06-08T20:16:02Z","studyId":28,"studyName":"The HALT Progression of Polycystic Kidney Disease","studyAcronym":"HALT PKD"},{"id":190,"title":"Data Update for CRIC","content":"Data have been updated for the Chronic Renal Insufficiency Cohort Study (CRIC). This update includes updated datasets and additional analysis and raw datasets.\r\n\r\nIf you have already been approved to receive the CRIC data package, please contact us through your request to download the updated data package.\r\n\r\nThe Chronic Renal Insufficiency Cohort (CRIC) Study is an observational study that examined risk factors for progression of chronic renal insufficiency (CRI) and cardiovascular disease (CVD) among CRI patients. The study enrolled adults aged 21 to 74 years with a broad spectrum of renal disease severity, half of whom were diagnosed with diabetes mellitus. Subjects underwent extensive clinical evaluation at baseline and at annual clinic visits and via telephone at 6 month intervals.","publishedDate":"2022-05-17T20:51:02Z","studyId":15,"studyName":"Chronic Renal Insufficiency Cohort Study","studyAcronym":"CRIC"},{"id":188,"title":"Data Update for TEDDY","content":"Data have been updated for The Environmental Determinants of Diabetes in the Young (TEDDY) study. This update includes additional analysis datasets for M162 and M238.\r\n\r\nIf you have already been approved to receive the TEDDY data package, please contact us through your request to download the updated data package.\r\n\r\nThe TEDDY study is a multicenter prospective cohort study that was established in response to these gaps in understanding of type 1 diabetes (T1D). The primary objectives of the study include identifying environmental factors—such as infectious agents, dietary factors, and psychosocial factors—that trigger or protect against the development of islet autoimmunity and T1D and examining genetic-environmental interactions to investigate interactive effects that contribute to T1D.","publishedDate":"2022-03-14T22:00:00Z","studyId":24,"studyName":"The Environmental Determinants of Diabetes in the Young","studyAcronym":"TEDDY"},{"id":187,"title":"Data Update for TN01","content":"Data have been updated for the TrialNet Pathway to Prevention (TN01) study. This update includes study data through 2020.\r\n\r\nIf you have already been approved to receive the TN01 data package, please contact us through your request to download the updated data package.\r\n\r\nTrialNet is a network of 19 clinical centers worldwide that conducts research on the study, prevention, and early treatment of type 1 diabetes (T1D). The TrialNet Pathway To Prevention (TN01) is a screening and monitoring study that was established to provide a source of subjects for enrollment into prevention trials.","publishedDate":"2022-02-28T21:15:00Z","studyId":80,"studyName":"TrialNet Pathway To Prevention (formerly Natural History Study)","studyAcronym":"TN01"},{"id":186,"title":"Data Update for CRISP","content":"Data have been updated for the Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP). This update includes an additional dataset containing CRISP allele frequencies.\r\n\r\nIf you have already been approved to receive the CRISP data package, please contact us through your request to download the updated data package.\r\n\r\nThe Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) was established to develop and implement studies to test whether imaging techniques can provide accurate and reproducible markers of progression of renal disease in patients with polycystic kidney disease.","publishedDate":"2022-02-25T21:09:29Z","studyId":10,"studyName":"Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease","studyAcronym":"CRISP"},{"id":185,"title":"Data Update for TN07","content":"Data have been updated for the Oral Insulin for Prevention of Diabetes in Relatives at Risk for Type 1 Diabetes Mellitus (TN07) study. This update includes the final datasets for the TN07 study.\r\n\r\nIf you have already been approved to receive the TN07 data package, please contact us through your request to download the updated data package.\r\n\r\nThe TN07 study was a clinical trial that assessed the efficacy of oral insulin in the prevention or delay of the development of type 1 diabetes mellitus in subjects with mIAA and other autoantibodies and a proband with type 1 diabetes.","publishedDate":"2022-02-18T20:01:53Z","studyId":91,"studyName":"Oral Insulin for Prevention of Diabetes in Relatives at Risk for Type 1 Diabetes Mellitus","studyAcronym":"TN07"},{"id":184,"title":"New Study: JDRF-TEDDY Follow-Up","content":"A new study, JDRF Follow-Up of Children Diagnosed with Diabetes (JDRF-TEDDY Follow-Up), has been posted to the NIDDK Central Repository. Data and biospecimens from this study are now available for request.\r\n\r\nThe JDRF Follow-up of Children Diagnosed with Diabetes (JDRF-TEDDY Follow-Up) study sought to understand whether children were diagnosed at an earlier stage of T1D compared to children not enrolled in prospective studies, and to identify if they maintained the ability to produce C-peptide longer than children diagnosed through standard clinical care in the community. The JDRF-TEDDY Follow-Up study analyzed the preservation of C-peptide over time in children diagnosed with T1D through prospective studies and compared them to a group of age matched controls identified from the community.","publishedDate":"2021-12-07T15:22:11Z","studyId":288,"studyName":"JDRF Follow-up of Children Diagnosed with Diabetes","studyAcronym":"JDRF-TEDDY Follow-Up"},{"id":183,"title":"Data Update for FSGS/FONT","content":"Data have been updated for Novel Therapies to Treat Resistant Focal Segmental Glomerulosclerosis: Phase II Clinical Trial (FSGS/FONT). This update includes a new ancillary dataset containing FSGS APOL1 genotypes.\r\n\r\nIf you have already been approved to receive the FSGS/FONT data package, please contact us through your request to download the updated data package.\r\n\r\nThe FSGS Clinical Trial (FSGS-CT) was a multi-center, prospective, controlled, open label randomized trial designed to determine if treatment with mycophenolate mofetil (MMF) in conjunction with pulse steroids is superior to treatment with Cyclosporine-A (CSA) in inducing remission from proteinuria over 12 months.","publishedDate":"2021-11-24T19:48:31Z","studyId":31,"studyName":"Novel Therapies to Treat Resistant Focal Segmental Glomerulosclerosis: Phase II Clinical Trial","studyAcronym":"FSGS/FONT"},{"id":182,"title":"Data Update for DPP","content":"Data have been updated for The Diabetes Prevention Program (DPP). This update includes a new dataset containing additional measures (age, weight, and BMI) from study baseline.\r\n\r\nIf you have already been approved to receive the DPP data package, please contact us through your request to download the updated data package.\r\n\r\nThe Diabetes Prevention Program (DPP) is a clinical trial that investigated whether modest weight loss through dietary changes and increased physical activity or treatment with the oral diabetes drug metformin (Glucophage) could prevent or delay the onset of type 2 diabetes in high-risk individuals with prediabetes.","publishedDate":"2021-11-22T17:41:59Z","studyId":38,"studyName":"Diabetes Prevention Program","studyAcronym":"DPP"},{"id":180,"title":"Data Update for CKiD","content":"Data have been updated for The Chronic Kidney Disease in Children Cohort Study (CKiD). This update includes an additional analysis dataset (Pierce et al. AJE 2011) and follow-up data through July 31, 2018.\r\n\r\nIf you have already been approved to receive the CKiD data package, please contact us through your request to download the updated data package.\r\n\r\nChronic kidney disease (CKD) is a life-long condition that often results in substantial morbidity and premature death due to complications from a progressive decrease in kidney function. The early detection of, and initiation of therapy for, CKD is key to delaying or preventing progression to end-stage renal disease (ESRD). The CKiD study is a prospective cohort study of children with CKD that investigates risk factors and outcomes of the disease.","publishedDate":"2021-11-08T13:52:52Z","studyId":39,"studyName":"The Chronic Kidney Disease in Children Cohort Study","studyAcronym":"CKiD"},{"id":179,"title":"New Study: PERL","content":"A new study, A Multicenter Clinical Trial of Allopurinol to Prevent Kidney Function Loss in Type 1 Diabetes (PERL), has been posted to the NIDDK Central Repository. Data and biospecimens from this study are now available for request.\r\n\r\nThe PERL Study was a double-blinded, international clinical trial conducted with patients with type 1 diabetes that had an increased risk of developing kidney disease. Participants were randomly assigned to take allopurinol or placebo for three years, during which they were followed through periodical visits. Kidney function was measured at the beginning and at the end of the treatment period to assess whether patients taking allopurinol experienced a slower loss of kidney function over time compared to those taking the placebo.","publishedDate":"2021-10-20T15:33:37Z","studyId":204,"studyName":"A Multicenter Clinical Trial of Allopurinol to Prevent Kidney Function Loss in Type 1 Diabetes","studyAcronym":"PERL"},{"id":178,"title":"Data Update for FAVORIT","content":"Data have been updated for the Folic Acid for Vascular Outcome Reduction in Transplantation Trial (FAVORIT). This update includes results of sample stability testing for a subset of biospecimens through multiple freeze/thaw cycles.\r\n\r\nIf you have already been approved to receive the FAVORIT data package, please contact us through your request to download the updated data package.\r\n\r\nFAVORIT is a multicenter, randomized, double-blind clinical trial to determine whether total homocysteine (tHcy)-lowering treatment with a standard multivitamin augmented by a high dose combination of folic acid, vitamin B12, and vitamin B6, versus treatment with an identical multivitamin containing no folic acid and estimated average requirement (EAR) amounts of vitamin B6 and vitamin B12, reduces cardiovascular disease (CVD) outcomes among clinically stable renal transplant recipients (RTRs) with elevated tHcy levels.","publishedDate":"2021-10-18T16:16:48Z","studyId":17,"studyName":"Folic Acid for Vascular Outcome Reduction in Transplantation Trial","studyAcronym":"FAVORIT"},{"id":177,"title":"Data Update for TEDDY","content":"Data have been updated for the Environmental Determinants of Diabetes in the Young (TEDDY) study. This update includes additional analysis datasets for M105 and M158.\r\n\r\nIf you have already been approved to receive the TEDDY data package, please contact us through your request to download the updated data package.\r\n\r\nThe TEDDY study is a multicenter prospective cohort study that was established in response to these gaps in understanding of T1D. The primary objectives of the study include identifying environmental factors—such as infectious agents, dietary factors, and psychosocial factors—that trigger or protect against the development of islet autoimmunity and T1D and examining genetic-environmental interactions to investigate interactive effects that contribute to T1D.","publishedDate":"2021-10-04T16:45:30Z","studyId":24,"studyName":"The Environmental Determinants of Diabetes in the Young","studyAcronym":"TEDDY"},{"id":176,"title":"New Study: TODAY Genetics","content":"A new study, Treatment Options for Type 2 Diabetes in Adolescents \u0026 Youth (TODAY) Genetics, has been posted to the NIDDK Central Repository. Data from this study are now available for request. \r\n\r\nThe TODAY Genetics study was an ancillary study of the TODAY interventional trial conducted under the auspices of the TODAY study group. The primary objective of the TODAY Genetics study was to explore relationships between candidate genes and Type 2 Diabetes (T2D) using blood and phenotypic information collected from participants. In addition, the study investigated the role of Genetics in obesity, insulin resistance, and cardiac risk in T2D patients.","publishedDate":"2021-09-23T14:44:23Z","studyId":169,"studyName":"TODAY Genetics Study","studyAcronym":"TODAY Genetics"},{"id":175,"title":"New Study: TiME","content":"A new study, Time to Reduce Mortality in End-Stage Renal Disease (TiME) Trial, has been posted to the NIDDK Central Repository. Data from this study are now available for request.\r\n\r\nThe TiME trial was a cluster-randomized, parallel-group pragmatic clinical trial for patients initiating treatment with maintenance hemodialysis. Facilities were randomized in a 1:1 distribution to the Intervention arm or the Usual Care arm. The primary objective of the TiME trial was to determine whether hemodialysis duration of a minimum of 4.25 hours (versus usual care) in patients with end-stage renal disease has benefits on mortality, hospitalizations, and health-related quality of life. The TiME trial also aimed to demonstrate the capacity to conduct large, pragmatic clinical trials with two large dialysis provider organizations.","publishedDate":"2021-09-08T16:18:23Z","studyId":289,"studyName":"Time to Reduce Mortality in End-Stage Renal Disease","studyAcronym":"TiME"},{"id":174,"title":"Data Update for Look AHEAD","content":"Data have been updated for the Look AHEAD: Action for Health in Diabetes study. This update contains data from the Look AHEAD Continuation Study (Look AHEAD-C), which builds on the Look AHEAD study to determine the long-term impact of an intensive lifestyle intervention on 1) physical function and mobility disability, and 2) cognitive function and cognitive impairment. Collection of cognitive function measures began in Year 8 of the study and continued through Year 13.\r\n\r\nIf you have already been approved to receive the Look AHEAD data package, please contact us through your request to download the updated data package.\r\n\r\nThe Look AHEAD study was a clinical trial designed to assess whether an intensive lifestyle intervention program designed to achieve and maintain weight loss by decreased caloric intake and increased physical activity improves the long-term cardiovascular morbidity and mortality of overweight patients with type 2 diabetes.","publishedDate":"2021-09-07T18:49:41Z","studyId":61,"studyName":"Look AHEAD: Action for Health in Diabetes","studyAcronym":"Look AHEAD"},{"id":173,"title":"Data Update for DCCT/EDIC","content":"Data have been updated for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) study. This update includes an additional analysis dataset (EDIC Year 24 Microvascular CVD) and raw data for EDIC years 19 through 24.\r\n \r\nIf you have already been approved to receive the DCCT/EDIC data package, please contact us through your request to download the updated data package. \r\n\r\nThe Diabetes Control and Complications Trial (DCCT) was a multicenter, randomized clinical trial designed to compare intensive with conventional diabetes therapy with regard to their effects on the development and progression of the early vascular and neurologic complications of type 1 insulin-dependent diabetes mellitus. The Epidemiology of Diabetes Interventions and Complications (EDIC) study was initiated as follow-up to examine the long-term effects of the original DCCT interventions on diabetic complications such as cardiovascular events and advanced retinal and renal disease.","publishedDate":"2021-08-27T15:57:52Z","studyId":16,"studyName":"Diabetes Control and Complications Trial / Epidemiology of Diabetes Interventions and Complications","studyAcronym":"DCCT/EDIC"},{"id":172,"title":"Data Update for TEDDY","content":"Data have been updated for the Environmental Determinants of Diabetes in the Young (TEDDY) study. This update includes an additional analysis dataset (M123) and a dataset containing results from TEDDY OLINK analysis. \r\n\r\nIf you have already been approved to receive the TEDDY data package, please contact us through your request to download the updated data package.\r\n\r\nThe TEDDY study is a multicenter prospective cohort study that was established in response to these gaps in understanding of T1D. The primary objectives of the study include identifying environmental factors—such as infectious agents, dietary factors, and psychosocial factors—that trigger or protect against the development of islet autoimmunity and T1D and examining genetic-environmental interactions to investigate interactive effects that contribute to T1D.","publishedDate":"2021-08-18T21:20:52Z","studyId":24,"studyName":"The Environmental Determinants of Diabetes in the Young","studyAcronym":"TEDDY"},{"id":171,"title":"New Study: HAPO-FUS","content":"A new study, Hyperglycemia and Adverse Pregnancy Outcomes Follow-Up Study (HAPO-FUS), has been posted to the NIDDK Central Repository. Data and biospecimens from this study are now available for request.\r\n\r\nThe HAPO Follow-up Study was initiated to determine whether elevated blood sugar during pregnancy, below the threshold for gestational diabetes, influences either development of type 2 diabetes mellitus in mothers or adiposity and disorders of glucose metabolism in offspring at 8-12 years of age. The HAPO Follow-Up Study enrolled 7,000 mother-child pairs who originally participated in the HAPO Study. Mothers and children were required to complete a single study visit for measurement of height, weight, blood pressure, body fat, insulin, and blood sugar and lipid levels. The primary outcome measures assessed in relation to maternal glycemia during pregnancy were development of diabetes in mothers and obesity and altered glucose metabolism in children, as well as other metabolic abnormalities in both mothers and offspring.","publishedDate":"2021-08-09T21:17:27Z","studyId":150,"studyName":"Hyperglycemia and Adverse Pregnancy Outcome Follow-Up Study","studyAcronym":"HAPO-FUS"},{"id":170,"title":"Data Update for Look AHEAD","content":"Data have been updated for the Look AHEAD: Action for Health in Diabetes study. This update contains data from an ancillary study, Look AHEAD Brain, which aimed to assess whether participation in the 10-year lifestyle intervention, as part of Look AHEAD, had an impact on white matter hyperintensity and loss of brain tissue among individuals with type 2 diabetes. A subset of Look AHEAD study participants underwent standardized brain magnetic resonance imaging in conjunction with tests assessing cognitive function 10-12 years post-randomization. \r\n\r\nIf you have already been approved to receive the Look AHEAD data package, please contact us through your request to download the updated data package.\r\n\r\nThe Look AHEAD study was a clinical trial designed to assess whether an intensive lifestyle intervention program designed to achieve and maintain weight loss by decreased caloric intake and increased physical activity improves the long-term cardiovascular morbidity and mortality of overweight patients with type 2 diabetes.","publishedDate":"2021-07-30T19:25:09Z","studyId":61,"studyName":"Look AHEAD: Action for Health in Diabetes","studyAcronym":"Look AHEAD"},{"id":169,"title":"Data Update for LABS","content":"Data have been updated for the Longitudinal Assessment of Bariatric Surgery (LABS) study. This update contains data from an ancillary study regarding psychosocial issues associated with bariatric surgery. This ancillary prospective cohort study aimed to understand the mental health impacts of bariatric surgery and changes in mental health outcomes over a 7-year follow-up period. Data were collected on psychosocial issues such as eating disorders, substance abuse, affective disorders, and cognitive function.\r\n\r\nIf you have already been approved to receive the LABS data package, please contact us through your request to download the updated data package.\r\n\r\nThe LABS study was an observational study designed to assess the risks and health benefits associated with bariatric surgery and to identify aspects of the procedures and patient characteristics associated with optimal outcomes.","publishedDate":"2021-07-29T22:43:56Z","studyId":34,"studyName":"Longitudinal Assessment of Bariatric Surgery","studyAcronym":"LABS"},{"id":168,"title":"Data Update for DPP","content":"Data have been updated for the Diabetes Prevention Program (DPP) study. This update contains supplemental measurements using biospecimens that were obtained during the original DPP clinical trial. These measurements include antibodies, biomarkers, hormones, and vitamin D levels to assess the relationships between sex hormones, diabetes risk factors, and the progression to diabetes. \r\n\r\nIf you have already been approved to receive the DPP data package, please contact us through your request to download the updated data package.\r\n\r\nThe Diabetes Prevention Program (DPP) is a clinical trial that investigated whether modest weight loss through dietary changes and increased physical activity or treatment with the oral diabetes drug metformin (Glucophage) could prevent or delay the onset of type 2 diabetes in high risk individuals with prediabetes.","publishedDate":"2021-07-27T16:11:56Z","studyId":38,"studyName":"Diabetes Prevention Program","studyAcronym":"DPP"},{"id":167,"title":"New Study: FORCE","content":"A new study, FibroScan in Pediatric Cholestatic Liver Disease (FORCE), has been posted to the NIDDK Central Repository. Data and biospecimens from this study are now available for request.\r\n\r\nThe FORCE study was a cross-sectional and longitudinal assessment of the utility of liver stiffness measurement (LSM) in children with chronic cholestatic liver disease. FORCE participants were also enrolled in the PROBE, BASIC, or LOGIC studies, and were evaluated for a period of up to 24 months to assess the non-invasive ultrasound tool (FibroScan™) to detect and quantify global liver fibrosis in children with biliary atresia (BA), alpha-1 antitrypsin deficiency (A1ATD), and Alagille syndrome (ALGS). Baseline data are currently available.","publishedDate":"2021-05-28T15:24:41Z","studyId":187,"studyName":"FibroScan in Pediatric Cholestatic Liver Disease","studyAcronym":"FORCE"},{"id":166,"title":"New Study: RISE Pediatric Medication","content":"A new study, Restoring Insulin Secretion – Pediatric Medication Study (RISE Pediatric Medication), has been posted to the NIDDK Central Repository. Data and biospecimens from this study are now available for request.\r\n\r\nThe RISE Pediatric Medication Study was a two-arm, multi-center clinical trial. Study participants were enrolled at four recruitment centers and randomized into two treatment groups. The first group received metformin alone for 12 months. The second group received glargine, a man-made insulin, for three months followed by metformin for the remaining nine months of the treatment period. Beta-cell function and insulin sensitivity were assessed at baseline, the end of the active treatment period, and three months after treatment was withdrawn.","publishedDate":"2021-02-26T21:08:38Z","studyId":269,"studyName":"Restoring Insulin Secretion – Pediatric Medication Study","studyAcronym":"RISE Pediatric Medication"},{"id":165,"title":"Data Update for TEDDY","content":"Data have been updated for the Environmental Determinants of Diabetes in the Young (TEDDY) study. This update includes two additional analysis datasets (M62 and M237). \r\n\r\nIf you have already been approved to receive the TEDDY data package, please contact us through your request to download the updated data package.\r\n\r\nThe TEDDY study is a multicenter prospective cohort study that was established in response to these gaps in understanding of T1D. The primary objectives of the study include identifying environmental factors—such as infectious agents, dietary factors, and psychosocial factors—that trigger or protect against the development of islet autoimmunity and T1D and examining genetic-environmental interactions to investigate interactive effects that contribute to T1D.","publishedDate":"2021-02-25T02:54:15Z","studyId":24,"studyName":"The Environmental Determinants of Diabetes in the Young","studyAcronym":"TEDDY"},{"id":164,"title":"New Study: RISE BetaFat","content":"A new study, Beta Cell Restoration Through Fat Mitigation (BetaFat), has been posted to the NIDDK Central Repository. Data and biospecimens from this study are now available for request.\r\n\r\nThe Beta Cell Restoration Through Fat Mitigation (BetaFat) study was created to determine if weight loss through gastric banding surgery would be more effective than metformin medication at sustaining or improving beta-cell function in individuals with prediabetes or early type 2 diabetes, who are also mildly to moderately obese.","publishedDate":"2021-02-25T02:51:25Z","studyId":270,"studyName":"Beta Cell Restoration Through Fat Mitigation","studyAcronym":"BetaFat"},{"id":163,"title":"New Study: RISE Adult Medication","content":"A new study, Restoring Insulin Secretion - Adult Medication Study (RISE Adult Medication), has been posted to the NIDDK Central Repository. Data and biospecimens from this study are now available for request.\r\n\r\nThe RISE Adult Medication Study was a partially double-blind, placebo-controlled, four-arm clinical trial. Study participants were randomized into four groups and received treatment for 12 months. During the treatment period, the first group received Metformin alone; the second group received Glargine for three months, followed by Metformin for the remaining nine months; the third group received Liraglutide in combination with Metformin; and the fourth group was treated with placebo. Following the 12-month treatment period, each group underwent treatment withdrawal for three months. Insulin sensitivity and beta-cell function was evaluated at baseline, the end of the treatment period, and the end of the withdrawal period.","publishedDate":"2020-12-31T17:44:26Z","studyId":268,"studyName":"Restoring Insulin Secretion - Adult Medication Study","studyAcronym":"RISE Adult Medication"},{"id":162,"title":"New Study: ASSESS-AKI","content":"A new study, Assessment, Serial Evaluation, and Subsequent Sequelae in Acute Kidney Injury (ASSESS-AKI), has been posted to the NIDDK Central Repository. Data and biospecimens from this study are now available for request.\r\n\r\nThe Assessment, Serial Evaluation, and Subsequent Sequelae of Acute Kidney Injury (ASSESS-AKI) Study investigates differences in the occurrence of renal and cardiovascular outcomes and death within a diverse, matched cohort of patients with and without acute kidney injury (AKI). This prospective study enrolls a cohort of 1100 adult participants with a broad range of AKI and matched hospitalized participants without AKI at 3 Clinical Research Centers, as well as 100 children undergoing cardiac surgery at 3 Clinical Research Centers. Participants are followed for up to four years, and undergo serial evaluation during the index hospitalization, at three months post-hospitalization, and at annual clinic visits, with telephone interviews occurring during the intervening six-month intervals. Biospecimens are collected at each visit, in addition to information on lifestyle behaviors, quality of life and functional status, cognitive function, receipt of therapies, interim renal and cardiovascular events, electrocardiography, and urinalysis.","publishedDate":"2020-12-31T17:23:37Z","studyId":74,"studyName":"Assessment, Serial Evaluation, and Subsequent Sequelae in Acute Kidney Injury","studyAcronym":"ASSESS-AKI"},{"id":161,"title":"New Study: TarGut","content":"A new study, Gut Microbiome and p-Inulin in CKD - TarGut CKD Study (TarGut), has been posted to the NIDDK Central Repository. Data and biospecimens from this study are now available for request.\r\n\r\nThe Gut Microbiome and p-Inulin in CKD (TarGut) Study was formed to determine if the gut microbiome of patients with CKD could be improved with treatment of p-inulin, a type of prebiotic. After recruitment and enrollment, TarGut participants are evaluated for a period of 28 weeks. This 28-week study period consists of three phases: an 8-week pre-treatment phase, 12-week active treatment phase, and 8-week post-treatment phase. During the active treatment phase participants take the p-inulin supplement daily, but participants don’t receive any intervention during the pre- and post-treatment phases. Biological samples are collected from study participants every week during the 28-week study period and assessed to determine microbial composition and function.","publishedDate":"2020-11-18T14:21:02Z","studyId":210,"studyName":"Gut Microbiome and p-Inulin in CKD - TarGut CKD Study","studyAcronym":"TarGut"},{"id":160,"title":"Data Update for AASK Trial","content":"Data have been updated for the African American Study of Kidney Disease and Hypertension Study (AASK Trial) study. Additional lab data have been added to the data package.\r\n\r\nIf you have already been approved to receive the AASK Trial data package, please contact us through your request to download the updated data package.\r\n\r\nThe African American Study of Kidney Disease and Hypertension study (AASK Trial) was a multi-center, randomized clinical trial that investigated the effects of blood pressure (BP) control and the use of specific antihypertensive regimens on the progression of chronic kidney disease (CKD). The study was designed to address the high incidence of CKD in African Americans with hypertension. A two by three factorial study design, including two levels of BP control as defined by mean arterial pressure (MAP) and three different anti-hypertensive regimens, was used. Participants were randomized into two levels of BP control groups, either a goal MAP \u003c 92 mmHg or a goal MAP between 102-107 mmHg inclusive.. The antihypertensive drugs used for treatment were amlodipine, a calcium channel blocker; ramipril, an angiotensin-converting enzyme inhibitor; and metoprolol, a β-blocker. The trial was double-blind (drug administration only). The change in glomerular filtration rate (GFR) as determined by iothalamate clearance was measured as the primary outcome to test the regimens’ efficacy in slowing the rate of decline of kidney function.","publishedDate":"2020-11-18T13:18:12Z","studyId":56,"studyName":"African American Study of Kidney Disease and Hypertension Study (Clinical Trial)","studyAcronym":"AASK Trial"},{"id":159,"title":"Data Update for MDRD","content":"Data have been updated for the Modification of Diet in Renal Disease (MDRD) study. Additional lab data have been added to the data package.\r\n\r\nIf you have already been approved to receive the MDRD data package, please contact us through your request to download the updated data package.\r\n\r\nThe Modification of Diet in Renal Disease (MDRD) study consisted of two randomized clinical trials that investigated whether protein restriction and control of blood pressure had an effect on the progression of chronic kidney disease (CKD). The study tested two hypotheses—that (1) a reduction in dietary protein and phosphorous intake and (2) the maintenance of blood pressure at a level below that usually recommended safely and effectively delays the progression of CKD.","publishedDate":"2020-11-18T13:15:05Z","studyId":1,"studyName":"Modification of Diet in Renal Disease","studyAcronym":"MDRD"},{"id":158,"title":"New Study: APRON","content":"A new study, Aprepitant for the Relief of Nausea in Patients With Chronic Nausea and Vomiting of Presumed Gastric Origin Trial (APRON), has been posted to the NIDDK Central Repository. Data and biospecimens from this study are now available for request.\r\n\r\nThe Aprepitant for the Relief of Nausea in Patients with Chronic Nausea and Vomiting of Presumed Gastric Origin (APRON) study is a multicenter, randomized, placebo-controlled clinical trial designed to test the safety and efficacy of aprepitant in reducing symptoms among patients with gastroparesis.","publishedDate":"2020-10-27T17:53:23Z","studyId":117,"studyName":"Aprepitant for the Relief of Nausea in Patients With Chronic Nausea and Vomiting of Presumed Gastric Origin Trial","studyAcronym":"APRON"},{"id":157,"title":"Data Update for DILIN Retrospective","content":"Data have been updated for the DILIN Retrospective study. Data through the grant 3 cycle (2018) are now available.\r\n\r\nIf you have already been approved to receive the DILIN Retrospective data package, please contact us through your request to download the updated data package.\r\n\r\nDrug-induced liver injury (DILI) is the single most common reason for regulatory actions concerning drugs, including failure to gain approval for marketing, removal from the market place, and restriction of prescribing indications. DILI is also a significant cause of morbidity and mortality in many patient populations. To stimulate and facilitate research into DILI, the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) has recently established the Drug-Induced Liver Injury Network (DILIN). One of the initial projects to be conducted by the network is to retrospectively establish a nationwide registry of patients who have suffered severe idiosyncratic liver injury associated with drugs (ILIAD), and to collect, and store serum, DNA from these patients (hereafter referred to as the “ILIAD protocol”). This ILIAD protocol will serve as a resource for subsequent mechanistic investigations of the basis for susceptibility to severe idiosyncratic DILI.","publishedDate":"2020-10-23T19:55:50Z","studyId":160,"studyName":"DILIN: Retrospective","studyAcronym":"DILIN Retro"},{"id":156,"title":"Data Update for DILIN Prospective","content":"Data have been updated for the DILIN Prospective study. Data through the grant 3 cycle (2018) are now available.\r\n\r\nIf you have already been approved to receive the DILIN Prospective data package, please contact us through your request to download the updated data package.\r\n\r\nThe DILIN prospective study is an ongoing multicenter observational study. Patients (2 years of age or older) were enrolled in this study if there was a strong clinical suspicion that a liver injury event was caused by a medication or an herbal agent occurring within 6 months before enrollment. Additionally, patients must meet one of the biochemical criteria for enrollment into this study.","publishedDate":"2020-10-23T19:52:41Z","studyId":163,"studyName":"DILIN: Prospective","studyAcronym":"DILIN Pro"},{"id":154,"title":"Data Update for CRIC","content":"Data have been updated for the Chronic Renal Insufficiency Cohort (CRIC) study. Additional variables have been added to the derived datasets.\r\n\r\nThe Chronic Renal Insufficiency Cohort (CRIC) Study is an observational study that examined risk factors for progression of chronic renal insufficiency (CRI) and cardiovascular disease (CVD) among CRI patients. The study enrolled adults aged 21 to 74 years with a broad spectrum of renal disease severity, half of whom were diagnosed with diabetes mellitus. Subjects underwent extensive clinical evaluation at baseline and at annual clinic visits and via telephone at 6 month intervals. Data on quality of life, dietary assessment, physical activity, health behaviors, depression, cognitive function, health care resource utilization, as well as blood and urine specimens were collected. Measures of kidney function and occurrence of new and worsening CVD are the primary outcomes, among others.","publishedDate":"2020-10-13T14:15:32Z","studyId":15,"studyName":"Chronic Renal Insufficiency Cohort Study","studyAcronym":"CRIC"},{"id":153,"title":"Data Update for FLINT","content":"Data have been updated for the Farnesoid X Receptor Ligand Obeticholic Acid in NASH Treatment (FLINT) study. The data package now includes the form data for the study.\r\n\r\nIf you have already been approved to receive the FLINT data package, please contact us through your request to download the updated data package.\r\n\r\nThe Farnesoid X Receptor (FXR) Ligand Obeticholic Acid in Nonalcoholic Steatohepatitis (NASH) Treatment (FLINT) trial was a multicenter, randomized, placebo-controlled clinical trial conducted by the NASH CRN to investigate the safety and efficacy of treatment of obeticholic acid compared to placebo in adults with nonalcoholic fatty liver disease.","publishedDate":"2020-10-12T19:42:43Z","studyId":118,"studyName":"The Farnesoid X Receptor Ligand Obeticholic Acid in NASH Treatment","studyAcronym":"FLINT"},{"id":152,"title":"Data Update for GLUMIT","content":"Data have been updated for the Continuous Glucose Monitoring and Insulin Pump Therapy in Diabetic Gastroparesis (GLUMIT) study. The data package now includes the form data for the study.\r\n\r\nIf you have already been approved to receive the GLUMIT data package, please contact us through your request to download the updated data package.\r\n\r\nThe Safety, Feasibility, and Potential Efficacy of Continuous Glucose Monitoring and Insulin Pump Therapy in Diabetic Gastroparesis (GLUMIT-DG) study is a multicenter, uncontrolled clinical trial that was established by the Gastroparesis Clinical Research Consortium (GpCRC) to assess the safety and utility of CGM in guiding insulin pump therapy in patients with type 1 and type 2 diabetes and gastroparesis.","publishedDate":"2020-10-12T19:40:29Z","studyId":104,"studyName":"Continuous Glucose Monitoring and Insulin Pump Therapy in Diabetic Gastroparesis","studyAcronym":"GLUMIT"},{"id":151,"title":"Data Update for CyNCH","content":"Data have been updated for the Cysteamine Bitartrate Delayed-Release for the Treatment of NAFLD in Children (CyNCh) study. The data package now includes the form data for the study.\r\n\r\nIf you have already been approved to receive the CyNCh data package, please contact us through your request to download the updated data package. \r\n\r\nThe CyNCh (Cysteamine Bitartrate Delayed-Release for the Treatment of NAFLD in Children) study is a prospective, multicenter, double-blind clinical trial designed by the NASH Clinical Research Network to determine whether treatment with cysteamine improves disease severity in children diagnosed with NAFLD. Children between the ages of 8 and 17 years with biopsy-confirmed moderate to severe NAFLD were eligible for the CyNCh study. Participants were enrolled and randomized to treatment with either delayed-release cysteamine bitartrate capsules or placebo capsules. Improvement in NAFLD at 52 weeks, defined as a decrease in NAFLD Activity Score (NAS) of at least 2 and no worsening of fibrosis, was assessed as the primary outcome measure. Secondary outcome measures, assessed at 52 weeks, included reduction in serum aminotransferase and gamma-glytamyl transpeptidase, reduction in MRI-determined hepatic fat fraction, changes in markers of oxidation and anti-oxidant status, changes in histology and symptoms, and self-reported quality of life.","publishedDate":"2020-10-12T18:47:41Z","studyId":148,"studyName":"Cysteamine Bitartrate Delayed-Release for the Treatment of Nonalcoholic Fatty Liver Disease (NAFLD) in Children","studyAcronym":"CyNCh"},{"id":150,"title":"Data Update for Teen-LABS Study","content":"Data have been updated for the Adolescent Bariatrics: Assessing Health Benefits \u0026 Risks (Teen-LABS) study. The data package now includes additional analysis datasets through Year 4. \r\n\r\nThe objective of the Teen-LABS study is to use standardized techniques to assess the short and longer-term safety and efficacy of bariatric surgery in adolescents compared to adults.","publishedDate":"2020-10-08T18:39:39Z","studyId":53,"studyName":"Adolescent Bariatrics: Assessing Health Benefits \u0026 Risks","studyAcronym":"Teen-LABS"},{"id":149,"title":"New Study: COMBINE","content":"A new study, The CKD Optimal Management With BInders and NicotinamidE (COMBINE), has been posted to the NIDDK Central Repository. Data and biospecimens from this study are now available for request.\r\n\r\nIn people with chronic kidney disease, kidneys struggle to get rid of enough phosphorus, so FGF23 levels increase in the blood to help get rid of extra phosphorus. Over time, with progressive loss of kidney function, both phosphorus and FGF23 can build up in the blood simultaneously. Researchers believe that too much phosphorus and FGF23 in the blood may lead to weak bones, increase the risk of heart problems, and accelerate progression of kidney disease. However, the best way to control phosphorus and FGF23 levels in the blood in patients with chronic kidney disease is not known. COMBINE is a study to determine new methods to lower serum phosphorus levels and levels of FGF23 in chronic kidney disease patients.","publishedDate":"2020-10-07T18:39:29Z","studyId":176,"studyName":"The CKD Optimal Management With BInders and NicotinamidE","studyAcronym":"COMBINE"},{"id":148,"title":"New Study: BASE","content":"A new study, Bicarbonate Administration to Stabilize Estimated Glomerular Filtration Rate (eGFR) (BASE), has been posted to the NIDDK Central Repository. Data and biospecimens from this study are now available for request.\r\n\r\nSodium bicarbonate may help prevent kidney failure in people with chronic kidney disease. However, the dose to prescribe in order to test this possibility in a clinical trial is uncertain. The BASE pilot clinical trial hoped to determine the best dose of sodium bicarbonate to prescribe in a future study that will test the long-term safety and efficacy of sodium bicarbonate as a treatment to preserve kidney function in individuals with chronic kidney disease.","publishedDate":"2020-10-06T21:36:47Z","studyId":183,"studyName":"Bicarbonate Administration to Stabilize Estimated Glomerular Filtration Rate (eGFR)","studyAcronym":"BASE"},{"id":147,"title":"Data Update for TEDDY","content":"Data have been updated for The Environmental Determinants of Diabetes in the Young (TEDDY). This update includes additional analysis datasets from the M176 publication as well as the updated questionnaire data through December 2018. \r\n\r\nIf you have already been approved to receive the TEDDY data package, please contact us through your request to download the updated data package. \r\n\r\nThe TEDDY study is a multicenter prospective cohort study that was established in response to these gaps in understanding of T1D. The primary objectives of the study include identifying environmental factors—such as infectious agents, dietary factors, and psychosocial factors—that trigger or protect against the development of islet autoimmunity and T1D and examining genetic-environmental interactions to investigate interactive effects that contribute to T1D.","publishedDate":"2020-10-02T19:27:30Z","studyId":24,"studyName":"The Environmental Determinants of Diabetes in the Young","studyAcronym":"TEDDY"},{"id":146,"title":"Data Update for CRISP","content":"Data have been updated for the Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) study. The data package now includes data through the CRISP 3 cycle. \r\n\r\nIf you have already been approved to receive the CRISP data package, please contact us through your request to download the updated data package. \r\n\r\nThe Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) was established to develop and implement studies to test whether imaging techniques can provide accurate and reproducible markers of progression of renal disease in patients with polycystic kidney disease. Autosomal-dominant polycystic kidney disease (ADPKD) is characterized by gradual renal enlargement and cyst growth prior to loss of renal function; however, standard radiographic imaging has not provided the resolution and accuracy necessary to detect small changes in renal volume or to reliably measure renal cyst volumes. The CRISP cohort study longitudinally observed ADPKD individuals using high-resolution magnetic resonance (MR) imaging to determine if change in renal and cyst volumes can be detected over a short period of time, and if they correlate with decline in renal function early in disease.","publishedDate":"2020-10-02T19:20:08Z","studyId":10,"studyName":"Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease","studyAcronym":"CRISP"},{"id":145,"title":"Data Update for LOGIC (ChiLDReN)","content":"Data have been updated for the Longitudinal Study of Genetic Causes of Intrahepatic Cholestasis (LOGIC) study. This study is part of the Childhood Liver Disease Research Network (ChiLDReN). Analysis data from a publication by Dr. Kamath are now available for request.\r\n\r\nIf you have already been approved to receive the LOGIC data package, please contact us through your request to download the updated data package. \r\n\r\nThe primary objectives of the LOGIC study include determining the frequency of poor growth and decreased bone mineral density and its predictors; identifying modifier genes that influence the incidence, severity, and progression of liver disease among affected individuals; and developing a repository of biospecimens to be used in ancillary studies of predictor biomarkers.","publishedDate":"2020-10-02T19:16:41Z","studyId":100,"studyName":"Longitudinal Study of Genetic Causes of Intrahepatic Cholestasis","studyAcronym":"LOGIC"},{"id":144,"title":"Data Update for PROBE (ChiLDReN)","content":"Data have been updated for the A Prospective Database of Infants With Cholestasis (PROBE) study. This study is part of the Childhood Liver Disease Research Network (ChiLDReN). Analysis data from a publication by Dr. Squires are now available for request.\r\n\r\nPROBE is a multi-center project that established a prospective database of clinical information and a repository of blood and tissue samples from children with diagnoses of neonatal liver diseases, such as biliary atresia and neonatal hepatitis, in order to perform research in these liver problems. Children were screened and enrolled at presentation at the participating pediatric liver sites. Subjects diagnosed with biliary atresia were followed intensively for the first year, at 18 months of age, and then annually up to 15 years of age. Other subjects diagnosed with cholestasis were followed on the same schedule; if there was complete (clinical and biochemical) resolution of their underlying liver disease off all therapy, there was one follow up visit within one year (preferably scheduled at the time of the next planned follow up visit or at 12 months of age, whichever was later) for data collection and to obtain blood samples. The development of a serum and tissue bank of specimens from children with various neonatal cholestatic disorders are used for future investigations into the etiology and pathogenesis of hepatobiliary injury in the infant.","publishedDate":"2020-10-01T11:11:08Z","studyId":99,"studyName":"A Prospective Database of Infants With Cholestasis","studyAcronym":"PROBE"},{"id":143,"title":"Data Update for TrialNet 10","content":"Data have been updated for the TrialNet 10 Anti-CD3 Prevention (TN10 Anti-CD3 Prevention). \r\n\r\nTeplizumab (Anti-CD3) is a monoclonal antibody that interferes in the autoimmune attack of pancreatic beta cells. Previous studies have shown that teplizumab reduces the loss of insulin production in type 1 diabetics during the first year after diagnosis. TrialNet 10 is a phase 2 prevention trial of TrialNet, studying the effect of teplizumab on insulin production in the relatives of type 1 diabetics who are at high risk of developing the disease. TrialNet 10 is projected to last 4-6 years with an enrollment period of 2-3 years. The approximate enrollment of the study is 140-170 individuals between the ages of 8-45 years. Subjects will be randomly assigned to either the active or placebo group of the study, and monitored and tested over time until diagnosed with diabetes.","publishedDate":"2020-08-12T18:32:38Z","studyId":113,"studyName":"Anti-CD3 Mab (Teplizumab) for Prevention of Diabetes in Relatives At-Risk for Type 1 Diabetes Mellitus","studyAcronym":"TN10"},{"id":142,"title":"New Study: HFM","content":"A new study, Hemodialysis Fistula Maturation (HFM), has been posted to the NIDDK Central Repository. Analysis datasets from the baseline visit are now available for request. Data and biospecimens from this study are now available for request.\r\n\r\nThe Hemodialysis Fistula Maturation Study was a prospective, multicenter observational study that was established by the Hemodialysis Fistula Maturation Consortium (HFMC) to identify the clinical and biological factors associated with AVF maturation outcomes. The primary objectives of the study included improving prediction of AVF maturation and exploring the mechanism of AVF failure by examining the relationship between clinical usability and anatomy, biology, clinical attributes, and processes of care.","publishedDate":"2020-06-12T01:37:13Z","studyId":84,"studyName":"Hemodialysis Fistula Maturation Consortium","studyAcronym":"HFMC"},{"id":141,"title":"Data Update for Look AHEAD","content":"Data have been updated for the Look AHEAD: Action for Health in Diabetes study. The data package now contains data through the end of the post intervention program. \r\n\r\nIf you have already been approved to receive the Look Ahead data package, please contact us through your request to download the updated data package. \r\n\r\nThe primary objective of the Look AHEAD study was to test whether an intensive lifestyle intervention program designed to achieve and maintain weight loss by decreased caloric intake and increased physical activity improves the long-term cardiovascular morbidity and mortality of overweight patients with type 2 diabetes.","publishedDate":"2020-06-12T01:34:59Z","studyId":61,"studyName":"Look AHEAD: Action for Health in Diabetes","studyAcronym":"Look AHEAD"},{"id":140,"title":"New Study: PUSH (ChiLDReN)","content":"A new study, Prediction by Ultrasound of the Risk of Hepatic Cirrhosis in Cystic Fibrosis Liver Disease (PUSH), has been posted to the NIDDK Central Repository. Analysis datasets from the baseline visit are now available for request. \r\n\r\nPUSH is a prospective longitudinal study that aims to determine the utility of abdominal ultrasound to predict the development of cirrhosis in patients with cystic fibrosis. Participants will undergo abdominal ultrasound at enrollment and, based on the outcome, will be placed in one of four groups. Within a five year period subjects will undergo other sample collection procedures in addition to abdominal ultrasound. This study will also monitor the effects of cystic fibrosis on associated pulmonary and nutritional issues.","publishedDate":"2020-06-12T01:31:37Z","studyId":102,"studyName":"Prediction by Ultrasound of the Risk of Hepatic Cirrhosis in Cystic Fibrosis Liver Disease","studyAcronym":"CFLD PUSH"},{"id":139,"title":"Data Update for TEDDY","content":"Data have been updated for The Environmental Determinants of Diabetes in the Young (TEDDY). This update includes additional analysis datasets from the M64 publication. \r\n\r\nIf you have already been approved to receive the TEDDY data package, please contact us through your request to download the updated data package. \r\n\r\nThe TEDDY study is a multicenter prospective cohort study that was established in response to these gaps in understanding of T1D. The primary objectives of the study include identifying environmental factors—such as infectious agents, dietary factors, and psychosocial factors—that trigger or protect against the development of islet autoimmunity and T1D and examining genetic-environmental interactions to investigate interactive effects that contribute to T1D.","publishedDate":"2020-06-12T01:29:33Z","studyId":24,"studyName":"The Environmental Determinants of Diabetes in the Young","studyAcronym":"TEDDY"},{"id":138,"title":"New Study: LURN","content":"A new study, Symptoms of Lower Urinary Tract Dysfunction Network (LURN), has been posted to the NIDDK Central Repository. Data, biospecimens, and images from this study are now available for request.\r\n\r\nThe Symptoms of Lower Urinary Tract Dysfunction Phenotyping Study (LURN) was established to gain a better understanding of lower urinary tract symptoms in an effort to improve the lives of those with LUTD. LURN participants were enrolled at multiple sites within the United States. Patients were assigned to one of four subgroups, based on their symptoms, the outcomes of clinical assessments, and other characteristics. Biological samples were collected from study participants and patients were required to complete certain assessments and examinations at standard time-points during the study period.\r\n\r\nThe purpose of the Symptoms of Lower Urinary Tract Dysfunction Phenotyping Study was to develop a framework for identifying and defining the subtypes of LUTS; create new questionnaires in order to improve the measurement of patient experiences of LUTS; and generate and share data, tools, and biological samples with clinical and research communities, in an effort to advance the understanding of LUTS and improve patients’ lives.","publishedDate":"2020-05-08T14:18:38Z","studyId":174,"studyName":"Symptoms of Lower Urinary Tract Dysfunction Phenotyping Study","studyAcronym":"LURN"},{"id":137,"title":"Data Update for TEDDY","content":"Data have been updated for The Environmental Determinants of Diabetes in the Young (TEDDY). This update includes eight additional analysis datasets (M65, M68, M90a, M104, M111, M128, M142, and M224). \r\n\r\nIf you have already been approved to receive the TEDDY data package, please contact us through your request to download the updated data package. \r\n\r\nThe TEDDY study is a multicenter prospective cohort study that was established in response to these gaps in understanding of T1D. The primary objectives of the study include identifying environmental factors—such as infectious agents, dietary factors, and psychosocial factors—that trigger or protect against the development of islet autoimmunity and T1D and examining genetic-environmental interactions to investigate interactive effects that contribute to T1D.","publishedDate":"2020-03-20T17:50:00Z","studyId":24,"studyName":"The Environmental Determinants of Diabetes in the Young","studyAcronym":"TEDDY"},{"id":136,"title":"New Studies: CIT-02-CIT-06","content":"Five new studies (CIT02-CIT-06) from the Clinical Islet Transplantation Consortium (CITC) have been posted to the NIDDK Central Repository and is available for request. \r\n\r\nThe CIT consortium conducted a total of 9 studies across North America (CIT02 through CIT08) and the Nordic region (CIT01). CIT08 was a long-term follow-up study for interested participants at the North American sites. The target population is individuals with type 1 diabetes, normal kidney function, and intractable hypoglycemia. All studies treated participants with up to 3 separate infusions of islets.","publishedDate":"2020-02-12T21:53:28Z","studyId":null,"studyName":null,"studyAcronym":null},{"id":135,"title":"New Study: IBSOS","content":"A new study, Irritable Bowel Syndrome Outcome Study (IBSOS), has been posted to the NIDDK Central Repository. Data from this study are now available for request. \r\n\r\nThe Irritable Bowel Syndrome Outcome Study (IBSOS) sought to address the limitations of standard therapist-administered CBT by developing an effective self-administered version of the treatment method. IBSOS participants were randomized into one of three treatment groups and underwent four weeks of symptom monitoring. One group received the standard ten sessions of clinic-based CBT, one group received four sessions of minimal-contact CBT, and the remaining group received four sessions of supportive counseling and education without any prescribed behavior changes. Following the symptom monitoring phase, patients underwent treatment and follow-up phases. Assessments were regularly conducted during the study and the results were evaluated between the groups.","publishedDate":"2020-01-27T15:36:37Z","studyId":209,"studyName":"Irritable Bowel Syndrome Outcome Study","studyAcronym":"IBSOS"},{"id":134,"title":"Data Update for CRIC","content":"Data have been updated for the Chronic Renal Insufficiency Cohort (CRIC) study. Additional data through 2018 from Phase 1 and Phase 3 are now available.\r\n\r\nThe Chronic Renal Insufficiency Cohort (CRIC) Study is an observational study that examined risk factors for progression of chronic renal insufficiency (CRI) and cardiovascular disease (CVD) among CRI patients. The study enrolled adults aged 21 to 74 years with a broad spectrum of renal disease severity, half of whom were diagnosed with diabetes mellitus. Subjects underwent extensive clinical evaluation at baseline and at annual clinic visits and via telephone at 6 month intervals. Data on quality of life, dietary assessment, physical activity, health behaviors, depression, cognitive function, health care resource utilization, as well as blood and urine specimens were collected. Measures of kidney function and occurrence of new and worsening CVD are the primary outcomes, among others.","publishedDate":"2019-12-16T17:55:47Z","studyId":15,"studyName":"Chronic Renal Insufficiency Cohort Study","studyAcronym":"CRIC"},{"id":133,"title":"Data Update for TEDDY","content":"Data have been updated for The Environmental Determinants of Diabetes in the Young (TEDDY). This update includes one analysis dataset (M112) and the dietary biomarker data.\r\n\r\nThe TEDDY study is a multicenter prospective cohort study that was established in response to these gaps in understanding of T1D. The primary objectives of the study include identifying environmental factors—such as infectious agents, dietary factors, and psychosocial factors—that trigger or protect against the development of islet autoimmunity and T1D and examining genetic-environmental interactions to investigate interactive effects that contribute to T1D.","publishedDate":"2019-09-17T15:22:42Z","studyId":24,"studyName":"The Environmental Determinants of Diabetes in the Young","studyAcronym":"TEDDY"},{"id":132,"title":"Data Update for DCCT/EDIC","content":"Data have been updated for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) study. The data package now includes Glycemic Variation (glyc_var) analysis data. \r\n\r\nThe Diabetes Control and Complications Trial (DCCT) was a multicenter, randomized clinical trial designed to compare intensive with conventional diabetes therapy with regard to their effects on the development and progression of the early vascular and neurologic complications of type 1 insulin-dependent diabetes mellitus. The Epidemiology of Diabetes Interventions and Complications (EDIC) study was initiated as follow-up to examine the long-term effects of the original DCCT interventions on diabetic complications such as cardiovascular events and advanced retinal and renal disease.","publishedDate":"2019-09-13T16:35:48Z","studyId":16,"studyName":"Diabetes Control and Complications Trial / Epidemiology of Diabetes Interventions and Complications","studyAcronym":"DCCT/EDIC"},{"id":131,"title":"New Study: PALF","content":"A new study, Pediatric Acute Liver Failure (PALF), has been posted to the NIDDK Central Repository. Both data and biospecimens are now available for request. \r\n\r\nThe mission of the Pediatric Acute Liver Failure (PALF) study was to develop methods to predict whether a child will require a life-saving procedure in order to recover from acute liver failure.","publishedDate":"2019-09-11T14:51:15Z","studyId":45,"studyName":"Pediatric Acute Liver Failure","studyAcronym":"PALF"},{"id":130,"title":"Data Update for DCCT/EDIC","content":"Data have been updated for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) study. The data package now includes the Optimal Frequency of Retinopathy (Optimret) analysis data. \r\n\r\nThe Diabetes Control and Complications Trial (DCCT) was a multicenter, randomized clinical trial designed to compare intensive with conventional diabetes therapy with regard to their effects on the development and progression of the early vascular and neurologic complications of type 1 insulin-dependent diabetes mellitus. The Epidemiology of Diabetes Interventions and Complications (EDIC) study was initiated as follow-up to examine the long-term effects of the original DCCT interventions on diabetic complications such as cardiovascular events and advanced retinal and renal disease.","publishedDate":"2019-05-31T20:10:48Z","studyId":16,"studyName":"Diabetes Control and Complications Trial / Epidemiology of Diabetes Interventions and Complications","studyAcronym":"DCCT/EDIC"},{"id":129,"title":"Data Update for EPISOD","content":"Data have been updated for the Evaluating Predictors and Interventions in Sphincter of Oddi Dysfunction (EPISOD). Data from the follow-up period are now available for request.\r\n\r\nThe EPISOD trial is a parallel, randomized, double-blinded, sham-controlled, multicenter Phase III clinical trial of endoscopic sphincterotomy as treatment for adults 18 to 65 years of age diagnosed with SOD III.","publishedDate":"2019-05-31T20:02:03Z","studyId":178,"studyName":"Evaluating Predictors and Interventions in Sphincter of Oddi Dysfunction","studyAcronym":"EPISOD"},{"id":128,"title":"Data Update for CRIC","content":"Data have been updated for the Chronic Renal Insufficiency Cohort (CRIC) study. Data from CRIC Phase 3 are now available. Additional data from Phase 1 were updated. \r\n\r\nThe Chronic Renal Insufficiency Cohort (CRIC) Study is an observational study that examined risk factors for progression of chronic renal insufficiency (CRI) and cardiovascular disease (CVD) among CRI patients. The study enrolled adults aged 21 to 74 years with a broad spectrum of renal disease severity, half of whom were diagnosed with diabetes mellitus. Subjects underwent extensive clinical evaluation at baseline and at annual clinic visits and via telephone at 6 month intervals. Data on quality of life, dietary assessment, physical activity, health behaviors, depression, cognitive function, health care resource utilization, as well as blood and urine specimens were collected. Measures of kidney function and occurrence of new and worsening CVD are the primary outcomes, among others.","publishedDate":"2019-05-31T19:41:22Z","studyId":15,"studyName":"Chronic Renal Insufficiency Cohort Study","studyAcronym":"CRIC"},{"id":127,"title":"Data Update for LOGIC","content":"Data have been updated for the Longitudinal Study of Genetic Causes of Intrahepatic Cholestasis (LOGIC) study. The data package now includes two additional analysis datasets (Techman and DXA) from two publications. \r\n\r\nLOGIC is a observational study with the objectives to determine the frequency of poor growth and decreased bone mineral density and its predictors; identify modifier genes that influence the incidence, severity, and progression of liver disease among affected individuals; and develop a repository of biospecimens to be used in ancillary studies of predictor biomarkers.","publishedDate":"2019-05-31T19:01:57Z","studyId":100,"studyName":"Longitudinal Study of Genetic Causes of Intrahepatic Cholestasis","studyAcronym":"LOGIC"},{"id":126,"title":"New Study: CureGN","content":"A new study, Cure Glomerulonephropathy (CureGN), has been posted to the NIDDK Central Repository and is available for request. The data pacakge includes one analysis dataset from the IgA publication.\r\n\r\nCure Glomerulonephropathy Network (CureGN) is a multi-center consortium that seeks to establish an infrastructure for the advancement of glomerular disease studies. CureGN recruits and maintains a large and diverse population of glomerular disease patients. The study established a database of patients diagnosed with the following conditions: minimal change disease (MCD), focal segmental glomerulosclerosis (FSGS), membranous nephropathy (MN), and immunoglobulin A nephropathy (IgAN).","publishedDate":"2019-05-31T18:52:58Z","studyId":171,"studyName":"Cure Glomerulonephropathy","studyAcronym":"CureGN"},{"id":125,"title":"Data Update for TEDDY","content":"Data have been updated for The Environmental Determinants of Diabetes in the Young (TEDDY). This update includes seven additional analysis datasets (M106a, M127, M138, M160, M165a, M165b, M177).\r\n\r\nThe TEDDY study is a multicenter prospective cohort study that was established in response to these gaps in understanding of T1D. The primary objectives of the study include identifying environmental factors—such as infectious agents, dietary factors, and psychosocial factors—that trigger or protect against the development of islet autoimmunity and T1D and examining genetic-environmental interactions to investigate interactive effects that contribute to T1D.","publishedDate":"2019-05-31T18:41:00Z","studyId":24,"studyName":"The Environmental Determinants of Diabetes in the Young","studyAcronym":"TEDDY"},{"id":124,"title":"New Study: CIT-01","content":"A new study, Safety and Effectiveness of Low Molecular Weight Sulfated Dextran in Islet Transplantation (CIT-01), has been posted to the NIDDK Central Repository and is available for request. \r\n\r\nCIT01 participants were randomized to study treatment including Low Molecular Weight Sulfated Dextran (LMW-DS) and study treatment without LMW-DS.The primary objective of this study was to evaluate the safety and efficacy of Low Molecular Weight Dextran Sulfate (LMW-DS) to enhance engraftment and prevent IBMIR in islet transplantation to Type 1 diabetic subjects. The secondary objective was to gather additional safety and efficacy information about the combination of Low Molecular Weight Sulfated Dextran with islet transplantation.","publishedDate":"2019-05-13T19:44:54Z","studyId":191,"studyName":"Safety and Effectiveness of Low Molecular Weight Sulfated Dextran in Islet Transplantation","studyAcronym":"CIT-01"},{"id":123,"title":"New Study: TrialNet19","content":"A new study, ATG-GCSF in New Onset Type 1 Diabetes (TN19), has been posted to the NIDDK Central Repository and is available for request. TN19 was a three-arm, 1:1:1 randomized, placebo controlled, double-blinded trial in which at least 28 subjects will receive active Anti-Thymocyte Globulin and Granulocyte colony-stimulating factor (ATG-GCSF), at least 28 subjects will receive ATG alone and at least 28 subjects will receive placebo alone within 100 days from diagnosis of Type 1 Diabetes (T1D). TrialNet researchers were testing whether ATG used alone or in combination with GCSF will help people continue to make some of their own insulin.","publishedDate":"2019-05-10T20:42:46Z","studyId":185,"studyName":"Antithymocyte Globulin (ATG) and Pegylated Granulocyte Colony Stimulating Factor (GCSF) in New Onset Type 1 Diabetes","studyAcronym":"TN19"},{"id":122,"title":"Data Update for TEDDY","content":"Data have been updated for The Environmental Determinants of Diabetes in the Young (TEDDY). This update includes three additional analysis datasets (M34, M109, and M21).\r\n\r\nThe TEDDY study is a multicenter prospective cohort study that was established in response to these gaps in understanding of T1D. The primary objectives of the study include identifying environmental factors—such as infectious agents, dietary factors, and psychosocial factors—that trigger or protect against the development of islet autoimmunity and T1D and examining genetic-environmental interactions to investigate interactive effects that contribute to T1D.","publishedDate":"2019-05-10T19:33:11Z","studyId":24,"studyName":"The Environmental Determinants of Diabetes in the Young","studyAcronym":"TEDDY"},{"id":121,"title":"Data Update for PROBE","content":"Data have been updated for the Prospective Database of Infants With Cholestasis (PROBE) study. The data package now includes an additional analysis dataset (Shneider) from a publication. \r\n\r\nPROBE is a multi-center project to establish a prospective database of clinical information and a repository of blood and tissue samples from children with diagnoses of neonatal liver diseases, such as biliary atresia and neonatal hepatitis, in order to perform research in these liver problems.","publishedDate":"2019-03-12T21:05:59Z","studyId":99,"studyName":"A Prospective Database of Infants With Cholestasis","studyAcronym":"PROBE"},{"id":120,"title":"Data Update for GLUMIT","content":"Analysis data are now available for request from the Continuous Glucose Monitoring and Insulin Pump Therapy in Diabetic Gastroparesis (GLUMIT) study.\r\n\r\nThe Safety, Feasibility, and Potential Efficacy of Continuous Glucose Monitoring and Insulin Pump Therapy in Diabetic Gastroparesis (GLUMIT-DG) study is a multicenter, uncontrolled clinical trial that was established by the Gastroparesis Clinical Research Consortium (GpCRC) to assess the safety and utility of CGM in guiding insulin pump therapy in patients with type 1 and type 2 diabetes and gastroparesis.","publishedDate":"2019-03-12T21:03:00Z","studyId":104,"studyName":"Continuous Glucose Monitoring and Insulin Pump Therapy in Diabetic Gastroparesis","studyAcronym":"GLUMIT"},{"id":119,"title":"Data Update for TEDDY","content":"Data have been updated for The Environmental Determinants of Diabetes in the Young (TEDDY). This update includes eight additional analysis datasets (M180, M102, M45, M124, M74, M53, M113, and M38a).\r\n\r\nThe TEDDY study is a multicenter prospective cohort study that was established in response to these gaps in understanding of T1D. The primary objectives of the study include identifying environmental factors—such as infectious agents, dietary factors, and psychosocial factors—that trigger or protect against the development of islet autoimmunity and T1D and examining genetic-environmental interactions to investigate interactive effects that contribute to T1D.","publishedDate":"2019-03-12T20:58:02Z","studyId":24,"studyName":"The Environmental Determinants of Diabetes in the Young","studyAcronym":"TEDDY"},{"id":118,"title":"Data Update for TrialNet 01","content":"Data have been updated for the TrialNet Pathway To Prevention (formerly Natural History Study) (TN01 NH). \r\n\r\nThe primary aim of the study is to identify subjects for TrialNet prevention and investigation trials, but can also be used for assessing the predictive value of existing and novel risk markers of T1D, and for examining the demographic, immunologic, and metabolic characteristics of individuals at risk for developing T1D.","publishedDate":"2019-03-12T20:54:57Z","studyId":80,"studyName":"TrialNet Pathway To Prevention (formerly Natural History Study)","studyAcronym":"TN01"},{"id":117,"title":"Data Update for START","content":"Data have been updated for the Steroids in the Treatment of Biliary Atresia (START) study. The data package now includes analysis datasets (Bezerra) from a publication. START is a clinical trial with the objective to determine the efficacy of corticosteroids on the outcome of infants with biliary atresia.","publishedDate":"2019-02-07T23:41:57Z","studyId":98,"studyName":"A Randomized, Double-Blinded, Placebo-Controlled Trial of Corticosteroid Therapy Following Portoenterostomy in Infants with Biliary Atresia","studyAcronym":"START"},{"id":116,"title":"Data Update for LOGIC","content":"Data have been updated for the Longitudinal Study of Genetic Causes of Intrahepatic Cholestasis (LOGIC) study. The data package now includes analysis datasets (PedsQL) from a publication. LOGIC is a observational study with the objectives to determine the frequency of poor growth and decreased bone mineral density and its predictors; identify modifier genes that influence the incidence, severity, and progression of liver disease among affected individuals; and develop a repository of biospecimens to be used in ancillary studies of predictor biomarkers.","publishedDate":"2019-02-07T23:15:38Z","studyId":100,"studyName":"Longitudinal Study of Genetic Causes of Intrahepatic Cholestasis","studyAcronym":"LOGIC"},{"id":115,"title":"New Study: TrialNet07","content":"A new study, Oral Insulin for Prevention of Diabetes in Relatives at Risk for Type 1 Diabetes Mellitus (TN07), has been posted to the NIDDK Central Repository and is available for request. TN07 was a randomized clinical trial with the goal to assess the efficacy of oral insulin in the prevention or delay of the development of Type 1 diabetes mellitus in subjects with mIAA and other autoantibodies and a proband with Type 1 diabetes.","publishedDate":"2019-02-07T23:11:02Z","studyId":91,"studyName":"Oral Insulin for Prevention of Diabetes in Relatives at Risk for Type 1 Diabetes Mellitus","studyAcronym":"TN07"},{"id":114,"title":"Data Update for PROBE Study","content":"Data have been updated for the Prospective Database of Infants With Cholestasis (PROBE) study. The data package now includes an additional analysis dataset (Superina) from a publication. PROBE is a multi-center project to establish a prospective database of clinical information and a repository of blood and tissue samples from children with diagnoses of neonatal liver diseases, such as biliary atresia and neonatal hepatitis, in order to perform research in these liver problems.","publishedDate":"2019-02-07T19:06:45Z","studyId":99,"studyName":"A Prospective Database of Infants With Cholestasis","studyAcronym":"PROBE"},{"id":113,"title":"Data Update for CKiD Study","content":"Data have been updated for the Chronic Kidney Disease in Children (CKiD) study. The data package now includes data through December 2015. The CKiD study is a prospective cohort study of children with chronic kidney disease (CKD) that investigates risk factors and outcomes of the disease. The CKiD study had various objectives, including: (1) identifying and quantifying novel and traditional risk factors for progression of CKD; (2) characterizing how CKD progression effects neurodevelopment, cognitive abilities, and behavior; (3) describing the prevalence of cardiovascular disease and associated risk factors; and (4) examining the effects of declining kidney function on growth in children with CKD.","publishedDate":"2019-02-07T16:21:34Z","studyId":39,"studyName":"The Chronic Kidney Disease in Children Cohort Study","studyAcronym":"CKiD"},{"id":112,"title":"New Study: STONE","content":"A new study, The Study of Tamsulosin for Urolithiasis in the Emergency Department (STONE), has been posted to the NIDDK Central Repository and is available for request. STONE study was a clinical trial with the objective to determine if tamsulosin promotes the passage of urinary stones within 28 days among emergency department patients.","publishedDate":"2019-02-06T13:41:09Z","studyId":192,"studyName":"The Study of Tamsulosin for Urolithiasis in the Emergency Department","studyAcronym":"STONE"},{"id":111,"title":"Specimens and Updated Data Available For CIT-07","content":"Specimens and updated data are available to be requested for the Islet Transplantation in Type 1 Diabetes (CIT-07) study. See the Data Dictionary included on the study page for a complete list of datasets that are available for request.\r\n\r\nThe Islet Transplantation in Type 1 Diabetes (CIT-07) study is a prospective, multicenter, single-arm clinical trial that was conducted by the CITC to investigate the safety and efficacy of islet transplantation when combined with an immunosuppressive medication regimen for treating type 1 diabetes in individuals with hypoglycemia unawareness. Individuals with type 1 diabetes with type 1 diabetes, dependence on insulin for at least 5 years at study entry, and at least one episode of severe hypoglycemia in the past 12 months were eligible for enrollment.","publishedDate":"2018-12-11T23:43:57Z","studyId":92,"studyName":"Islet Transplantation in Type 1 Diabetes","studyAcronym":"CIT-07/08"},{"id":110,"title":"Data Update for TrialNet 01","content":"Data have been updated for the TrialNet Pathway To Prevention (formerly Natural History Study) (TN01 NH). The research labs dataset has been updated and split into two datasets. \r\n\r\nThe primary aim of the study is to identify subjects for TrialNet prevention and investigation trials, but can also be used for assessing the predictive value of existing and novel risk markers of T1D, and for examining the demographic, immunologic, and metabolic characteristics of individuals at risk for developing T1D.","publishedDate":"2018-08-29T19:54:04Z","studyId":80,"studyName":"TrialNet Pathway To Prevention (formerly Natural History Study)","studyAcronym":"TN01"},{"id":109,"title":"Data Update for TEDDY","content":"Data have been updated for The Environmental Determinants of Diabetes in the Young (TEDDY). This update includes form data as well as five additional analysis datasets (M24. M54, M56, M57, and M77).\r\n\r\nThe TEDDY study is a multicenter prospective cohort study that was established in response to these gaps in understanding of T1D. The primary objectives of the study include identifying environmental factors—such as infectious agents, dietary factors, and psychosocial factors—that trigger or protect against the development of islet autoimmunity and T1D and examining genetic-environmental interactions to investigate interactive effects that contribute to T1D.","publishedDate":"2018-08-29T19:41:57Z","studyId":24,"studyName":"The Environmental Determinants of Diabetes in the Young","studyAcronym":"TEDDY"},{"id":108,"title":"New Biorepository Location at Precision","content":"The biorepository has moved to a new location at Precision for Medicine in Frederick, MD. All incoming shipments should be sent to the following address:\r\n\r\nPrecision for Medicine\r\n8425 Precision Way, Suite M \r\nFrederick, MD 21701\r\nATTN: Eduard Chani\r\n\r\nPrecision can be contacted via the following means:\r\n\r\nPhone: 240-306-4100\r\nFax: 301 668 3416\r\nEmail: niddk.mailbox@precisionformedicine.com\r\n\r\nAll communication regarding shipments should be sent to the email address noted above, including the electronic manifests and notifications associated with incoming shipments. Study staff may \u003ca href=\"https://repository.niddk.nih.gov/contact/\"\u003econtact the repository\u003c/a\u003e with any questions about the new location.\r\n","publishedDate":"2018-04-23T18:49:06Z","studyId":null,"studyName":null,"studyAcronym":null},{"id":107,"title":"Data Update for TrialNet 01 ","content":"Data have been updated for the TrialNet Pathway To Prevention (formerly Natural History Study) (TN01 NH). The primary aim of the study is to identify subjects for TrialNet prevention and investigation trials, but can also be used for assessing the predictive value of existing and novel risk markers of T1D, and for examining the demographic, immunologic, and metabolic characteristics of individuals at risk for developing T1D. Data collected on patients recruited through 2016 are now available from the Repository.","publishedDate":"2018-04-19T20:46:45Z","studyId":80,"studyName":"TrialNet Pathway To Prevention (formerly Natural History Study)","studyAcronym":"TN01"},{"id":106,"title":"Repository Website Moving to .gov","content":"On or about January 27, the Repository website will get a facelift and move to a .gov URL. Please update your bookmarks once we move. All current registrations and site functionality will be available on the revised site. A sneak peek is provided. \u003ca href=\"/static/home.png\"\u003eClick here\u003c/a\u003e to view.","publishedDate":"2018-01-24T15:40:09Z","studyId":null,"studyName":null,"studyAcronym":null},{"id":105,"title":"Data Update for A2ALL ","content":"Data have been updated for the Adult-to-Adult Living Donor Liver Transplantation Cohort Study (A2ALL). The primary objective of the study was to determine whether the decision to undergo adult-to-adult living donor liver transplant is beneficial for the patients who choose this type of transplant. Images from subjects enrolled in A2ALL are not included in the data package, but are now available upon request. ","publishedDate":"2017-06-28T15:19:12Z","studyId":27,"studyName":"Adult Living Donor Liver Transplantation Studies","studyAcronym":"A2ALL"},{"id":104,"title":"Additional Receipt Date for PAR-17-270","content":"Applications for the X01 \u003ca href=\"https://grants.nih.gov/grants/guide/pa-files/PAR-17-270.html\"\u003ePAR-17-270\u003c/a\u003e will now be accepted on July 31, 2017. For additional details, please see the following notification: \u003ca href=\"https://grants.nih.gov/grants/guide/notice-files/NOT-DK-17-013.html\"\u003eNOT-DK-17-013: Notice of Additional Receipt Date for PAR-17-270 NIDDK Central Repositories Non-renewable Sample Access (X01).\u003c/a\u003e ","publishedDate":"2017-06-14T15:21:02Z","studyId":null,"studyName":null,"studyAcronym":null},{"id":103,"title":"Data Update for TEDDY Study ","content":"Data have been updated for The Environmental Determinants of Diabetes in the Young (TEDDY) study. The data package includes an additional analysis dataset from a publication. The TEDDY study is a multicenter prospective cohort study that was established in response to these gaps in understanding of T1D. The primary objectives of the study include identifying environmental factors—such as infectious agents, dietary factors, and psychosocial factors—that trigger or protect against the development of islet autoimmunity and T1D and examining genetic-environmental interactions to investigate interactive effects that contribute to T1D.","publishedDate":"2017-06-08T19:40:44Z","studyId":24,"studyName":"The Environmental Determinants of Diabetes in the Young","studyAcronym":"TEDDY"},{"id":102,"title":"New Study: ALTOLD","content":"A new study, Assessing Long Term Outcomes in Living Kidney Donors (ALTOLD), has been posted to the NIDDK Central Repository and is available for request. ALTOLD enrolled 200 pairs of living kidney donors and equally healthy two-kidney controls, and was intended to be a prospective controlled study to better understand the effects of a mild reduction in kidney function from kidney donation in otherwise normal individuals. ","publishedDate":"2017-05-24T20:23:29Z","studyId":189,"studyName":"Assessing Long Term Outcomes in Living Kidney Donors","studyAcronym":"ALTOLD"},{"id":101,"title":"New Study: FONT II","content":"A new study, Novel Therapies for Resistant FSGS: Phase II Clinical Trial (FONT II), has been posted to the NIDDK Central Repository and is available for request. The FONT II trial was a randomized, multicenter Phase I/II clinical trial designed to investigate the potential efficacy of novel therapies for resistant FSGS. Two different therapies, adalimumab (a human anti-TNF-α antibody) and galactose, were evaluated against standard conservative therapy for resistant FSGS, which consists of the combination of lisinopril, losartan, and atorvastatin. ","publishedDate":"2017-05-15T19:16:22Z","studyId":82,"studyName":"FONT 2 Study: Novel Therapies for Resistant FSGS Phase II Clinical Trials","studyAcronym":"FONT II"},{"id":100,"title":"New Study: CyNCh","content":"A new study, Cysteamine Bitartrate Delayed-Release for the Treatment of Nonalcoholic Fatty Liver Disease (NAFLD) in Children (CyNCh), has been posted to the NIDDK Central Repository and is available for request. The current data package includes analysis datasets related to the primary outcome publication. The CyNCh study is a prospective, multicenter, double-blind clinical trial designed by the NASH Clinical Research Network to determine whether treatment with cysteamine improves disease severity in children diagnosed with NAFLD.","publishedDate":"2017-04-28T19:52:32Z","studyId":148,"studyName":"Cysteamine Bitartrate Delayed-Release for the Treatment of Nonalcoholic Fatty Liver Disease (NAFLD) in Children","studyAcronym":"CyNCh"},{"id":99,"title":"Data Update for TEDDY Study ","content":"Data have been updated for The Environmental Determinants of Diabetes in the Young (TEDDY) study. The data package includes two additional analysis datasets from publications. The TEDDY study is a multicenter prospective cohort study that was established in response to these gaps in understanding of T1D. The primary objectives of the study include identifying environmental factors—such as infectious agents, dietary factors, and psychosocial factors—that trigger or protect against the development of islet autoimmunity and T1D and examining genetic-environmental interactions to investigate interactive effects that contribute to T1D.","publishedDate":"2017-04-26T20:16:12Z","studyId":24,"studyName":"The Environmental Determinants of Diabetes in the Young","studyAcronym":"TEDDY"},{"id":98,"title":"Data Update for LABS","content":"Data have been updated for the Longitudinal Assessment of Bariatric Surgery (LABS) study. The LABS observational study was established to assess the risks and health benefits associated with bariatric surgery and to identify aspects of the procedures and patient characteristics associated with optimal outcomes. The data package now includes data from an ancillary study, Psychosocial Changes Associated with Weight Loss, which examined sexual functioning, sex hormones, and relevant psychosocial constructs in individuals with obesity who sought surgical weight loss (and were in enrolled in LABS) compared to a group of individuals with obesity that sought non-surgical weight loss.","publishedDate":"2017-04-20T19:23:56Z","studyId":34,"studyName":"Longitudinal Assessment of Bariatric Surgery","studyAcronym":"LABS"},{"id":97,"title":"Data Update for Teen-LABS Study","content":"Data have been updated for the Adolescent Bariatrics: Assessing Health Benefits \u0026 Risks (Teen-LABS) study. The data package now includes additional analysis datasets through three years post-surgery. The objective of the Teen-LABS study is to use standardized techniques to assess the short and longer-term safety and efficacy of bariatric surgery in adolescents compared to adults.","publishedDate":"2017-03-27T17:39:30Z","studyId":53,"studyName":"Adolescent Bariatrics: Assessing Health Benefits \u0026 Risks","studyAcronym":"Teen-LABS"},{"id":96,"title":"New Study: CIT-07","content":"A new study, Islet Transplantation in Type 1 Diabetes (CIT-07), has been posted to the NIDDK Central Repository and is available for request. The study aimed to determine the safety and efficacy of islet transplantation when combined with an immunosuppressive medication regimen in treating patients with type 1 diabetes and hypoglycemia unawareness.","publishedDate":"2017-03-17T17:18:05Z","studyId":92,"studyName":"Islet Transplantation in Type 1 Diabetes","studyAcronym":"CIT-07/08"},{"id":95,"title":"PAR-17-123 Open For Applications","content":"Applications are now being accepted for the R01, PAR-17-123. This opportunity provides funding and access to biosamples from the NIDDK Central Repository. For more information, visit the following link: \u003ca href=\"https://grants.nih.gov/grants/guide/pa-files/PAR-17-123.html\"\u003ePAR-17-123: Biomarkers for Diabetes, Digestive, Kidney and Urologic Diseases Using Biosamples from the NIDDK Repository (R01)\u003c/a\u003e.","publishedDate":"2017-03-08T18:31:00Z","studyId":null,"studyName":null,"studyAcronym":null},{"id":94,"title":"Data Update for PROBE Study ","content":"Data have been updated for the Prospective Database of Infants With Cholestasis (PROBE) study. The data package now includes an analysis dataset from the baseline visit. PROBE is a multi-center project to establish a prospective database of clinical information and a repository of blood and tissue samples from children with diagnoses of neonatal liver diseases, such as biliary atresia and neonatal hepatitis, in order to perform research in these liver problems.","publishedDate":"2017-03-07T13:38:29Z","studyId":99,"studyName":"A Prospective Database of Infants With Cholestasis","studyAcronym":"PROBE"},{"id":93,"title":"Data Update for TEDDY Study ","content":"Data have been updated for The Environmental Determinants of Diabetes in the Young (TEDDY) study. The data package includes two additional analysis datasets from publications. The TEDDY study is a multicenter prospective cohort study that was established in response to these gaps in understanding of T1D. The primary objectives of the study include identifying environmental factors—such as infectious agents, dietary factors, and psychosocial factors—that trigger or protect against the development of islet autoimmunity and T1D and examining genetic-environmental interactions to investigate interactive effects that contribute to T1D.","publishedDate":"2017-03-01T20:54:07Z","studyId":24,"studyName":"The Environmental Determinants of Diabetes in the Young","studyAcronym":"TEDDY"},{"id":92,"title":"Data Update for DCCT/EDIC Study","content":"Data have been updated for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) study. The data package now includes cardiovascular (CVD) analysis data. The Diabetes Control and Complications Trial (DCCT) was a multicenter, randomized clinical trial designed to compare intensive with conventional diabetes therapy with regard to their effects on the development and progression of the early vascular and neurologic complications of type 1 insulin-dependent diabetes mellitus. The Epidemiology of Diabetes Interventions and Complications (EDIC) study was initiated as follow-up to examine the long-term effects of the original DCCT interventions on diabetic complications such as cardiovascular events and advanced retinal and renal disease. ","publishedDate":"2017-02-24T19:51:39Z","studyId":16,"studyName":"Diabetes Control and Complications Trial / Epidemiology of Diabetes Interventions and Complications","studyAcronym":"DCCT/EDIC"},{"id":91,"title":"Data Update for Look AHEAD","content":"Data have been updated for the Look AHEAD: Action for Health in Diabetes study. The data package now includes the primary and secondary outcomes data. The primary objective of the Look AHEAD study was to test whether an intensive lifestyle intervention program designed to achieve and maintain weight loss by decreased caloric intake and increased physical activity improves the long-term cardiovascular morbidity and mortality of overweight patients with type 2 diabetes.","publishedDate":"2016-12-22T13:09:09Z","studyId":61,"studyName":"Look AHEAD: Action for Health in Diabetes","studyAcronym":"Look AHEAD"},{"id":90,"title":"Data Update for TEDDY Study ","content":"Data have been updated for The Environmental Determinants of Diabetes in the Young (TEDDY) study. The data package includes two additional analysis datasets from publications. The TEDDY study is a multicenter prospective cohort study that was established in response to these gaps in understanding of T1D. The primary objectives of the study include identifying environmental factors—such as infectious agents, dietary factors, and psychosocial factors—that trigger or protect against the development of islet autoimmunity and T1D and examining genetic-environmental interactions to investigate interactive effects that contribute to T1D.","publishedDate":"2016-12-16T14:31:17Z","studyId":24,"studyName":"The Environmental Determinants of Diabetes in the Young","studyAcronym":"TEDDY"},{"id":89,"title":"Data Update for CKiD Study","content":"Data have been updated for the Chronic Kidney Disease in Children (CKiD) study. The data package now includes data through July 2014. The CKiD study is a prospective cohort study of children with chronic kidney disease (CKD) that investigates risk factors and outcomes of the disease. The CKiD study had various objectives, including: (1) identifying and quantifying novel and traditional risk factors for progression of CKD; (2) characterizing how CKD progression effects neurodevelopment, cognitive abilities, and behavior; (3) describing the prevalence of cardiovascular disease and associated risk factors; and (4) examining the effects of declining kidney function on growth in children with CKD.","publishedDate":"2016-12-14T13:57:47Z","studyId":39,"studyName":"The Chronic Kidney Disease in Children Cohort Study","studyAcronym":"CKiD"},{"id":88,"title":"New Study: Gastroparesis Registry","content":"A new study, Gastroparesis Registry (GpR), has been posted to the NIDDK Central Repository and is available for request. The Gastroparesis Registry is an observational study created by the Gastroparesis Clinical Research Consortium (GpCRC) to enroll a sufficiently large number of patients to elucidate the etiology and clinical features of the condition.","publishedDate":"2016-12-09T19:20:39Z","studyId":138,"studyName":"Gastroparesis Registry","studyAcronym":"GpR"},{"id":87,"title":"Data Update for TEDDY Study ","content":"Data have been updated for The Environmental Determinants of Diabetes in the Young (TEDDY) study. The data package includes one additional analysis dataset from publication 19 (Aronsson). The TEDDY study is a multicenter prospective cohort study that was established in response to these gaps in understanding of T1D. The primary objectives of the study include identifying environmental factors—such as infectious agents, dietary factors, and psychosocial factors—that trigger or protect against the development of islet autoimmunity and T1D and examining genetic-environmental interactions to investigate interactive effects that contribute to T1D.","publishedDate":"2016-11-22T18:27:01Z","studyId":24,"studyName":"The Environmental Determinants of Diabetes in the Young","studyAcronym":"TEDDY"},{"id":86,"title":"Data Update for TEDDY Study","content":"Data have been updated for The Environmental Determinants of Diabetes in the Young (TEDDY) study. The data package includes one additional analysis dataset from publication 101 (Uusitalo). The TEDDY study is a multicenter prospective cohort study that was established in response to these gaps in understanding of T1D. The primary objectives of the study include identifying environmental factors—such as infectious agents, dietary factors, and psychosocial factors—that trigger or protect against the development of islet autoimmunity and T1D and examining genetic-environmental interactions to investigate interactive effects that contribute to T1D.","publishedDate":"2016-10-19T21:17:58Z","studyId":24,"studyName":"The Environmental Determinants of Diabetes in the Young","studyAcronym":"TEDDY"},{"id":85,"title":"Data Update for TEDDY Study","content":"Data have been updated for The Environmental Determinants of Diabetes in the Young (TEDDY) study. The data package includes four additional analysis datasets from publications. The TEDDY study is a multicenter prospective cohort study that was established in response to these gaps in understanding of T1D. The primary objectives of the study include identifying environmental factors—such as infectious agents, dietary factors, and psychosocial factors—that trigger or protect against the development of islet autoimmunity and T1D and examining genetic-environmental interactions to investigate interactive effects that contribute to T1D.","publishedDate":"2016-10-11T19:43:08Z","studyId":24,"studyName":"The Environmental Determinants of Diabetes in the Young","studyAcronym":"TEDDY"},{"id":84,"title":"Data Update for A2ALL ","content":"Data have been updated for the Adult-to-Adult Living Donor Liver Transplantation Cohort Study (A2ALL). The data package now includes data from the Cohort and Core phases of the study. A2ALL compared the outcomes of adult-to-adult living donor liver transplant (AALDLT) with deceased donor liver transplant (DDLT). The primary objective of the study was to determine whether the decision to undergo adult-to-adult living donor liver transplant is beneficial for the patients who choose this type of transplant. ","publishedDate":"2016-10-10T20:02:08Z","studyId":27,"studyName":"Adult Living Donor Liver Transplantation Studies","studyAcronym":"A2ALL"},{"id":83,"title":"New Study: LABS","content":"A new study, Longitudinal Assessment of Bariatric Surgery (LABS), has been posted to the NIDDK Central Repository and is available for request. The LABS observational study was established to assess the risks and health benefits associated with bariatric surgery and to identify aspects of the procedures and patient characteristics associated with optimal outcomes. The current data package available includes data from LABS-1 and LABS-2. ","publishedDate":"2016-09-08T12:49:48Z","studyId":34,"studyName":"Longitudinal Assessment of Bariatric Surgery","studyAcronym":"LABS"},{"id":82,"title":"Data Update for the HALT-PKD Study","content":"Data have been updated for The HALT Progression of Polycystic Kidney Disease (HALT-PKD) study. The data package now includes the endpoints data. The HALT-PKD studies are two simultaneous multicenter clinical trials designed to test the efficacy of interruption of the renin-angiotestin-aldosterone system (RAAS) on the progression of cystic disease and the decline in renal function in ADPKD. ","publishedDate":"2016-07-14T17:28:18Z","studyId":28,"studyName":"The HALT Progression of Polycystic Kidney Disease","studyAcronym":"HALT PKD"},{"id":81,"title":"Data Update: BACH Study","content":"Data have been updated for the Boston Area Community Health (BACH) Survey study. The data package now includes data from follow-up phases two (2008-2010) and three (2010-2012) of the BACH study. The primary aim of the BACH study was to estimate the prevalence of urologic conditions such as interstitial cystitis (IC), urinary incontinence, benign prostatic hyperplasia, prostatitis, hypogonadism, and impaired sexual function by race/ethnicity, age, sex, and socioeconomic status (SES). ","publishedDate":"2016-06-23T20:17:28Z","studyId":19,"studyName":"Boston Area Community Health Survey","studyAcronym":"BACH"},{"id":80,"title":"New Study: HBRN Pediatric","content":"A new study, Hepatitis B Research Network (HBRN) Pediatric Cohort, has been posted to the NIDDK Central Repository and is available for request. The current data package available includes the baseline data from the HBRN Pediatric study. The primary objectives of the HBRN Pediatric study cohort are to investigate the natural history of the Hepatitis B and to identify predictors of disease activation and progression in children between the ages of 6 months and 18 years. ","publishedDate":"2016-06-23T20:12:49Z","studyId":133,"studyName":"Hepatitis B Research Network Pediatric Cohort Study","studyAcronym":"HBRN Cohort P"},{"id":79,"title":"Data Update for the NAFLD Pediatric Study","content":"Data have been updated for the NAFLD Pediatric Database study. The data package now includes the complete NAFLD Pediatric database. The Nonalcoholic Fatty Liver Disease (NAFLD) Pediatric database is a multicenter, observational study designed to study the etiology, contributing factors, natural history, complications, and treatment of Nonalcoholic Steatohepatitis (NASH) in children between the ages of 2 and 17.","publishedDate":"2016-06-17T15:28:43Z","studyId":166,"studyName":"Nonalcoholic Fatty Liver Disease (NAFLD) Pediatric Database","studyAcronym":"NAFLD Pediatric"},{"id":78,"title":"Data Update for DPPOS","content":"Data have been updated for the Diabetes Prevention Program Outcomes Study (DPPOS). The data package now includes data through Phase 2 (January 2014) of the study. The Diabetes Prevention Program Outcomes Study is the long-term follow-up of the original DPP study. The DPPOS study sought to evaluate the effects of the interventions on the further development of diabetes and diabetes complications, including retinopathy, microangiopathy, and cardiovascular disease. ","publishedDate":"2016-06-02T19:18:33Z","studyId":40,"studyName":"Diabetes Prevention Program Outcomes Study","studyAcronym":"DPPOS"},{"id":77,"title":"New Study: ACTIVE/ADIPOSE","content":"A new study, A Cohort Study to Investigate the Value of Exercise in ESRD/Analyses Designed to Investigate the Paradox of Obesity and Survival in ESRD (ACTIVE/ADIPOSE), has been posted to the NIDDK Central Repository and is available for request. The ACTIVE/ADIPOSE study is a prospective, multicenter observational study designed to characterize the prevalence and progression of frailty among patients undergoing hemodialysis for end-stage renal disease (ESRD). ","publishedDate":"2016-05-31T14:43:05Z","studyId":111,"studyName":"A Cohort Study to Investigate the Value of Exercise in ESRD/Analyses Designed to Investigate the Paradox of Obesity and Survival in ESRD","studyAcronym":"ACTIVE/ADIPOSE"},{"id":76,"title":"Data Update for TEDDY Study","content":"Data have been updated for The Environmental Determinants of Diabetes in the Young (TEDDY) study. The data package now includes one additional analysis dataset from the MP40 (RROTH) publication. ","publishedDate":"2016-05-10T19:18:27Z","studyId":24,"studyName":"The Environmental Determinants of Diabetes in the Young","studyAcronym":"TEDDY"},{"id":75,"title":"Data Update for the NAFLD Adult Study","content":"Data have been updated for the NAFLD Adult Database study. The data package now includes the complete NAFLD Adult database. The Nonalcoholic Fatty Liver Disease (NAFLD) Adult database is a multicenter, observational study designed to study the etiology, contributing factors, natural history, complications, and treatment of Nonalcoholic Steatohepatitis (NASH).","publishedDate":"2016-05-05T17:52:34Z","studyId":165,"studyName":"Nonalcoholic Fatty Liver Disease (NAFLD) Adult Database","studyAcronym":"NAFLD Adult"},{"id":74,"title":"Data Update for the NORIG Study","content":"Data have been updated for the NORIG study. The data package now includes the complete NORIG data. The Nortriptyline for Idiopathic Gastroparesis (NORIG) study is a multicenter, randomized, clinical trial that was designed by the Gastroparesis Clinical Research Consortium (GpCRC) to test whether treatment with nortriptyline, a TCA with reduced anticholinergic side effects, results in symptomatic improvement in patients with idiopathic gastroparesis.","publishedDate":"2016-03-21T19:14:26Z","studyId":null,"studyName":null,"studyAcronym":null},{"id":73,"title":"New Study: ALFSG","content":"A new study, Acute Liver Failure Study Group (ALFSG), has been posted to the NIDDK Central Repository and is available for request. The current data package available includes data through 4/2/2014.","publishedDate":"2016-03-11T20:24:36Z","studyId":null,"studyName":null,"studyAcronym":null},{"id":72,"title":"New Study: FHN Nocturnal Trial","content":"A new study, Frequent Hemodialysis Network (FHN) Nocturnal Trial, has been posted to the NIDDK Central Repository and is available for request. The current data package available includes the complete FHN Nocturnal data.","publishedDate":"2016-03-11T20:20:39Z","studyId":null,"studyName":null,"studyAcronym":null},{"id":71,"title":"Data Update for the CRIC Study","content":"Data have been updated for the Chronic Renal Insufficiency Cohort (CRIC) study. Data from the recruitment and follow-up phases of the study through 3/31/2013 are now available. Additionally, the data package now includes variables related to APOL1, Echocardiogram, Electrocardiogram, and censored composite and individual outcomes.","publishedDate":"2016-02-23T14:05:48Z","studyId":null,"studyName":null,"studyAcronym":null},{"id":70,"title":"New Study: MAPP","content":"A new study, Multidisciplinary Approach to the Study of Pelvic Pain (MAPP), has been posted to the NIDDK Central Repository and is available for requests.","publishedDate":"2016-02-01T14:16:32Z","studyId":null,"studyName":null,"studyAcronym":null},{"id":69,"title":"Data Update for the TOMUS Study","content":"Data have been updated for the Trial Of Mid-Urethral Slings (TOMUS) study. Data from the 5-year observational cohort (ETOMUS) are now available for request.","publishedDate":"2016-01-19T14:10:04Z","studyId":null,"studyName":null,"studyAcronym":null},{"id":68,"title":"New Study: FDTT","content":"A new study, Functional Dyspepsia Treatment Trial (FDTT), has been posted to the NIDDK Central Repository and is available for requests.","publishedDate":"2016-01-13T19:24:50Z","studyId":null,"studyName":null,"studyAcronym":null},{"id":67,"title":"New Study: TrialNet 06","content":"A new study, Nutritional Intervention to Prevent (NIP) Type 1 Diabetes Pilot Trial (TN06), has been posted to the NIDDK Central Repository and is available for requests.","publishedDate":"2016-01-13T19:21:58Z","studyId":null,"studyName":null,"studyAcronym":null},{"id":66,"title":"Data Update for the DCCT/EDIC Study","content":"Data have been updated for the DCCT/EDIC study. The EDIC Ocular analysis dataset is now available for request.","publishedDate":"2016-01-12T19:16:13Z","studyId":null,"studyName":null,"studyAcronym":null},{"id":65,"title":"Data Update for the Look AHEAD Study","content":"Data have been updated for the Look AHEAD study. The data package now includes data through the end of the intervention program. Note that the primary and secondary outcomes data are not currently available for request.","publishedDate":"2016-01-08T20:05:37Z","studyId":null,"studyName":null,"studyAcronym":null},{"id":64,"title":"New Study: CUTIE","content":"A new study, Careful Urinary Tract Infection Evaluation (CUTIE), has been posted to the NIDDK Central Repository and is available for requests.","publishedDate":"2016-01-04T16:03:38Z","studyId":null,"studyName":null,"studyAcronym":null},{"id":63,"title":"Data Update for the DCCT/EDIC Study","content":"Data have been updated for the DCCT/EDIC study. The EDIC Year 18 Nephropathy and Retinopathy analysis datasets are now available for request.","publishedDate":"2015-12-31T18:48:54Z","studyId":null,"studyName":null,"studyAcronym":null},{"id":62,"title":"New Study: Metabolic Control Study","content":"A new study, Effect of Metabolic Control at Onset of Diabetes on Progression of Type 1 Diabetes, has been posted to the NIDDK Central Repository and is available for requests.","publishedDate":"2015-12-31T18:41:21Z","studyId":null,"studyName":null,"studyAcronym":null},{"id":61,"title":"New Study: EPISOD","content":"A new study, Evaluating Predictors and Interventions in Sphincter of Oddi Dysfunction (EPISOD), has been posted to the NIDDK Central Repository and is available for requests.","publishedDate":"2015-12-31T18:39:29Z","studyId":null,"studyName":null,"studyAcronym":null},{"id":60,"title":"New Study: RIVUR","content":"A new study, Randomized Intervention for Children with VesicoUreteral Reflux (RIVUR), has been posted to the NIDDK Central Repository and is available for requests.","publishedDate":"2015-12-09T13:03:33Z","studyId":null,"studyName":null,"studyAcronym":null},{"id":59,"title":"Data Update for the DCCT/EDIC Study","content":"Data have been updated for the DCCT/EDIC study. The CMRI analysis dataset is now available for request. Note that variables regarding myocardial infarctions are not currently included in the dataset.","publishedDate":"2015-11-20T14:09:40Z","studyId":null,"studyName":null,"studyAcronym":null},{"id":58,"title":"Data Update for HALT-PKD Study","content":"Data have been updated for The HALT Progression of Polycystic Kidney Disease (HALT-PKD) study. The complete HALT-PKD data package is now available for request.","publishedDate":"2015-11-16T15:49:14Z","studyId":null,"studyName":null,"studyAcronym":null},{"id":57,"title":"Data Update for TEDDY Study","content":"Data have been updated for The Environmental Determinants of Diabetes in the Young (TEDDY) study. The data package includes five additional analysis datasets from publications.","publishedDate":"2015-11-04T15:33:37Z","studyId":null,"studyName":null,"studyAcronym":null},{"id":56,"title":"New Study: HBRN Adult","content":"A new study, Hepatitis B Research Network Cohort Adult, has been posted to the NIDDK Central Repository and is available for request. The current data package available includes the baseline data from the HBRN Adult study.","publishedDate":"2015-10-30T13:17:09Z","studyId":null,"studyName":null,"studyAcronym":null},{"id":55,"title":"Data Update for the DCCT/EDIC Study","content":"Data have been updated for the DCCT/EDIC study. Data from the DCCT/EDIC study up to June 2012 (the end of EDIC Year 19) are available from the Repository. Also, the EDIC Year 12 Carotid IMT analysis dataset and cystatin c analysis dataset are now available.","publishedDate":"2015-10-30T13:07:52Z","studyId":null,"studyName":null,"studyAcronym":null},{"id":54,"title":"Data Update for the CORI Study","content":"Data have been updated for the CORI study. The data package now includes data from the CORI V4 warehouse as well as additional data dictionaries for both the CORI V3 and V4 databases. ","publishedDate":"2015-10-22T18:59:23Z","studyId":null,"studyName":null,"studyAcronym":null},{"id":53,"title":"New Study: FHN Daily Trial","content":"A new study, Frequent Hemodialysis (FHN) Network Daily Trial, has been posted to the NIDDK Central Repository and is available for request. The current data package available includes the complete FHN Daily data. ","publishedDate":"2015-08-24T19:41:09Z","studyId":null,"studyName":null,"studyAcronym":null},{"id":52,"title":"Data Update for the TONIC Study","content":"Data have been updated for the TONIC study. The data package now includes the complete TONIC data. ","publishedDate":"2015-08-12T14:39:39Z","studyId":null,"studyName":null,"studyAcronym":null},{"id":51,"title":"Data Update for the PIVENS Study","content":"Data have been updated for the PIVENS study. The data package now includes the complete PIVENS data. ","publishedDate":"2015-08-12T14:37:36Z","studyId":null,"studyName":null,"studyAcronym":null},{"id":50,"title":"Data Update for CKiD Study","content":"Data have been updated for the Chronic Kidney Disease (CKiD) in Children Cohort study. The current data package available includes data from the CKiD study through July 2013.","publishedDate":"2015-05-08T18:03:00Z","studyId":null,"studyName":null,"studyAcronym":null},{"id":49,"title":"CKiD Workshop","content":"The Data Coordinating Center at the Johns Hopkins University of the CKiD (Chronic Kidney Disease in Children) study funded by the National Institute of Diabetes and Digestive and Kidney Diseases is organizing a workshop in Baltimore, Maryland on May 11th and May 12th. The purpose of the workshop is to enhance the use of CKiD data by promoting the resources available at the data repository to junior investigators and data analysts with interest in pediatric nephrology. Applications as well as more specific information about the workshop/venue can be found at \u003ca href=\"http://statepi.jhsph.edu/ckid/workshop\"\u003ehttp://statepi.jhsph.edu/ckid/workshop\u003c/a\u003e.","publishedDate":"2015-03-31T16:46:39Z","studyId":null,"studyName":null,"studyAcronym":null},{"id":48,"title":"New Study: TODAY","content":"A new study, Treatment Options for Type 2 Diabetes in Adolescents \u0026 Youth (TODAY), has been posted to the NIDDK Central Repository and is available for request.","publishedDate":"2015-01-13T22:04:13Z","studyId":null,"studyName":null,"studyAcronym":null},{"id":47,"title":"Data Update for the SISTEr Study","content":"Data have been updated for the SISTEr study. The data package now includes data from the E-SISTEr 5 year follow-up study. ","publishedDate":"2015-01-05T14:44:30Z","studyId":null,"studyName":null,"studyAcronym":null},{"id":46,"title":"New Study: NORIG","content":"A new study, Nortriptyline for Idiopathic Gastroparesis (NORIG), has been posted to the NIDDK Central Repository and is available for request. The current data package available includes the analysis datasets that were used to perform the DSIC included in the study description page. ","publishedDate":"2014-12-22T20:48:28Z","studyId":null,"studyName":null,"studyAcronym":null},{"id":45,"title":"Data Update for the CRISP Study","content":"Data have been updated for the CRISP study. The data package now includes data through 2012. ","publishedDate":"2014-11-03T22:35:34Z","studyId":null,"studyName":null,"studyAcronym":null},{"id":44,"title":"New Study: CORI","content":"A new study, Clinical Outcomes Research Initiative (CORI), has been posted to the NIDDK Central Repository and is available for requests. The current data package contains data from the v3 warehouse from 2000 through 2010.","publishedDate":"2014-10-09T17:15:11Z","studyId":null,"studyName":null,"studyAcronym":null},{"id":43,"title":"Familial Barrett’s Esophagus Data Available","content":"Data from the Familial Barrett’s Esophagus (FBEC) study are now available for request.","publishedDate":"2014-10-08T19:23:57Z","studyId":null,"studyName":null,"studyAcronym":null},{"id":42,"title":"New Study: ValUE","content":"A new study, Value of Urodynamic Evaluation (ValUE), has been posted to the NIDDK Central Repository and is available for requests.","publishedDate":"2014-08-06T18:50:49Z","studyId":null,"studyName":null,"studyAcronym":null},{"id":41,"title":"Data Update for the DILIN Prospective Study","content":"Data have been updated for the DILIN Prospective study. The data package now includes data through June 2013. ","publishedDate":"2014-08-06T18:47:15Z","studyId":null,"studyName":null,"studyAcronym":null},{"id":40,"title":"Data Update for the DILIN Retrospective Study","content":"Data have been updated for the DILIN Retrospective study. The data package now includes data through June 2013. ","publishedDate":"2014-08-06T18:44:41Z","studyId":null,"studyName":null,"studyAcronym":null},{"id":39,"title":"New Study: HALT-PKD","content":"A new study, The HALT Progression of Polycystic Kidney Disease (HALT-PKD), has been posted to the NIDDK Central Repository and is available for requests. ","publishedDate":"2014-07-07T21:30:09Z","studyId":null,"studyName":null,"studyAcronym":null},{"id":38,"title":"Data Update for the Look AHEAD Study","content":"Data have been updated for the Look AHEAD study. The data package now includes data from the baseline and year 4 visits.","publishedDate":"2014-07-07T21:27:26Z","studyId":null,"studyName":null,"studyAcronym":null},{"id":37,"title":"New Study: TOMUS","content":"A new study, Trial Of Mid-Urethral Slings (TOMUS), has been posted to the NIDDK Central Repository and is available for requests.","publishedDate":"2014-05-23T20:41:02Z","studyId":null,"studyName":null,"studyAcronym":null},{"id":36,"title":"Data Update for TEDDY Study","content":"Data have been updated for The Environmental Determinants of Diabetes in the Young (TEDDY) study. The data package now includes data from the three month visit.","publishedDate":"2014-05-19T13:16:32Z","studyId":null,"studyName":null,"studyAcronym":null},{"id":35,"title":"New Study: MIST2","content":"A new study, Intraprostatic Injection of Botulinum Toxin for the Management of Benign Prostatic Hyperplasia (MIST2), has been posted to the NIDDK Central Repository and is available for requests. ","publishedDate":"2014-05-19T13:13:14Z","studyId":null,"studyName":null,"studyAcronym":null},{"id":34,"title":"New Study: NASH NAFLD Pediatric Database","content":"A new study, Nonalcoholic Steatohepatitis Research Network (NASH CRN) Nonalcoholic Fatty Liver Disease (NAFLD) Pediatric Database, has been posted to the NIDDK Central Repository and is available for requests. The current data package available includes the analysis datasets that were used to perform the DSIC included in the study description page. ","publishedDate":"2014-05-19T13:11:50Z","studyId":null,"studyName":null,"studyAcronym":null},{"id":33,"title":"New Study: NASH NAFLD Adult Database","content":"A new study, Nonalcoholic Steatohepatitis Research Network (NASH CRN) Nonalcoholic Fatty Liver Disease (NAFLD) Adult Database, has been posted to the NIDDK Central Repository and is available for requests. The current data package available includes the analysis datasets that were used to perform the DSIC included in the study description page. ","publishedDate":"2014-05-19T13:07:27Z","studyId":null,"studyName":null,"studyAcronym":null},{"id":32,"title":"Data Update for CKiD Study","content":"Data have been updated for the Chronic Kidney Disease (CKiD) in Children Cohort study. The current data package available includes data from the CKiD study through 2008.","publishedDate":"2014-03-06T19:44:44Z","studyId":null,"studyName":null,"studyAcronym":null},{"id":31,"title":"New Study: DILIN Prospective","content":"A new study, DILIN Prospective, has been posted to the NIDDK Central Repository and is available for requests. The current data package available includes data from the DILIN Prospective study through 2009.","publishedDate":"2014-03-06T19:36:04Z","studyId":null,"studyName":null,"studyAcronym":null},{"id":30,"title":"New Study: NASH TONIC","content":"A new study, Nonalcoholic Steatohepatitis Research Network (NASH CRN) Treatment of Nonalcoholic Fatty Liver Disease in Children (TONIC), has been posted to the NIDDK Central Repository and is available for requests. The current data package available includes the analysis datasets that were used to perform the DSIC included in the study description page. ","publishedDate":"2014-02-19T21:15:48Z","studyId":null,"studyName":null,"studyAcronym":null},{"id":29,"title":"New Study: NASH PIVENS","content":"A new study, Nonalcoholic Steatohepatitis Research Network (NASH CRN) Pioglitazone vs Vitamin E vs Placebo for Treatment of Non-Diabetic Patients With Nonalcoholic Steatohepatitis (PIVENS), has been posted to the NIDDK Central Repository and is available for requests. The current data package available includes the analysis datasets that were used to perform the DSIC included in the study description page. ","publishedDate":"2014-02-19T21:09:30Z","studyId":null,"studyName":null,"studyAcronym":null},{"id":28,"title":"New Study: DILIN Retrospective","content":"A new study, DILIN Retrospective, has been posted to the NIDDK Central Repository and is available for requests. The current data package available includes data from the DILIN Retrospective study through 2009.","publishedDate":"2014-02-19T21:01:47Z","studyId":null,"studyName":null,"studyAcronym":null},{"id":27,"title":"New Study: FSGS","content":"A new study, Focal Segmental Glomerulosclerosis (FSGS) Clinical Trial, has been posted to the NIDDK Central Repository and is available for requests.","publishedDate":"2014-02-07T18:45:14Z","studyId":null,"studyName":null,"studyAcronym":null},{"id":26,"title":"Data Update for TEDDY Study","content":"Data have been updated for The Environmental Determinants of Diabetes in the Young (TEDDY) study. It now includes data from the baseline visit and an analysis dataset regarding the Sternery HLA manuscript. ","publishedDate":"2014-01-10T21:07:59Z","studyId":null,"studyName":null,"studyAcronym":null},{"id":25,"title":"Data Update for CRIC Study","content":"Data have been updated for the Chronic Renal Insufficiency Cohort Study (CRIC) study. It now includes data from follow-up visits through March 31, 2011.","publishedDate":"2014-01-10T21:01:02Z","studyId":null,"studyName":null,"studyAcronym":null},{"id":24,"title":"New Funding Opportunity","content":"A new opportunity to request access to non-renewable samples from NIDDK is available! PAR-14-065: Research Using Biosamples from Selected Type 1 Diabetes Clinical Studies (DP3): \u003ca href=\"http://grants.nih.gov/grants/guide/pa-files/PAR-14-065.html\" target=\"_new\"\u003ehttp://grants.nih.gov/grants/guide/pa-files/PAR-14-065.html\u003c/a\u003e.","publishedDate":"2014-01-09T15:24:26Z","studyId":null,"studyName":null,"studyAcronym":null},{"id":23,"title":"Data Update for FAVORIT Study","content":"Data have been updated for the Folic Acid for Vascular Outcome Reduction in Transplantation Trial (FAVORIT) study. It now includes 12 new datasets: 2 updated versions of summary files, 5 new Baseline/Followup datasets, and 5 new Blind Matching Replicates datasets of the new Baseline/Followup datasets. ","publishedDate":"2014-01-08T21:16:49Z","studyId":null,"studyName":null,"studyAcronym":null},{"id":22,"title":"PAR-11-306 Open For Applications","content":"Grant applications to request access to non-renewable samples from NIDDK are due November 1st. \u003ca href=\"http://grants1.nih.gov/grants/guide/pa-files/PAR-11-306.html\"\u003ePAR-11-306: NIDDK Central Repositories Non-renewable Sample Access (X01)\u003c/a\u003e.","publishedDate":"2013-10-01T16:12:59Z","studyId":null,"studyName":null,"studyAcronym":null},{"id":21,"title":"New Funding Opportunity","content":"A new opportunity to request access to non-renewable samples from NIDDK is available! PAR-13-228: Biomarkers for Diabetes, Digestive, Kidney and Urologic Diseases Using Biosamples from the NIDDK Repository (R01): \u003ca href=\"http://grants1.nih.gov/grants/guide/pa-files/PAR-13-228.html\" target=\"_new\"\u003ehttp://grants1.nih.gov/grants/guide/pa-files/PAR-13-228.html\u003c/a\u003e.","publishedDate":"2013-06-03T04:00:00Z","studyId":null,"studyName":null,"studyAcronym":null},{"id":20,"title":"Special Studies","content":"NIDDK Reference Calibrators for Islet Autoanitbody Measurements and T1DGC Immunochip HLA reference Panel are available on the \u003ca href=\"/pages/special_studies/\"\u003e\"Special Studies\"\u003c/a\u003e page.","publishedDate":"2013-03-19T04:00:00Z","studyId":null,"studyName":null,"studyAcronym":null},{"id":4,"title":"RICE Data","content":"RICE study data is available on the \u003ca href=\"/search/study/\"\u003e\"Study Search\"\u003c/a\u003e page.","publishedDate":"2013-03-19T04:00:00Z","studyId":null,"studyName":null,"studyAcronym":null},{"id":6,"title":"New Funding Opportunity","content":"A new funding opportunity was opened on March 2, 2013, \u003ca href=\"http://grants.nih.gov/grants/guide/pa-files/par-13-013.html\"\u003ePAR-13-013\u003c/a\u003e! This FOA invites applications for ancillary studies using archived samples from the DCCT/EDIC, DPT-1, TrialNet, and GoKind type 1 diabetes clinical trials and studies. Ancillary studies are expected to generate scientific discoveries on type 1 diabetes primary pathogenesis or the pathogenesis of complications, and biomarkers of disease progression or clinical responses to interventions. Applications must be submitted by April 2, 2013.","publishedDate":"2013-01-21T05:00:00Z","studyId":null,"studyName":null,"studyAcronym":null},{"id":5,"title":"CAMUS Data","content":"\u003ca href=\"/studies/camus/\"\u003eCAMUS\u003c/a\u003e study data have been posted and curation is completed.","publishedDate":"2013-01-09T05:00:00Z","studyId":null,"studyName":null,"studyAcronym":null},{"id":3,"title":"SyNCH HCV Data","content":"\u003ca href=\"/studies/synch/\"\u003eSyNCH HCV\u003c/a\u003e study data have been posted and curation is completed.","publishedDate":"2013-01-09T05:00:00Z","studyId":null,"studyName":null,"studyAcronym":null},{"id":19,"title":"DCC Online Form","content":"The new DCC Online Form has been released. (then, when you click additional information): This online form allows study DCCs to review, add and update study information online. If you are a study DCC and would like to update your information, please \u003ca href=\"https://www.niddkrepository.org/niddk/jsp/user/login.jsp\"\u003elog in\u003c/a\u003e, scroll over Tools and click \u003cb\u003eDCC Study Entry\u003c/b\u003e. ","publishedDate":"2012-09-05T19:03:16Z","studyId":null,"studyName":null,"studyAcronym":null},{"id":18,"title":"Upcoming Study Data","content":"Upcoming study data: TEDDY V2.","publishedDate":"2012-09-04T19:16:15Z","studyId":null,"studyName":null,"studyAcronym":null},{"id":17,"title":"TrialNet-Natural History Data","content":"\u003ca href=\"https://www.niddkrepository.org/niddk/jsp/public/dataset.jsp#TN01\"\u003eTN-NH\u003c/a\u003e study data have been posted and curation is completed.","publishedDate":"2012-09-04T18:54:54Z","studyId":null,"studyName":null,"studyAcronym":null},{"id":2,"title":"The Agony and the Ecstasy: A Tale of Repository Data Analysts ","content":"View the \u003ca href=\"https://www.niddkrepository.org/niddkdocs/Presentations/JSM12_Pugh_pres.pdf\" target=\"_blank\"\u003epresentation\u003c/a\u003e and \u003ca href=\"https://www.niddkrepository.org/niddkdocs/Presentations/JSM12_Pugh_paper.pdf\" target=\"_blank\"\u003e paper\u003c/a\u003e presented at The Joint Statistical Meetings (JSM) 2012.","publishedDate":"2012-08-09T04:00:00Z","studyId":null,"studyName":null,"studyAcronym":null},{"id":1,"title":"AASK Sample Availability","content":"Whole Genome Amplified DNAs from the AASK study will be available for distribution by March 2012. Each set will contain 5 micrograms each from each of more than 700 samples. The cost for each set will be $5000. To apply, follow the instructions for the Automated DNA Request System (https://www.niddkrepository.org/niddk/jsp/public/sampleInstruction.jsp).","publishedDate":"2011-12-28T05:00:00Z","studyId":null,"studyName":null,"studyAcronym":null},{"id":16,"title":"DAC - Fistula Data","content":"\u003ca href=\"https://www.niddkrepository.org/niddk/jsp/public/dataset.jsp#FISTULA\"\u003eDAC - Fistula\u003c/a\u003e study data have been posted and curation is completed.","publishedDate":"2011-10-05T04:00:00Z","studyId":null,"studyName":null,"studyAcronym":null},{"id":15,"title":"CRIC Data","content":"\u003ca href=\"https://www.niddkrepository.org/niddk/jsp/public/dataset.jsp#CRIC\"\u003eCRIC\u003c/a\u003e study data have been posted and curation is completed.","publishedDate":"2011-10-05T04:00:00Z","studyId":null,"studyName":null,"studyAcronym":null},{"id":14,"title":"Studies search tool","content":"\u003ca href=\"https://www.niddkrepository.org/niddk/pqt.do?methodToCall=viewAdvancedSearch\"\u003eStudies search tool\u003c/a\u003e is available on the website.","publishedDate":"2011-08-02T04:00:00Z","studyId":null,"studyName":null,"studyAcronym":null},{"id":7,"title":"Coming Soon","content":"\u003ca href=\"http://www.niddkrepository.org/niddk/jsp/public/coming.jsp\"\u003eStudies\u003c/a\u003e will be available soon\n","publishedDate":"2011-08-01T15:11:09Z","studyId":null,"studyName":null,"studyAcronym":null},{"id":13,"title":"HEALTHY Data","content":"\u003ca href=\"https://www.niddkrepository.org/niddk/jsp/public/dataset.jsp#HEALTHY\"\u003eHEALTHY\u003c/a\u003e study data have been posted and curation is completed.","publishedDate":"2011-06-14T04:00:00Z","studyId":null,"studyName":null,"studyAcronym":null},{"id":12,"title":"Repository Presentation at ISBER 2011","content":"A \u003ca href=\"https://www.niddkrepository.org/niddkdocs/resources/Repository_Presentation-ISBER2011.pdf\"\u003epresentation about the NIDDK Repository\u003c/a\u003e by Dr Rebekah Rasooly was delivered at the International Society for Biological and Environmental Repositories (ISBER) 2011 Annual Meeting. ","publishedDate":"2011-05-23T04:00:00Z","studyId":null,"studyName":null,"studyAcronym":null},{"id":11,"title":"Cost for Data and Samples","content":"New \u003ca href=\"http://www.niddkrepository.org/niddk/jsp/public/cost.jsp\"\u003ePricing Structure\u003c/a\u003e for Data and Samples.","publishedDate":"2010-12-01T05:00:00Z","studyId":null,"studyName":null,"studyAcronym":null},{"id":10,"title":"Non-renewable Sample Request","content":"The Repository has a \u003ca href=\"http://www.niddkrepository.org/niddk/jsp/public/rfa_nonrenewable.jsp\"\u003enew process\u003c/a\u003e to apply for non-renewable samples. It is an NIH application to \u003cA href=\"http://grants.nih.gov/grants/guide/pa-files/PAR-10-090.html\"\u003ePAR-10-090\u003c/A\u003e.","publishedDate":"2010-10-25T04:00:00Z","studyId":null,"studyName":null,"studyAcronym":null},{"id":9,"title":"DCCT/EDIC Ancillary Studies","content":"A list of measurements that various DCCT/EDIC Ancillary studies have already made are available on the website: \u003ca href=\"http://www.niddkrepository.org/niddk/jsp/public/EDIC/dcctAncillary.jsp\"\u003eDCCT/EDIC Ancillary Measurements\u003c/a\u003e. The NIDDK Repository does not plan to duplicate these measurements by new investigators. The NIDDK Repository has not assessed these additional data for completeness. They are being made available as they were provided by the investigators.","publishedDate":"2010-06-02T04:00:00Z","studyId":null,"studyName":null,"studyAcronym":null},{"id":8,"title":"Automated DNA Sample Request System","content":"The NIDDK Central Repository is pleased to offer an Automated DNA Sample Request System (ASRS) to renewable sample requestors. To begin the Automated DNA Sample Request process, please go to the \"\u003ca href=\"http://www.niddkrepository.org/niddk/sampleGeneral.do?methodToCall=view\u0026isnew=true\"\u003eRequest Samples\u003c/a\u003e\" page. A \u003cA href=\"https://www.niddkrepository.org/niddkdocs/ASRS/Researcher/Default.htm\" target=_blank\u003eUser guide\u003c/A\u003e (\u003cA href=\"https://www.niddkrepository.org/niddkdocs/NIDDK_ASRS_UserGuide_v1.0.pdf\"\u003ePDF\u003c/A\u003e) is available. Should you have any questions, please contact \u003cA href=\"mailto:NIDDKAdmin@rti.org\"\u003eNIDDKAdmin@rti.org\u003c/A\u003e. If you have any comments, please \u003ca href=\"http://www.niddkrepository.org/niddk/jsp/public/feedback.jsp\"\u003eenter your feedback\u003c/a\u003e.","publishedDate":"2010-04-14T04:00:00Z","studyId":null,"studyName":null,"studyAcronym":null}],"news":[{"id":269,"title":"New Features and Enhancements Coming to NIDDK-CR: A Smarter, Sleeker Experience!","content":"We’re thrilled to announce exciting system upgrades to the NIDDK-CR platform! Get ready for dynamic new features and functionalities, including interactive graphs, comprehensive study information pages, advanced file exploration tools, and next-level search experience. These enhancements are designed with users in mind to make locating and accessing studies and resources faster and easier than ever. Stay tuned for the release date announcement!—this is one update you won’t want to miss!","publishedDate":"2024-11-22T19:03:37Z"},{"id":268,"title":"Coming Soon! NIH Data Sharing Index (S-index) Challenge","content":"The S-index challenge, \u003ca href = \"https://www.nei.nih.gov/about/news-and-events/news/nei-launches-challenge-promote-data-sharing\" target =\"_blank\" rel =\"noopener noreferrer\"\u003eled by the National Eye Institute (NEI)\u003c/a\u003e, aims to incentivize and reward data sharing by promoting a new metric, the S-index, that will assess how effectively researchers share data. This metric will incorporate factors such as adherence to Findable, Accessible, Interoperable, and Reusable (FAIR) standards, data timeliness, completeness of annotation, frequency of utilization in other studies, and related publications and patents. Phase 1 for this challenge is to generate a proof of concept proposal and will open on April 21, 2025 at 8:00 a.m. EDT. Check out \u003ca href = \"https://www.challenge.gov/?challenge=nih-data-sharing-index-s-index-challenge\" target =\"_blank\" rel =\"noopener noreferrer\"\u003eChallenge.gov\u003c/a\u003e to learn more about the challenge, how to enter, eligibility, and cash prizes.","publishedDate":"2024-11-14T20:51:04Z"},{"id":260,"title":"2024 DataWorks! Prize Challenge – Phase 1 now open!","content":"The Federation of American Societies for Experimental Biology (FASEB) and the National Institutes of Health (NIH) partnered together to host the 2024 DataWorks! Prize. This challenge is a collaboration with the seven generalist repositories participating in the NIH-funded Generalist Repositories Ecosystem Initiative (GREI) and will focus on best practices in data reuse and secondary analysis that advance human health. NIDDK-CR data may be used for this challenge in combination with data from a participating GREI repository. Phase 1 for this challenge closes on 11:59 p.m. EDT on October 23, 2024. Check out \u003ca href = \"https://www.challenge.gov/?challenge=2024-dataworks-prize\u0026tab=overview\" target = \"_blank\" rel = \"noopener noreferrer\"\u003e Challenge.gov\u003c/a\u003e to learn more about the challenge, how to enter, eligibility, and prizes.","publishedDate":"2024-08-22T15:08:41Z"},{"id":247,"title":"Winners of the Data Centric Challenge presented their winning solution at the May 10th ODSS Data Sharing and Reuse Seminar – Recording Available","content":"Winners of the Intermediate/Advanced-level Data Centric Challenge, Dr. Ali Loveys and Fiona Meng from FI Consulting, presented Laying the Foundation for AI-Ready Data at the ODSS Data Sharing and Reuse Seminar on May 10, 2024. The FI Consulting team successfully consolidated and unified multiple TrialNet data sets and identified data outliers, then enhanced raw data to ensure consistent variable representation and identified numeric and categorical “missingness” to prevent modeling bias, thus enhancing TrialNet data for AI-readiness. \u003ca href=\"https://www.youtube.com/watch?v=CrABW02QB30\"\u003eView the recording from the past webinar \u003c/a\u003e.","publishedDate":"2024-06-26T13:59:22Z"},{"id":243,"title":"New NIDDK Central Repository Policy Released!","content":"NIDDK Central Repository (NIDDK-CR) has released a revised policy that aligns with the NIH Data Management and Sharing (DMS) policy and NIDDK DMS Guidance: \u003ca href=\"https://grants.nih.gov/grants/guide/notice-files/NOT-DK-24-003.html\" target=\"__blank\"\u003ehttps://grants.nih.gov/grants/guide/notice-files/NOT-DK-24-003.html\u003c/a\u003e. More details and complete NIDDK-CR Resource Archival and Sharing policy are available under “Helpful Information”- “General Information”: \u003ca href =\"https://repository.niddk.nih.gov/pages/general_information/\" target=\"__blank\"\u003ehttps://repository.niddk.nih.gov/pages/general_information\u003c/a\u003e","publishedDate":"2024-03-29T20:32:54Z"},{"id":241,"title":"NIDDK Central Repository Data Centric Challenge – Winners Announced!","content":"In September 2023, the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Central Repository announced the Data Centric Challenge aimed at enhancing NIDDK datasets for future artificial intelligence (AI) applications. Challenge participants were tasked to generate an AI-ready dataset that can be used for future data challenges and produce methods to enhance the AI-readiness of NIDDK data. Participation in the Challenge was tiered (i.e., beginner-level and intermediate/advanced-level) and utilized data from two longitudinal studies focused on type 1 diabetes (TEDDY and TrialNet). NIDDK is excited to announce \u003cstrong\u003eICF Inc\u003c/strong\u003e. and \u003cstrong\u003eFI Consulting\u003c/strong\u003e as the Data Centric Challenge winners. Visit Challenge.gov to read more about the winning solutions: \u003ca href=\"https://www.challenge.gov/?challenge=niddk-central-repository-data-centric-challenge\u0026tab=winners\" target=\"_blank\" rel=\"noopener noreferrer\"\u003ehttps://www.challenge.gov/?challenge=niddk-central-repository-data-centric-challenge\u0026tab=winners\u003c/a\u003e","publishedDate":"2024-02-28T21:38:57Z"},{"id":216,"title":"Ready for use: Study Digital Object Identifiers (DOIs) and citations to increase research visibility","content":"DOIs are now available for every NIDDK-CR R4R study! DOIs increase resource visibility and accessibility and enable appropriate credit citation and interoperability. Researchers are encouraged to use them when making public releases using NIDDK-CR R4R resources. A study’s DOI can be found at the top of the study’s overview page along with citation guidance. Additionally, a data availability statement, with data package version and DOI, is available to requestors who are submitting publications.","publishedDate":"2023-04-07T19:28:50Z"},{"id":215,"title":"NIH’s New Data Management and Sharing Policy is in effect!","content":"As of January 25, 2023, the \u003ca href=\"https://grants.nih.gov/grants/guide/notice-files/NOT-OD-21-013.html\" target=\"_blank\" rel=\"noopener noreferrer\"\u003eNIH Policy for Data Management and Sharing\u003c/a\u003e (DMS) is in effect. All research that is funded in whole or in part by NIH is required to submit a DMS plan outlining how scientific data and accompanying metadata will be managed and shared. NIH DMS plans should address the elements described in the \u003ca href=\"https://grants.nih.gov/grants/guide/notice-files/NOT-OD-21-014.html\" target=\"_blank\" rel=\"noopener noreferrer\"\u003eSupplemental Information to the NIH DMS Policy\u003c/a\u003e. NIH has provided a DMS plan format on the \u003ca href=\"https://sharing.nih.gov/data-management-and-sharing-policy/planning-and-budgeting-for-data-management-and-sharing/writing-a-data-management-and-sharing-plan#writing-a-data-management-and-sharing-plan\" target=\"_blank\" rel=\"noopener noreferrer\"\u003eWriting a Data Management and Sharing Plan\u003c/a\u003e page on the \u003ca href=\"https://sharing.nih.gov/\" target=\"_blank\" rel=\"noopener noreferrer\"\u003eNIH Scientific Data Sharing website\u003c/a\u003e. NIDDK is offering Institute-specific guidance for \u003ca href=\"https://www.niddk.nih.gov/research-funding/research-resources/data-management-sharing\" target=\"_blank\" rel=\"noopener noreferrer\"\u003eWriting a DMS Plan\u003c/a\u003e and provides \u003ca href=\"https://www.niddk.nih.gov/research-funding/research-resources/data-management-sharing/dms-tools-examples\" target=\"_blank\" rel=\"noopener noreferrer\"\u003eNIDDK DMS Tools and Examples.\u003c/a\u003e","publishedDate":"2023-04-07T19:25:18Z"},{"id":217,"title":"Updates to the NIDDK-CR Resources for Research (R4R) biospecimen request process are coming soon","content":"This revamped, streamlined process for requesting biospecimens incorporates user feedback to better facilitate access to biospecimens. Certain requests will still require an X01 Resource Access Award; however, many will need only an administrative review or will leverage existing grant applications peer review if one was submitted. The new request process is designed to share NIDDK-CR resources with more researchers faster and easier to continue fostering innovative research. Researchers can visit \u003ca href=\"https://repository.niddk.nih.gov/search/counts/\"\u003ethe Material Counts page\u003c/a\u003e to explore the available resources and start a request.","publishedDate":"2022-11-30T19:59:29Z"},{"id":218,"title":"NIDDK Central Repository joins Vivli to strengthen and expand the data ecosystem","content":"Vivli and the National Institute of Diabetes and Digestive and Kidney Disease (NIDDK), part of the National Institutes of Health (NIH), will be working together to broaden exposure and strengthen NIDDK data ecosystem. As part of Vivli’s award to serve as one of six generalist repositories that will work with the NIH Office of Data Science Strategy under its Generalist Repository Ecosystem Initiative (\u003ca href=\" https://datascience.nih.gov/exploring-generalist-repository-nih-funded-data\"\u003eGREI\u003c/a\u003e), NIDDK will include NIDDK Central Repository (NIDDK-CR) resources in the Vivli global clinical research data sharing platform. NIDDK-CR’s resources inclusion within Vivli as part of GREI improves discoverability and reuse of NIDDK-CR hosted resources making data more Findable, Accessible, Interoperable, and Reusable (FAIR), increases the scientific value by providing additional opportunities to the NIDDK scientific community, and maximizes the contributions of research participants. \n\nTo learn more: contact Dr. Rebecca Rodriguez or visit the \u003ca href=\"https://vivli.org/ourmember/niddk-cr-r4r-a-program-of-the-national-institute-of-diabetes-and-digestive-and-kidney-diseases-nih/\"\u003eVivli member page\u003c/a\u003e.","publishedDate":"2022-10-07T01:09:48Z"},{"id":219,"title":"NLP-based CDE tagging to improve FAIRness of studies in the NIDDK Central Repository","content":"The NIDDK Central Repository (CR) plays a crucial role in making data Findable, Accessible, Interoperable, and Reusable (FAIR). To enhance FAIRness of studies in the Repository, NIDDK and Booz Allen Hamilton, the current Data Repository contractor, have piloted a natural language processing (NLP) pipeline project for harmonizing study variables with NIH CDEs and for identifying potential new CDEs from dataset variables mapped to ontology concepts. Initial results show highly specific mapping of variables to CDEs as well as successful identification of relevant concepts for new CDEs. The pipeline can be refined and applied to other studies to potentially improve FAIRness of the NIDDK CR. \nContact Dr. Rebecca Rodriguez with any questions.","publishedDate":"2021-11-17T16:26:30Z"}],"events":[],"stats":{"researchAreaStudyCounts":{"Diabetes":67,"Digestive Diseases":24,"Endocrine Diseases and Metabolic Diseases":6,"Hematologic Diseases":3,"Kidney Disease":44,"Liver Disease":47,"Multidisciplinary Research":49,"Nutrition":8,"Obesity":14,"Pancreatic Disease":3,"Urologic Diseases":27},"divisionStudyCounts":{"DDN":67,"DEM":57,"KUH":63},"specimenCountByType":{"Biological Macromolecule":{"totalCount":1369173,"materialTypeCounts":{"DNA":617763,"Extracted mRNA":528,"Mitochondrial RNA":1898,"Plasma Prot":5596,"Protein":1391,"RNA":741753,"RNA Supernatant":161,"cDNA":83}},"Cells":{"totalCount":1114784,"materialTypeCounts":{"B Cells":15049,"Buffy Coat":134509,"Cells":16019,"Dried Blood Spot":17022,"EBV PBMC (2nd)":4264,"EBV Transformed Cell Lines":253571,"Fibroblasts/skin":165,"Fibroblasts/tendon":5,"Islet Cells":118,"Lymphocytes":29980,"Non-Viable Cells":6362,"PB-PBMC":411320,"PBMC":28497,"R-RBC":181712,"Red Blood Cells":9955,"Stimulated Leukocytes":210,"Unstimulated Leukocytes":206,"Viable Cells":5820}},"Fluids":{"totalCount":13800010,"materialTypeCounts":{"24 h urine":140460,"BBT Serum":342,"BILE":150,"Bile-GB Aspirate":51,"Blood PBS":20474,"Cell Pellet":10,"Duodenal Fluid":1045,"Externally Produced Serum":686,"Frozen Plasma":9226,"MM Tolerance Test":5589,"Nasal Swab":143923,"Oral Glucose Tolerance Test":19955,"Overnight Urine":12827,"PAX gene":94,"Perineal Swab":593,"Plasma":4621231,"Plasma or Serum":18,"SER_RTLS":7,"STIM Tubes":4273,"Saliva":46997,"Serum":6244732,"Stool":602256,"Stool PBS":3203,"Supernatant":114799,"Tap Water from the Children's Homes":191249,"Timed Urine":309,"Urine":1450983,"Urine Assay Assure":3041,"Urine Pellet":34410,"Urine Supernatant":15587,"Vaginal Swab":1245,"Whole Blood":110245}},"Tissue":{"totalCount":225534,"materialTypeCounts":{"Bile Duct":4343,"Bile Duct Tissue":1,"Bile-GB Aspirate Tissue":44,"Biliary Remnant":1685,"Bladder Tissue":25919,"Cinci Core Bx":1,"Gallbladder":4386,"Gallbladder Tissue":94,"Hair":751,"Kidney Stone":10,"Liver Biopsy":3057,"Liver Explant":10,"Liver Perc Bx":619,"Liver Tissue":77594,"Liver Wedge Bx":891,"Lymph Node":372,"Lymph Node Tissue":15,"Nail Clipping":39184,"Needle Bx":509,"Percutaneous Bx":1179,"Placenta Tissue":2750,"Primary Tooth":2334,"Prostate Tissue":46961,"SI/Colon Tissue":136,"Tissue":810,"Vein Tissue":1008,"Wedge Bx":10871}}},"studiesWithAvailableData":157,"studiesWithAvailableSpecimen":102,"numDatasets":5767,"numDocuments":9750,"numImages":"15.8M"},"contentUpdates":{"newStudies":[],"newFiles":[],"updatedFiles":[]},"siteUrl":"https://repository.niddk.nih.gov"},"__N_SSP":true},"page":"/home","query":{},"buildId":"4IwPCL7p9Vb_-_lB6rNWm","isFallback":false,"isExperimentalCompile":false,"gssp":true,"scriptLoader":[]}</script></body></html>